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Abstract 
 
Protein phosphorylation, the most prevalent post-translational modification, is critical in the 
regulation of cellular events. Mapping the kinome is important in understanding how these 
processes occur and could provide a basis for new cancer therapies, but current methods are 
insufficient for this task. This research here was aimed at developing a new substrate identification 
strategy by combining two existing methods; steric complementation and cross-linking. 
 
Steric complementation was employed to generate a pyrazolo[3,4-d]pyrimidine ATP analogue that 
binds selectively to an analogue-sensitive (as-) kinase over the wild-type kinase and other 
intracellular kinases. The synthesis of C3-substituted pyrazolo[3,4-d]pyrimidines was extended to 
incorporate both alkyl and alkynyl substituents. A construct for the expression of PKCα (M417A) 
was generated and both PKCα and PKCα (M417A) expressed after lengthy optimisation. In vitro 
kinase radioassays were used to identify the most potent and selective inhibitor for PKCα (M417A). 
 
In order to allow late-stage introduction of photoactivatable groups into the pyrazolo[3,4-
d]pyrimidine scaffold, various functionalised hydrazines were synthesised. The most potent C3-
unsubstituted photoaffinity probes were selected for inhibition of PKCα and optimisation of both 
cross-linking and [3+2] Huisgen cyclisation to a fluorophore-containing azide allowed visualisation 
of the cross-linked products, although as yet, no substrate-selective labelling has been detected. 
 
The application of steric complementation to the photoaffinity probes was briefly investigated with 
a view to initially allowing improved detection of substrate-selective labelling, and ultimately 
achieving selective cross-linking to as-kinase substrates in intact cells. 
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Abbreviations 
 
Ac acetyl 
ADP adenosine diphosphate 
AICAR 5-amino-4-imidazolcarboxamide riboside 
Alloc allyloxycarbonyl 
AMP-PNP 5’-adenylyl imidodiphosphate 
aPKC atypical PKC 
APS ammonium persulfate 
aq. aqueous 
Ar aryl 
as- analogue-sensitive 
ATP adenosine triphosphate 
BBS BES-buffered saline 
BES N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid 
BIM I bisindolylmaleimide I 
Bn benzyl 
Boc tert-butoxycarbonyl 
br broad 
BSA bovine serum albumin 
BTCA benzyl trichloroacetimidate 
Bu butyl 
Bz benzoyl 
C- carboxy 
CAMK II Ca
2+
/calmodulin-dependent protein kinase II 
cAMP cyclic adenosine monophosphate 
cat. catalytic/catalyst 
cdk cyclin-dependent kinase 
Cbz benzyloxycarbonyl 
CDI 1,1’-carbonyldiimidazole 
CI chemical ionisation MS 
cPKC classical/conventional PKC 
COS7 African green monkey kidney cells 
d doublet/day(s) 
DAG 1,2-sn-diacylglycerol 
Dam DNA adenine methylase 
DCC dicyclohexylcarbodiimide 
dH2O distilled water 
DIAD diisopropyl azodicarboxylate 
DIBAL-H diisobutylaluminium hydride 
DLS dynamic light scattering 
DMAP dimethylaminopyridine 
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DME 1,2-dimethoxyethane 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMF dimethylformamide 
DMP Dess-Martin periodinane 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
DPPA diphenylphosphoryl azide 
dsDNA double-stranded DNA 
DTT dithiothreitol 
E. coli Escherichia coli 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA ethylenediaminetetraacetic acid 
EGTA ethyleneglycoltetraacetic acid 
EI electron impact MS 
eq. molar equivalents 
ES electrospray MS 
Et ethyl 
FBS foetal bovine serum 
Fyn Src-family proto-oncogenic tyrosine kinase 
GFP green fluorescent protein 
GSK glycogen synthase kinase 
GST glutathione S-transferase 
h hour(s) 
HBS Hepes-buffered saline 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRV human rhinovirus 
IC50 half maximal inhibitory concentration 
imid imidazole 
i
Pr isopropyl 
IPTG isopropyl β-D-thiogalactopyranoside 
IR infra-red 
IUPAC International Union of Pure and Applied Chemistry 
kDa kilo-Daltons 
Km Michaelis constant 
KOD Thermococcus kodakaraensis 
krpm kilo-revolutions per minute 
LB Luria-Bertani 
LC liquid chromatography 
LG leaving group 
m multiplet 
M molar 
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MAP mitogen-activate protein 
MBP myelin basic protein 
mCPBA meta-chloroperbenzoic acid 
Me methyl 
Mes mesityl, 2,4,6-trimethylphenyl 
μF microfarad(s) 
min minute(s) 
MM2 molecular mechanics 2 
MOPS 3-(N-morpholino)propanesulfonic acid 
Moz methoxybenzyloxycarbonyl 
mp melting point 
mRNA messenger RNA 
Ms mesyl/methanesulfonyl 
MS mass spectrum/mass spectrometry/molecular sieves 
m/z mass/charge ratio 
N normal 
N- amino- 
1-Na-PP1 1-tert-butyl-3-naphthylen-1-yl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
NBS N-bromosuccinimide 
n
Bu
 
normal-butyl 
nd not determined 
NETN NP40/EDTA/Tris-HCl/NaCl 
NHS N-hydroxysuccinimide 
NIS N-iodosuccinimide 
1-NM-PP1 1-tert-butyl-3-naphthalen-1-ylmethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
NMR nuclear magnetic resonance 
NMWL nominal molecular weight limit 
NP40 octylphenolpoly(ethyleneglycolether) 
nPKC novel PKC 
NTA nitrilotriacetic acid 
p phospho- 
PAL photoaffinity labelling 
PBS phosphate-buffered saline  
PBST PBS + 0.1% (v/v) Tween-20 
PCR polymerase chain reaction 
PDB Protein Data Bank 
PDK phosphoinositide-dependent protein kinase 
PEG poly(ethylene glycol) 
petrol petroleum ether (40-60 °C) 
Ph phenyl 
pin pinacolate 
PKA protein kinase A 
 9 
PKB protein kinase B 
PKC protein kinase C 
PMA phorbol-12-myristate-13-acetate 
PNBM para-nitrobenzylmesylate 
PP1 1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
ppm parts per million 
PS phosphatidylserine 
PVDF polyvinylidene difluoride 
py pyridine 
q quartet 
[R] reduction 
Rb retinoblastoma protein 
RNA ribonucleic acid 
RNAi RNA interference 
rt room temperature 
s second(s), singlet 
SAR structure-activity relationship 
SDS sodium dodecyl sulfate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
Sf9 Spodoptera frugiperda 
SFK Src-family kinase 
SNAr nucleophilic aromatic substitution 
Src proto-oncogenic tyrosine kinase 
SSS DNA sheared salmon sperm DNA 
t triplet 
T temperature 
TAE tris/acetate/EDTA 
TAMRA tetramethylrhodamine 
Taq Thermus aquaticus 
TBTA tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
t
Bu tert-butyl 
TCEP tris(2-carboxyethyl)phosphine hydrochloride 
Tf triflyl/trifluoromethanesulfonyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS tetramethylsilyl/tetramethylsilane 
TMEDA tetramethylethylenediamine 
TORC target of rapamycin complex 
Tris tris(hydroxymethyl)aminomethane 
Triton X-100 polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether 
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Ts tosyl/p-toluenesulfonyl 
Tween-20 polysorbate 20 
U unit(s) 
UV ultra-violet 
VT variable temperature 
 
Amino acid One-letter code Three-letter code 
alanine A Ala 
arginine R Arg 
asparagine N Asn 
aspartic acid D Asp 
cysteine C Cys 
glutamine Q Gln 
glutamic acid E Glu 
glycine G Gly 
histidine H His 
isoleucine I Ile 
leucine L Leu 
lysine K Lys 
methionine M Met 
phenylalanine F Phe 
proline P Pro 
serine S Ser 
threonine T Thr 
tryptophan W Trp 
tyrosine Y Tyr 
valine V Val 
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1 Introduction 
 
1.1 Kinases 
 
1.1.1 Protein Phosphorylation 
 
Protein phosphorylation is the most common post-translational modification of proteins, with 
approximately 30% of intracellular proteins being phosphorylated to various degrees.
1
 The change 
in phosphorylation state often alters the activity of the protein, contributing to the control of 
important cellular events including cell division. The regulation of phosphorylation is carried out by 
kinases and phosphatases, and these enzymes therefore play a vital role in the normal functioning of 
a cell. Understanding these biological pathways is crucial in developing therapies to combat disease, 
but many complex phosphorylation and dephosphorylation pathways have yet to be fully 
deconvoluted. New strategies are needed to investigate this further, and this research will focus on 
the determination of substrates of protein kinases. 
 
Currently, 518 human protein kinases have been identified.
2
 The catalytic domain of kinases 
contains two spatially-adjacent binding sites for adenosine triphosphate (ATP) and protein 
substrates, allowing the γ-phosphate group from ATP (and occasionally other nucleoside 
triphosphates) to be transferred to a residue on the substrate (Figure 1.1A). The spatial arrangement 
is illustrated in the crystal structure of PKB, which is bound to AMP-PNP, a non-hydrolysable 
version of ATP, and a peptide substrate based on its target site in GSK3 (Figure 1.1B). 
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Figure 1.1 – Proximity of ATP and protein substrate binding sites 
A. Schematic of phosphate transfer from ATP to protein substrate; B. Crystal structure illustrating spatial arrangement 
of ATP and protein substrate binding. PDB entry 1o6k3: PKB bound to GSK3 peptide (Gly-Arg-Pro-Arg-Thr-Thr-Ser-
Phe-Ala-Glu) and AMP-PNP. Image created using AstexViewerTM 
 
 
The transition state of this process is stabilised by hydrogen bonding to the conserved aspartate and 
lysine residues adjacent to the ATP binding site (Figure 1.2). 
 
 
 
Figure 1.2 – Mechanism of phosphorylation4 
 
The catalytic domain of kinases comprises a bi-lobular structure, with an N-terminal β-sheet lobe 
and a C-terminal α-helix. It is in the cleft between these two lobes where both ATP and protein 
substrate bind (Figure 1.3). 
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Figure 1.3 – Representative structures of a kinase catalytic domain5-7 
PDB entry 1hck5: cdk2 bound to ATP. Images created using PDB ProteinWorkshop Viewer and AstexViewerTM 
 
The ATP binding site is highly conserved between kinases. Conversely, the substrate binding site 
has significant variation, resulting in different substrate specificities. Kinases can be grouped 
according to the residue of the substrate that they phosphorylate: serine/threonine, tyrosine, 
histidine/arginine/lysine, cysteine or aspartate/glutamate.
8
 In eukaryotic cells, only serine/threonine, 
tyrosine, histidine and aspartate phosphorylation have been observed. Serine phosphorylation 
accounts for >95% of all phosphorylation, with 3-4% threonine phosphorylation.
9
 Tyrosine 
phosphorylation is less common due to its more dynamic nature, and histidine and aspartate 
phosphorylation are rare in eukaryotic systems.
10
 Tyrosine phosphorylation is fairly well understood, 
a result of effective purification by anti-phosphotyrosine antibodies (Section 1.2).
11
 However, 
despite the high occurrence of phosphorylation by serine/threonine kinases, the substrates of these 
kinases are frequently unknown. Due to their importance as drug targets, kinases have received 
much attention in the literature, resulting in the development of a plethora of techniques for 
identification of their substrates.
12,13
 
 
1.2 Determination of Kinase-Substrate Pairs 
 
Current approaches towards kinase-substrate pair determination include library-based methods, 
whereby substrate phosphorylation is investigated using either protein/peptide arrays
14
 or in-gel 
kinase assays.
15
 Alternatively, physical association between the kinase and substrate can be 
indirectly detected using yeast two-hybrid screens
16
 or phage display fusion libraries.
17
 These high-
throughput methods require small amounts of material, and the DNA can be amplified and 
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sequenced. Yeast two-hybrid screens have the further advantage that they are carried out in intact 
cells (albeit in yeast) and therefore may only find biologically relevant substrates. 
 
Affinity chromatography exploits the physical association between the kinase and its substrates by 
attaching the kinase to a solid support and isolating any proteins that bind.
13
 However this 
interaction is transient and not stable, making it difficult to detect low-abundance substrates, even 
when using significant quantities of kinase. Furthermore, this technique cannot distinguish 
substrate-binding from other associative interactions. A similar approach uses phospho-specific 
antibodies, raised against the consensus sequence of the kinase (if known). However, although this 
has proved successful for phosphotyrosine, phosphorylated serine and threonine residues generally 
have lower immunogenicity, resulting in lower specificity and affinity of the antibody.
13
 
 
The majority of substrate-determination methods performed in intact cells require the removal of 
kinase activity from the system, either permanently by genetic modification
17
, long-term by RNA 
interference (RNAi)
18
 or short-term by direct inhibition of the kinase.
19
 Genetic modification-
induced knock-out is inapplicable to kinases that are vital for survival and provides no information 
regarding the temporal variation of kinase activity. RNAi can be switched off, but has a long 
timescale and often induces non-specific events. Furthermore, both of these techniques completely 
remove the kinase from the cellular environment, and since proteins can also act as scaffolds for 
other proteins, it is difficult to distinguish effects purely resulting from removal of kinase activity. 
Although direct inhibition by small molecules is the most advantageous strategy, most kinase 
inhibitors are ATP competitive, and therefore finding selective inhibitors for specific kinases is a 
significant challenge, although a strategy has been developed to avoid this problem by the use of 
analogue-sensitive kinases (see Section 1.2.1). Furthermore, the recently-developed activity-based 
protein profiling provides a useful tool for the identification of selective kinase inhibitors.
20,21
 
However, even if a completely selective inhibitor is found, the direct substrates of the kinase of 
interest cannot necessarily be identified since kinases are frequently part of signal cascades, and 
therefore all phosphorylation events downstream of the kinase of interest are affected. 
 
The most direct and informative strategies for the detection of the substrates of a specific kinase 
involve modifying the phosphorylation reaction, rather than simply inhibiting it. A variety of 
methods have been developed that use ATP analogues to label kinase substrates for subsequent 
detection and isolation, and this project aims to develop a novel and improved variant. The use of 
analogue-sensitive kinases that specifically bind these ATP analogues is a prerequisite for the 
labelling of only the substrate(s) of the kinase of interest. Methods to achieve this selective kinase-
ATP analogue interaction are discussed in the next section, followed by evaluation of the differing 
strategies for labelling of the protein substrates. 
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1.2.1 Kinase-ATP Interface Modification 
 
As discussed previously, finding kinase-selective inhibitors is challenging, but modification of the 
highly conserved ATP binding site can generate an analogue-sensitive (as-) kinase that can be 
specifically targeted by ATP analogues. Methods for the modification of enzyme-substrate 
interfaces can be classified as either steric complementation, alteration of polar interactions or H-
bonding reversal. 
 
Steric Complementation 
 
Steric complementation is conceptually the more simple strategy as it only requires consideration of 
size and shape. Two sub-classes have been developed, the ‘bump-hole approach’ and the ‘dual 
bump-hole hole-bump approach’ (Figure 1.4). 
 
 
 
Figure 1.4 – Representation of steric complementation22 
 
Bump-Hole Approach 
 
A single alteration of the enzyme-substrate interface is known as the bump-hole approach. In the 
case of a kinase, the ATP binding site is enlarged by the reduction in size of the so-called 
‘gatekeeper’ residue, normally to alanine or glycine, allowing for accommodation of an ATP 
analogue with increased steric bulk. This ATP analogue can only bind to the as-kinase, although the 
as-kinase can still bind ATP. The alternative modification, whereby the size of the kinase binding 
site is diminished to accept only sterically reduced ATP analogues, would not preclude the binding 
of the ATP analogue to wild-type kinases, and therefore this is not a useful strategy. 
 
Shokat first applied the bump hole approach to the kinase-ATP 
interaction of protein tyrosine kinase v-Src.
23
 N
6
-substituted 
derivatives of ATP (A*TPs) were found to bind selectively to 
as-kinases; N
6
-(cyclopentyl) ATP had good affinity for as-
kinase v-Src (V323A, I338A), and there was little affinity for 
wild-type v-Src or other endogenous kinases (Figure 1.5). However, the introduction of two 
mutations resulted in a much lower affinity between N
6
-(cyclopentyl) ATP and v-Src (V323A, 
I338A) than between ATP and v-Src. The subsequent availability of the crystal structures of Src-
 
Figure 1.5 –A*TP 
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family kinases, especially those complexed to A*TPs, aided the design process, allowing for 
selection of single residues for mutation.
24,25
 N
6
-(Benzyl) ATP was shown to have even higher 
affinity for v-Src (I338G) than ATP does for v-Src. Figure 1.6 shows the binding of AMP-PNP (a 
hydrolytically stable mimic of ATP) to related protein c-Src and N
6
-(benzyl) ATP to c-Src 
(T338G).
26
 
 
 
 
Figure 1.6 – Crystal structures of c-Src bound with inhibitors 
A. PDB entry 2src27: AMP-PNP bound to c-Src, T338 residue highlighted; B. PDB entry 1ksw28: N6-(benzyl) ATP 
bound to c-Src (T338G), G338 residue highlighted. Images created using AstexViewerTM 
 
 
A disadvantage of A*TPs is the loss of binding energy resulting from disruption of the H-bonding 
interactions of the exocyclic amine with the hinge region of the kinase.
29
 Furthermore, although 
A*TPs have been effective at the identification of new kinase substrates in vitro, the presence of the 
triphosphate renders them cell-impermeable, hindering application to more biologically-relevant 
systems. Although permeabilisation of cells is possible, the γ-phosphate group of A*TPs is 
hydrolytically labile under these conditions, and no new substrates have yet been identified from 
intact cells using this technique.
30
 
 
Shokat has exploited C3-substituted pyrazolo[3,4-d]pyrimidines as 
alternatives to A*TPs for the selective inhibition of as-kinases 
(Figure 1.7). The exocyclic amine can still participate in H-bonding, 
potentially allowing for higher affinity interactions.
29,31
  
 
The bump-hole approach should be immediately applicable to the majority of kinases simply by 
identifying the gatekeeper residue either by analysis of the crystal structure or by sequence 
alignment with other kinases. However, the kinetic parameters of as-kinases are often altered, with 
as many as 30% of the kinases investigated using this approach being rendered inactive. Methods 
are being devised to identify a second-site suppressor mutation, which can rescue the activity of 
these kinases, and it is hoped that this will improve the extent of the kinome that can be explored 
 
Figure 1.7 – 3-Substituted 
pyrazolo[3,4-d]pyrimidines 
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using steric complementation.
32
 A further inherent issue with this approach is that since ATP is not 
excluded from binding the as-kinase, high affinity of the ATP analogue for the as-kinase is required 
to obtain reasonable efficacy in the cellular environment given the high intracellular ATP 
concentration. This problem can be negated in cell lysates by the depletion of ATP using apyrase, 
but this is not possible in intact cells.
33
 
 
Dual Bump-Hole Hole-Bump Approach 
 
This limitation of competitive binding of ATP can be removed by the introduction of a second steric 
complementation, a concomitant increase in the size of a second residue in the ATP binding site of 
the kinase along with a reduction in the size of the corresponding part of the ATP derivative. Shokat 
initially identified N
4
-(benzyl) ribavirin triphosphate as an inhibitor of v-Src (I338G) (Figure 1.8). 
However, in vitro studies showed that this A*TP could still bind to wild-type kinases due to its 
decreased rigidity coupled with the flexibility of the kinase. Furthermore, it could not transfer the γ-
phosphate group to kinase substrates due to binding in an unproductive orientation.
34
 This illustrates 
the difficulty in obtaining significant alteration of small molecules without affecting the selectivity 
and affinity for the as-kinase. More recently, rigidifying this molecule has successfully identified 5-
amino-4-imidazolcarboxamide riboside (AICAR) triphosphate, a substrate for p38 MAP kinase 
(T106G) but not wild-type p38 MAP kinase.
35
 However, a second mutation in the kinase active site 
has yet to be achieved to generate an entirely orthogonal as-kinase-A*TP pair in which the kinase 
can no longer bind ATP. 
 
 
 
 
Figure 1.8 – Initial work towards dual bump-hole hole-bump inhibitors 
 
Alternative Enzyme-Substrate Interface Modification 
 
An alternative to steric complementation is to alter charge-charge interactions at the enzyme-
substrate interface. Many such methods have been devised, and examples are shown in Figure 1.9. 
The main advantage of this method is that, analogous to the dual bump-hole hole-bump approach, it 
would potentially generate a kinase that has substantially decreased affinity for ATP. However, this 
method has not been applied to the kinase-ATP interaction, perhaps since the key interactions are 
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made between ATP and the peptide backbone of the kinase, which cannot be modified in this 
manner. 
 
 
 
Figure 1.9 – Representation of alteration of polar interactions and H-bonding reversal22 
 
A variety of steric complementation methods have been devised for enzyme-substrate interface 
modification. The bump-hole approach has been extensively developed for kinase-ATP interface 
modification, giving highly as-kinase selective inhibitors. Although this method has a significant 
disadvantage with respect to ATP competition, this has not yet been overcome by either the dual 
bump-hole hole-bump approach or alternative modifications. The bump hole approach is therefore 
currently the method of choice for selective as-kinase inhibition and was therefore used in this 
research. 
 
1.2.2 Specific Labelling of Substrates by as-Kinase-A*TP Pairs 
 
In order to determine the substrates of a kinase using interface modification, this approach must be 
coupled with another technique. The most widely used method is the transfer of a 
32
P- or 
33
P-
radiolabelled γ-phosphate group from [γ-32/33P]A*TP36 and this was first applied successfully to the 
identification of novel substrates of v-Src using [γ-32P]-N6-(benzyl) ATP.37 However, low-abundant 
substrates are hard to detect using this technique. 
 
This technique has therefore been adapted to allow pull-down of the 
substrates phosphorylated by A*TP. The first approach utilised a γ-
thiophosphate group (A*TP-γ-S, Figure 1.10)38, which could be 
alkylated post-transfer.
39
 Incorporation of biotin by this method, a 
molecule which has remarkable affinity for avidin, thus allows facile 
isolation of the substrates post-thiophosphorylation.
40
 However, it is 
necessary to perform the alkylation step at low pH in order to preferentially alkylate the 
thiophosphate over intrinsic nucleophilic residues. Alkylation with p-nitrobenzylmesylate (PNBM) 
 
Figure 1.10 – Shokat’s 
A*TP-γ-S derivative38 
 
 19 
negates the need for a pH change as antibodies raised against the phosphorothioate epitope allow 
for selective purification of the thiophosphorylated substrates.
38,41
 This overall approach has the 
advantage that A*TP-γ-S cannot be used by other ATPases, providing less background reaction 
than A*TP. However, a viable chemical synthesis has not yet been devised, leaving the approach 
dependent on enzymatic methods.
42
 Furthermore, not all kinases can efficiently use A*TP-γ-S, 
which combined with the frequent reduction in catalytic rate that is brought about by the gatekeeper 
mutation can render this technique ineffective, especially for the isolation of low-abundance 
substrates.
38
 
 
When complexed with the kinase, the γ-phosphate of 
ATP has been shown to be partially solvent-exposed, 
allowing this position to be functionalised for the 
transfer of bulky groups to the substrate, including 
those that allow for direct isolation.
43
 This has been 
successfully demonstrated using ATP-γ-biotin, which 
has been purported to have similar activity with serine/threonine kinases to ATP (Figure 1.11).
43-45
 
Although at present this method has not currently been applied to target a specific kinase, 
combining this approach with steric complementation should give an efficient method for the 
isolation of specific substrates, although again the phosphate groups preclude cell permeability. 
 
These methods all utilise a modified γ-phosphate, which is transferred from the A*TP to the 
substrate via the kinase’s catalytic machinery. In order for this to be successful, the triphosphate 
motif must be included to maintain the correct positioning next to the catalytic lysine, thereby 
precluding cell permeability. Although a suitable mimic for the triphosphate may resolve this issue, 
this has yet to be achieved. 
 
This research aims to develop a new substrate isolation technique employing a cell permeable ATP 
analogue containing a cross-linker, designed to result in covalent attachment to the protein substrate 
and provide a method for their facile isolation. Cross-linking would be independent of the 
phosphate transfer mechanism, alignment with the catalytic lysine would no longer be required and 
the cross-linking should therefore not prove reliant on the presence of the triphosphate. A variety of 
photoactivatable groups have been developed for use in cross-linkers to detect biological 
interactions. 
 
 
 
 
Figure 1.11 – A*TP-γ-biotin 
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Cross-Linkers 
 
As discussed above, cross-linkers allow the covalent attachment of one molecule to another, 
producing a permanent physical attachment. If a transient interaction is modified in this way, easier 
detection is achieved, allowing identification of novel associations. However, it is necessary to 
design a system which allows only substrates of the kinase of interest to be cross-linked. Direct 
addition of a highly reactive molecule to a molecular system would undoubtedly result in a variety 
of non-specific reactions. For specific interactions to be detected, it is therefore necessary to either 
unmask the reactive group once it reaches the target, or use a reactive group that is designed to only 
react with the target molecule. 
 
Photoaffinity Labelling 
 
Photoaffinity labelling (PAL) utilises a molecule that contains a masked functionality, which can be 
exposed by photo-irradiation, a more convenient and appropriate method than alternatives such as 
temperature change and the use of chemical reagents (Figure 1.12).
46,47
 
 
 
 
Figure 1.12 – Illustration of photoaffinity labelling 
 
A variety of photoactivatable groups have been developed, with some possessing the necessary 
attributes for use in biological systems; the resulting reactive group needs to have a short half-life to 
limit dissociation and off-target cross-linking, exhibit low reactivity with water and produce a stable 
covalent attachment to allow for isolation. Azides, diazirines and benzophenones fulfil these 
requirements, allowing successful application to the identification of biological interactions.
48
 
 
Photoactivation of azides is the most widely used method for photoaffinity labelling, with the 
resulting nitrene displaying diverse reactivity.
50
 Aryl azides predominate over alkyl azides for use in 
biological systems as they are more thermostable and have a 
longer, less destructive wavelength of activation.
51,52
 The 
appendage of azides to the ATP scaffold allowed the direct in vitro 
cross-linking of kinase-substrate pairs (Figure 1.13).
49
 However, 
both replacement of the triphosphate unit and the engineering of 
as-kinase-specificity into the probe would be required to allow 
identification of substrates of a single target kinase in intact cells. 
 
 
Figure 1.13 – Diazide ATP 
derivative49 
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Although used less than aryl azides, diazirines have also been employed in photoaffinity probes. 
Since the resulting carbenes have much more diverse reactivity than nitrenes, they have the ability 
to react with all 20 amino acid side chains. The development of electron-poor 3-trifluoromethyl-3-
aryl diazirines has allowed the suppression of rearrangement to relatively unreactive and thus 
longer-lived diazo groups, although they have a much more involved synthesis than their 
unsubstituted counterparts.
53
 
 
Benzophenones are advantageous for a number of reasons; their high stability under ambient 
conditions simplifies their synthesis,
47
 cross-linking is more efficient due to possible re-excitation 
of unreacted molecules that have returned to the ground state, and they preferentially insert into 
unreactive C-H bonds over water.
54
 However, hydrogen abstraction is very dependent on the 
approach angle, and therefore successful interactions can only occur with geometrically accessible 
C-H bonds (Figure 1.14). The number of potential reaction sites is further reduced by hindrance 
caused by the steric bulk of the benzophenone functionality compared with other available 
photoaffinity probes. 
 
 
 
Figure 1.14 – Required geometry of attack for H-abstraction by benzophenones54 
 
All three photoactivatable groups discussed allow for UV light-induced cross-linking in biological 
systems. Each functionality has specific advantages and disadvantages, and for the purpose of this 
research aryl azides were considered the most suitable due to their ease of synthesis and amenability 
to flexible positioning. 
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2 Aims 
 
The ultimate goal of this research is to develop a method that would allow the identification of 
unknown substrates of kinases via a novel combination of two substrate discrimination techniques. 
The method should be applicable to any protein kinase and enable application to intact cells for the 
discovery of only biologically relevant substrates. 
 
The first objective is to obtain selective binding of an ATP 
analogue with an as-kinase through steric complementation. A 
panel of 3-substituted pyrazolo[3,4-d]pyrimidines has previously 
been generated in the MRes section of this research (Figure 
2.1).
55*
 Good selectivity over the wild-type kinase and other 
cellular kinases is necessary and a high binding efficiency is 
required to compensate for the high intracellular concentration of ATP. 
 
The second objective is to synthesise a photoaffinity probe that is 
capable of cross-linking to wild-type kinase substrates. This will 
require optimisation of positioning of the photoactivatable group 
(Figure 2.2). 
 
Once the C3 substituent and cross-linking have been individually 
optimised, the third objective is to combine these to allow for 
application of selective cross-linking with as-kinases (Figure 2.3). 
 
The fourth objective is to carry out cross-linking in cell lysates and 
ultimately in intact cells to potentially identify new, biologically 
relevant kinase substrates. The attachment of the probe to the substrate allows isolation via affinity 
chromatography using solid-supported as-kinase. 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
 
 
Figure 2.1 – as-Kinase-
selective inhibitor 
 
 
 
Figure 2.2 – Photoaffinity 
probe 
 
 
 
Figure 2.3 – as-Kinase-
selective photoaffinity probe 
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3 Protein Generation 
 
3.1 Protein Kinase C 
 
Protein kinase C (PKC) is a serine/threonine kinase that phosphorylates serine and threonine side 
chains that are typically surrounded by basic residues in the protein substrates. This kinase has been 
shown to have a role in signal transduction pathways regulating gene expression, cell migration, cell 
growth and differentiation.
56
 
 
Several isozymes of the PKC have so far been identified, as well as at least three PKC-related 
kinases.
57
 The core PKC family can be further classified into three sub-families depending on the 
signalling molecules that regulate their activities:
58,59
 
- classical/conventional PKCs (cPKCs) – activated by 1,2-sn-diacylglycerol (DAG), 
phosphatidylserine (PS) and Ca
2+
 
- novel PKCs (nPKCs) – activated by DAG and PS, insensitive to Ca2+ 
- atypical PKCs (aPKCs) – activated by PS, insensitive to DAG and Ca2+ 
PKC is further regulated by an auto-inhibitory pseudosubstrate, part of its regulatory domain that 
contains basic residues, mimicking substrates of PKC and thus blocking the substrate binding site.
60
 
 
The primary structures of the isozymes in the PKC family show high similarity within sub-families, 
especially in the highly conserved catalytic region (Figure 3.1). 
 
 
 
Figure 3.1 – Structural similarity of the PKC family59,61 
 
This research focussed on PKCα, a conventional PKC. There are three phosphorylation sites on the 
catalytic domain of cPKCs that are required to be phosphorylated for the kinase to become active, 
which correspond to T497, T638 and S657 in PKCα (Figure 3.1).62 The suggested mechanism 
involves the phosphorylation of the T497 residue on the activation loop of PKCα by the upstream 
kinase, usually PDK1. The protein is then phosphorylated by the TORC2 complex at the turn motif 
site T638 and the hydrophobic C-terminal S657 site.
63
 At intermediate stages, the kinase is in a 
open form and is vulnerable to dephosphorylation.
64
 The full complement of phosphorylation 
promotes correct folding of the kinase, making it resistant to dephosphorylation. 
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Most kinases are regulated by phosphorylation of the activation loop, which contains a conserved 
Asp-Phe-Gly (DFG) motif.
65
 The phosphorylation state alters the conformation of the activation 
loop, with the extreme conformers being ‘DFG-in’ in the active phosphorylated kinase, which can 
bind ATP, and ‘DFG-out’ in the unphosphorylated kinase, where the activation loop occludes the 
ATP binding site, resulting in an inactive kinase. 
 
3.1.1 Protein Expression in Mammalian Cells 
 
A construct for the expression of bovine His6-tagged PKCα in mammalian cells was obtained from 
the Parker lab (N-His6-PKCα-pKS1).
64
 The presence of a His6-tag allows the isolation of the fused 
protein by affinity chromatography using solid-supported Ni-nitrilotriacetic acid (Ni-NTA) 
Sepharose
®
 and elution with imidazole, which can be removed if necessary by dialysis or filtration. 
The advantage of this tag is its small size (6 residues), resulting in minimal interference with 
enzyme activity without the possible need for removal post-purification. 
 
It was necessary to generate a construct for the expression of an as-PKCα and the choice of 
mutation of the gatekeeper residue to either glycine or alanine required the consideration of two 
factors: alanine usually minimises conformational alterations, which could result in decreased or 
altered protein function, whereas glycine generally confers higher selectivity over the wild-type 
protein.
66
 In previous work glycine was selected and a construct for the mammalian expression of 
His6-tagged PKCα (M417G) was successfully generated.
55*
 However, a subsequent study reported 
that PKCα (M417G) has ca. five-fold lower activity than PKCα, possibly due to a conformational 
change of the protein that could potentially affect the substrate specificity.
67
 However, PKCα 
(M417A) was shown to have comparable activity to PKCα, and was also shown to be selectively 
inhibited by A*TPs.
67
 PKCα (M417A) therefore represented a more suitable gatekeeper mutant for 
use in this research, requiring the generation of a suitable construct for expression. 
 
Generation of N-His6-PKCα (M417A) Constructs 
 
Two-step polymerase chain reaction (PCR)-based site-directed mutagenesis was used to introduce 
the gatekeeper mutation (Figure 3.2). This technique employs sense and antisense primers ( ) 
along with sense and antisense mutagenic primers ( ). The latter are complementary to the sense 
and antisense strands except for the mutated base(s). Two separate reactions are performed in the 
first round, generating two mutant strands, shorter than the original fragment, overlapping at the 
region coded for by the mutagenic primers. The second round is a single reaction, which generates  
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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 the complete mutated strand. This is then 
amplified by further rounds, isolated and 
subsequently subcloned into the appropriate 
vector to generate the final construct. 
 
Conditions for the first round of PCR 
required extensive optimisation. Initially, 
the previously prepared construct N-His6-
PKCα-pcDNA355* was used as the template, 
but none of the attempts were successful for 
either strand (Table 3.1, Entries 1-6). This 
failure was unexpected as similar simple 
conditions were used previously for the 
introduction of the corresponding M417G 
mutation
55*
, and repetition of this reaction 
using the corresponding M417G 3’ 
mutagenic primer for generating the 5’ 
strand proved successful (Entry 7). Due to 
the high similarity of the M417G and 
M417A mutagenic primers, it was 
unknown as to the reason for the failure of 
PCR with the latter primer. In order to increase the chances of success, N-His6-PKCα(M417G)-
pcDNA3 was used as the template as there were fewer base pair mismatches between the template 
and mutant primer since the engineered SnaBI restriction site was already present. Standard 
conditions immediately gave the 5’ strand (Entry 8) but significant optimisation still did not yield 
the 3’ strand (Entries 9-16). This suggested that the M417A 5(1)’ mutagenic primer may have 
additional secondary structure and therefore a new mutagenic primer was purchased (M417A 5’(2) 
mutagenic primer), which required little optimisation to successfully give the 3’ strand (Table 3.1, 
Entry 18). 
 
 
 
 
 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
 
Figure 3.2 – Schematic of two-step site-directed 
mutagenesis 
 
 26 
Table 3.1 – Conditions for first round of PCRa 
 
Entry Primers Template (μL) Enzyme Alterations Timing Result 
1 5’, 3’ wt (0.01) KOD - A - 
2 5’, 3’ wt (0.01) KOD 2.5 mM MgCl2 A - 
3 5’, 3’ wt (0.01) KOD 1 mM MgCl2 B - 
4 5’, 3’ wt (0.01) KOD 1 mM MgCl2 B - 
5 5’, 3’ wt (0.01) KOD  B - 
6 5’, 3’ wt (0.01) KOD 5 mM MgCl2 B - 
7 5’(long), 3’ wt (0.01) KOD - C -b 
8 5’(long), 3’ M417G (0.01) KOD - C 5’ strand only 
9 3’(long) M417G (0.01) KOD 1 mM MgCl2 D - 
10 3’(long) M417G (0.01) KOD - D - 
11 3’(long) M417G (0.01) KOD 5 mM MgCl2 D - 
12 3’(long) M417G (0.01) KOD 10 mM MgCl2 D - 
13 3’(long) M417G (0.04) KOD - D - 
14 3’(long) M417G (0.01) KOD KOD buffer 2 D - 
15 3’(long) M417G (0.01) KOD+Taq - D - 
16 3’(long) M417G (0.01) KOD+Taq  E - 
17c 3’(long) M417G (0.01) KOD 5 mM MgCl2 D - 
18c 3’(long) M417G (0.01) KOD - D 3’ strand 
 
a. Using M417A 5’(1) and M417A 3’ mutagenic primers; b. Conditions only successful for 5’ strand of PKCα using 
M417G 3’ mutagenic primer55*; cUsed M417A 5’(2) mutagenic primer 
A: denaturing: 15 s at 98 C; annealing: 2 s at 55 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
B: denaturing: 30 s at 98 C; annealing: 1 min at 55 C; polymerising: 30 s at 72 C; ramp rate 4 °C s-1; 30 cycles 
C: denaturing: 15 s at 98 C; annealing: 2 s at 39 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
D: denaturing: 15 s at 98 C; annealing: 2 s at 36 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
E: denaturing: 15 s at 98 C; annealing: 2 s at 36 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 30 cycles 
 
5’ primer: 5’-AATACGACTCACTATAG-3’;  
5’(long) primer: 5’-TCGAAATTAATACGACTCACTATAGGGAGACCC-3’ 
3’ primer: 5’-ATTTAGGTGACACTATAG-3’ 
3’(long) primer: 5’-GCATTTAGGTGACACTATAGAATAGGG-3’ 
M417A 5’(1) mutagenic primer: 5’-GTACTTCGTCGCGGAGTACGTAAACGGCGGGGA-3’ 
M417A 5’(2) mutagenic primer: 5’-CCGGCTGTACTTCGTCGCGGAGTACGTAAACG-3’ 
M417A 3’ mutagenic primer: 5’-GGTCCCCGCCGTTTACGTACTCCGCGACGAAGT-3’ 
M417G 3’ mutagenic primer: 5’-GGTCCCCGCCGTTTACGTACTCCCCGACGAAGT-3’ 
(GC and A/T are mutated bases, GCG/CGC/CCC is the codon for the gatekeeper residue, TACGTA is the SnaBI restriction 
site) 
 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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The second round of PCR required limited optimisation to generate the full length PCR product 
(Table 3.2, Entries 1-5). The EcoRI/XbaI fragment was ligated into pcDNA3 and the sequence of N-
His6-PKCα(M417A)-pcDNA3 was verified (see Figure 13.1). 
 
Table 3.2 – Conditions for second round of PCR 
 
Entry Primers Template/μL Enzyme Alterations Timing Successful 
1 5’(long), 3’ 0.01 KOD - A - 
2 5’(long), 3’ 0.2 KOD - A - 
3 5’, 3’ 0.2 KOD - B - 
4 5’, 3’ 0.2 KOD 5 mM MgCl2 B - 
5 5’, 3’ 0.2 KOD KOD buffer 2 B Yes 
 
A: denaturing: 15 s at 98 C; annealing: 2 s at 39 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
B: denaturing: 15 s at 98 C; annealing: 2 s at 55 C; polymerising: 20 s at 72 C; ramp rate 2 °C s-1; 25 cycles 
 
5’ primer: 5’-AATACGACTCACTATAG-3’;  
5’(long) primer: 5’-TCGAAATTAATACGACTCACTATAGGGAGACCC-3’ 
3’ primer: 5’-ATTTAGGTGACACTATAG-3’ 
 
The EcoRI/NotI insert was then subcloned into pKS1, giving N-His6-PKCα(M417A)-pKS1, 
providing an alternative expression vector for later optimisation. 
 
Two separate sets of constructs (derived from PKS1 and pcDNA3 expression vectors) were now 
available for the expression of His6-tagged PKCα, PKCα (M417G) and PKCα (M417A) in 
mammalian cells. However, previous attempts towards the expression of wild-type His6-PKCα 
using these constructs did not yield much protein.
55*
 PKCα is a fairly large protein (ca. 80 kDa) and 
it is known that shorter proteins tend to have higher-yielding expression, suggesting that the 
expression of the isolated catalytic domain of PKCα might be beneficial. Catalytic PKCα is 
constitutively active, which has the practical advantage of allowing for simpler and potentially less 
variable assays. However, the isolated catalytic domain has been shown to have a partially altered 
substrate specificity,
68,69
 suggesting that use of the full-length kinase would yield more biologically 
relevant results. Furthermore, the catalytic domain is less stable due to a greater susceptibility to 
dephosphorylation. It was therefore prudent to attempt the expression of both full-length and 
catalytic kinases (ca. 40 kDa) as this would give the project a greater chance of success, although 
any new substrates found with the isolated catalytic domain would require validation with the full 
length kinase. 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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In order to generate a construct for the expression of His6-tagged cat. PKCα directly from N-His6-
PKCα-pcDNA3, it would have been necessary to insert the section coding for the catalytic domain 
immediately after the His6-tag (Figure 3.3A). However, this strategy was not viable as no suitable 
restriction sites were present after the 3’ end of the His6-tag. It was therefore necessary to first 
remove the tag and reinsert it separately (Figure 3.3B). This presented an opportunity to switch to 
the alternative Strep-tag for purification as it has been shown that this tag generally allows the 
isolation of higher-purity proteins than the His6-tag.
70
 The Strep-tag is of a similar size to the His6-
tag (8 residues), has strong binding to streptavidin and the protein can be eluted by the addition of 
biotin.
71
 
 
 
 
Figure 3.3 – Strategies for generating expression vectors for cat. PKCα 
A. Insertion of cat. PKCα coding region into N-His6-PKCα-pcDNA3; B. Insertion of tag into pcDNA3 followed by 
insertion of cat. PKCα coding region 
 
 
Generation of N-Strep-PKCα Constructs 
 
In order to be able to transfer only the coding 
region for the catalytic domain of PKCα, it 
was necessary to use site-directed 
mutagenesis to introduce a restriction site just 
before the 5’ end and at the same time, the 3’ 
XbaI site was moved so that it was directly 
after the 3’ end of the coding region, 
reducing the length of the PCR product and 
thereby increasing the chances of success. 
The introduction of restriction sites at the 
termini of the coding region can be carried 
out using one-step site-directed mutagenesis (Figure 3.4). Due to the simplicity of the PCR that was 
required (compared to two-step site-directed mutagenesis, see Figure 3.2), and the hope that the 
 
Figure 3.4 – Introduction of terminal restriction 
sites via one-step site-directed mutagenesis 
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Strep-tag would provide higher purity proteins, it was considered prudent to simultaneously 
generate the full-length kinases by use of an alternative 5’ oligonucleotide, to allow the transferral 
of the coding region for the full-length untagged kinase. 
 
One-step site-directed mutageneses were carried out using N-His6-PKCα(M417A)-pcDNA3, N-His6-
PKCα(M417A)-pcDNA3 or N-His6-PKCα(M417A)-pcDNA3 as a template along with both 5’ and 3’ 
mutagenic primers under otherwise standard conditions (Table 3.3). All six PCR reactions to make 
the full length and catalytic fragments appeared successful, and the fragments were ligated into 
pcDNA3 using KpnI/XbaI. 
 
Table 3.3 – Conditions for PCR to generate full length and catalytic PKCα coding regions 
 
Template/μL Enzyme Timing 
0.02 KOD A 
 
A: denaturing: 15 s at 98 C; annealing: 2 s at 44 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
 
5’ primer (catalytic): 5’-GGGGGTACCCTCACGGACTTCAACTTCCTCATGG-3’ 
5’ primer (full length): 5’-GGGGGTACCTTCCCGGCCGCCGAGCCGG-3’ 
3’ primer: 5’-GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’ 
 
(TCA is the reverse complement of the stop codon, orange text is mutated bases, GGTACC/GGTACC is the KpnI 
restriction site, TCTAGA is the XbaI restriction site) 
 
The sequences were confirmed for all the constructs (see Figure 13.2, Figure 13.3) except for the 
DNA coding for full-length PKCα (M417A), which had a two-base pair deletion at the 3’ end of the 
coding region (PKCα(M417A)-pcDNA3*). A second attempt was carried out, and the same bases 
were found to have been deleted. Rather than repeat the PCR a third time, the error-free Kpn2I/SfuI 
region containing the mutated gatekeeper A417 residue of PKCα(M417A)-pcDNA3* was subcloned 
into cat.PKCα-pcDNA3 and the sequence of PKCα(M417A)-pcDNA3 confirmed (Figure 13.3). 
 
At this point, constructs containing all six PKCα coding regions had been generated, and the next 
step was to generate a construct containing both the start codon and Strep-tag into which the PKCα 
genes could be inserted. Oligonucleotides were designed containing both these elements along with 
the incorporation of partial restriction sites at the termini, mimicking digestion by the corresponding 
restriction enzymes and allowing for immediate ligation into the vector (Figure 3.5). 
 
sense strand: 5’-AGCTTCACCATGTGGAGCCACCCGCAGTTCGAAAAAGGGGGTAC-3’ 
antisense strand: 5’-CCCCTTTTTCGAACTGCGGGTGGCTCCACATGGTGA-3’ 
 
Figure 3.5 – Strep oligonucleotides 
 (ATG is the start codon, TGGAGCCACCCGCAGTTCGAAAAAGGG codes for the Strep-tag, A/AGCTT is the HindIII 
restriction site, TTCGAA is the SfuI restriction site, GGTAC/C is the KpnI restriction site) 
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Insertion of the Strep oligonucleotides directly into pcDNA3 
did not prove successful, most likely due to the close 
proximity of the HindIII and KpnI restriction sites in the 
polylinker of the vector (Figure 3.6). HindIII has a 
significantly reduced efficiency when cutting at the terminus of DNA, and therefore a sequential 
digest was attempted, again with no success. As an 
alternative strategy, the Strep oligonucleotides were ligated 
into a pcDNA3 construct containing a HindIII/XbaI insert 
(cdk2-pcDNA3), which also contained a KpnI site in the cdk2 
insert (Figure 3.7). This strategy was successful, and the 
sequence of Strep-pcDNA3 was confirmed (see Figure 13.4). 
 
The next step was to subclone the KpnI/XbaI inserts of 
PKCα-pcDNA3, PKCα(M417G)-pcDNA3, PKCα(M417A)-
pcDNA3, cat.PKCα-pcDNA3, cat.PKCα(M417G)-pcDNA3 
and cat.PKCα(M417A)-pcDNA3 into Strep-pcDNA3. 
However, initial attempts to digest the constructs with KpnI 
and XbaI failed to produce an insert, even when attempting sequential digests. Analysis of the 
sequences revealed that a GATC site had been introduced at 
the start of the XbaI restriction site (Figure 3.8). The 
majority of E. coli strains express Dam, an enzyme which 
uses S-adenosylmethionine to methylate an adenine base in 
regions of DNA with the sequence GATC, in this case 
blocking the XbaI site.
72
 The constructs were therefore used to transform Dam(-) E. coli strain 
GM2163 before purification. This allowed the KpnI/XbaI regions to be ligated into Strep-pcDNA3, 
generating N-Strep-PKCα-pcDNA3, N-Strep-PKCα(M417G)-pcDNA3, N-Strep-PKCα(M417A)-
pcDNA3, N-Strep-cat.PKCα-pcDNA3, N-Strep-cat.PKCα(M417G)-pcDNA3 and N-Strep-
cat.PKCα(M417A)-pcDNA3 (see Figure 13.5, Figure 13.6). Constructs for the expression of full 
length His6-tagged proteins and full length and catalytic Strep-tagged proteins in mammalian cells 
were therefore available. 
 
The next stage was to express the proteins in mammalian cells. However, low levels of protein 
expression had previously been observed following transfection of COS7 cells with N-His6-PKCα-
pKS1, N-His6-PKCα(M417G)-pKS1, N-His6-PKCα-pcDNA3 and N-His6-PKCα(M417G)-
5’-CCCAAGCTTGGTACCGAG-3’ 
Figure 3.6 – pcDNA3 sequence 
(AAGCTT is the HindIII restriction site, 
GGTACC is the KpnI restriction site) 
 
 
Figure 3.7 – Generation of Strep 
plasmids 
 
5’-AGCGCGGTATGATCTAGA-3’ 
 
Figure 3.8 – Dam methylation site 
 (TGA is the stop codon, TCTAGA is the 
XbaI restriction site, GATC is the Dam 
methylation site) 
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pcDNA3.
55*
 The reason for this was unclear and it was therefore necessary to investigate all the 
factors that could contribute to low expression. 
 
Lipofectamine
TM
 LTX Transfection 
 
The first investigation focussed on the viability of the plasmids. Although expensive, 
Lipofectamine
TM
 LTX is a widely used reagent for high-efficiency mammalian cell transfection, 
escorting the plasmid into the cells by encapsulation in cationic liposomes. Transfections of COS7 
cells were then carried out in a 24-well plate format using all 12 available constructs for expression 
of tagged-PKCα as well as various control plasmids: 
 
 His6-tagged proteins in both pKS1 and pcDNA3 (N-His6-PKCα-pKS1, control N-His6-PKCα-
pKS1 (known to express well), N-His6-PKCα(M417G)-pKS1, N-His6-PKCα(M417A)-pKS1, 
N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-pcDNA3, N-His6-PKCα(M417A)-pcDNA3) 
 catalytic and full-length Strep-tagged proteins (N-Strep-PKCα-pcDNA3, N-Strep-
PKCα(M417G)-pcDNA3, N-Strep-PKCα(M417A)-pcDNA3, N-Strep-cat.PKCα-pcDNA3, N-
Strep-cat.PKCα(M417G)-pcDNA3, N-Strep-cat.PKCα(M417A)-pcDNA3) 
 GFP-tagged PKCα (PKCα-pEGFP-C1) and GFP for quick analysis of transfection 
efficiency via fluorescence microscopy 
 
Initial fluorescence microscopy analysis showed successful, albeit low, expression of both GFP-
tagged PKCα and GFP. The observed expression of GFP was slightly higher (in ca. 10% of cells) 
than the GFP-tagged PKCα (in ca. 5% of cells), as expected due to the better expression of smaller 
proteins. The cells transfected with the 15 prepared plasmids were therefore lysed and the 
expression analysed using Western blotting. MC5, a standard PKCα antibody that binds to the 
regulatory domain, allowed detection of full-length proteins. However, differentiation of the tagged 
protein from the endogenously expressed kinase was not possible due to the low molecular weight 
of the His6- and Strep-tags, and an anti-His antibody was therefore used to confirm the expression 
of the His-tagged proteins. Although no anti-Strep antibody was available to allow for confirmation 
of the full length Strep-tagged proteins, expression of the catalytic kinases should have been 
detected by a PKCα C-terminal antibody. However, only the larger, endogenous protein was 
observed and it was postulated that the C-terminal antibody binds to an epitope that was no longer 
present in the catalytic proteins. It was possible to instead use an anti-phospho antibody, PKCα 
pS657/pT658, to confirm the expression of these kinases. 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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Nine out of the twelve prepared constructs were conclusively shown to be viable for the expression 
of tagged PKCα; the remaining three full length Strep-tagged kinases showed expression of PKCα 
over control levels, although no conclusive proof of exogenous expression was obtained. Variation 
in levels of expression from each plasmid was observed, although this did not appear to follow a 
specific trend, suggesting variation in transfection efficiency and quality of individual plasmid 
preparations as the likely causes. However, preparations of the constructs that had previously shown 
poor expression via calcium phosphate precipitation showed the highest expression of all the 
plasmids transfected using Lipofectamine
TM
-LTX, comparable to the expression of plasmid 
preparations known to express well in COS7 cells.
73
 It was therefore theorised that transfection 
efficiency (rather than plasmid quality, promotion ability or protein expression) was the major 
factor in the poor expression observed previously.
55*
 Since Lipofectamine
TM
-LTX is expensive and 
did not appear to give significantly enhanced expression over levels previously observed by calcium 
phosphate precipitation, the latter method was therefore used to further optimise transfection. 
 
Calcium Phosphate Precipitation 
 
Calcium phosphate precipitation for mammalian cell transfection is widely used, mainly due to the 
availability and low cost of the required components. This technique involves the precipitation of 
the DNA onto the cell surface by combination with calcium phosphate, although the mechanism of 
the subsequent DNA uptake is not fully understood. 
 
Two buffers are generally used for this purpose, BES-buffered saline (BBS) and Hepes-buffered 
saline (HBS).
74
 HBS is the most widely used, whereas BES maintains pH stability with changes in 
CO2 concentration. Both buffers were used for the transfection of Histone H2B-GFP, which was 
chosen to again allow quick analysis via fluorescence microscopy, with the localisation of the GFP 
to the nucleus by its attachment to histone also aiding detection. Although neither buffer showed 
substantial expression (ca. 5%), this was comparable to the transfection efficiency observed using 
Lipofectamine
TM
-LTX. The simpler and potentially less variable HBS protocol appeared to give 
slightly superior expression and was therefore selected for use in further transfection optimisation. 
 
Anecdotal evidence has suggested that both plate size and DNA concentration can have an effect on 
transfection efficiency. A range of plate sizes were used for the transfection of COS7 cells with 
varying amounts of Histone H2B-GFP, although no significant difference in expression levels was 
observed. 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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High cell density is also known to have a detrimental effect on DNA uptake and protein expression 
efficiency. PKCα-GFP was also used for this transfection study as it should give more relevant 
information for the expression of PKCα, but still allow for rapid analysis. A day after transfection, 
the cells were transferred to a larger plate. This did appear to have a positive impact on the 
expression levels, giving ca. 10% expression of both GFP-tagged proteins (Figure 3.9). 
 
 
 
Figure 3.9 – Highest transfection efficiency obtained by calcium phosphate precipitation 
 
Although the above transfection optimisation had a small positive impact on expression levels, this 
was not deemed sufficient for the generation of sufficient quantities of the multiple kinases required 
without the use of an impractical number of cells. Based on these results, it was decided to try an 
alternative, potentially higher yielding albeit harsher method of transfection to enable the 
continuing use of the mammalian constructs generated. 
 
Electroporation 
 
Electroporation has been shown to give high levels of protein expression in mammalian cells.
75
 
However, for each cell line it is necessary to find conditions that give high transfection efficiency 
without significant cell death. Fortunately, conditions for the expression of PKCα in COS7 cells had 
previously been reported.
64
 These conditions were thus used for electroporation for the expression 
of both Histone H2B-GFP and N-His6-PKCα-pcDNA3. The latter was chosen as an anti-His 
antibody was available for analysis of expression and this plasmid preparation gave the highest 
protein expression of all constructs tested in the Lipofectamine
TM
-LTX study. Since it is known that 
the use of carrier DNA can increase the uptake of the reporter plasmid, the effect of addition of 
sheared salmon sperm DNA (SSS DNA) was also investigated.
76
 Electroporation of reporter 
plasmid with or without carrier DNA was therefore attempted in COS7 cells. Analysis by 
fluorescence microscopy showed a reasonable level of expression of histone H2B-GFP in the cells 
without carrier DNA (ca. 30-40%, Figure 3.10A), with a significant reduction in expression when 
carrier DNA was added (ca. 10%) along with a slight reduction in cell viability (Figure 3.10B). 
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Figure 3.10 – Analysis of electroporation efficiency 
 
The cells electroporated with N-His6-PKCα-pcDNA3 were lysed and the protein purified via 
chelation to solid supported Ni-NTA Sepharose
®
. Good expression was obtained for the cells 
electroporated without carrier DNA, which again was shown to reduce protein expression (Figure 
3.11A). However, elution using imidazole was not successful, even at concentrations as high as 200 
mM (Figure 3.11B), with the majority of the protein remaining bound to the beads (Figure 3.11C). 
 
 
 
Figure 3.11 – Western blots of expression and purified N-His6-PKCα 
A. lysate; B. elution; C. Solid-supported Ni-NTA Sepharose® post-elution 
 
Although elution proved problematic, the next step would be to attempt the expression of the Strep-
tagged proteins as these were expected to generate higher purity proteins and would be unlikely to 
have similar issues with elution. However, electroporation proved impractical due to the large 
quantity of cells required, resulting from the significant cell death inherent to this technique. 
Furthermore, parallel work on an alternative expression system was proving more promising and 
therefore further work towards mammalian expression of PKCα was put on hold. However, these 
constructs should enable subsequent substrate identification work in intact mammalian cells if the 
photoaffinity labelling proves effective in vitro. 
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3.1.2 Protein Expression in Insect Cells 
 
Generation of Baculovirus Transfer Plasmids for Expression of N-His6-PKCα 
 
The problems encountered over the course of the optimisation of mammalian cell expression 
prompted investigation into alternative expression systems. Both insect and bacterial expression are 
available for the more robust expression of larger quantities of protein. However, although bacterial 
expression is the more widely used technique, PKCα is not expressed in an active form due to the 
absence of upstream kinases PDK1 and TORC2.
77
 Conversely, insect cells have proved successful 
in expressing fully phosphorylated PKCα, and this is the main method for expression of 
commercially available kinase.
78
 Insect cell expression requires the generation of a baculovirus 
containing the DNA coding for the protein of interest, which causes efficient infection and 
subsequent high level expression of the target protein (up to 40% of the total protein expressed) in 
insect cells. 
 
Baculovector pAcC4 was chosen as suitable restriction sites 
were present (NcoI at the 5’ end and XbaI at the 3’ end) that 
allowed for direct insertion of the His6-tagged PKCα coding 
region from N-His6-PKCα-pcDNA3 and the corresponding 
mutant plasmids. However, an additional NcoI site was present 
in the PKCα coding region, necessitating the use of a 3-way 
ligation (Figure 3.12). Numerous attempts were made at the 
ligation, but none were successful and the use of fresh plasmid 
preparations of both vector and PKCα construct did not improve the situation. Furthermore, 
attempts using this vector in unrelated two-way ligations also proved unsuccessful, and a new 
baculovector was therefore sought. 
 
Generation of pBacPAK-GST Baculovirus Transfer Plasmids 
 
Baculovector pBacPAK-GST
79
 was obtained as this would allow generation of N-His6-GST tagged 
proteins. Glutathione-S-transferase is an enzyme which binds tightly to solid-supported glutathione 
and generally gives the highest purity of all simple expression methods. Furthermore, GST has been 
shown to impart increased solubility on proteins to which it is tagged. However, this relatively large 
tag (26 kDa) results in a substantial increase in protein size, resulting in lower yields. For this 
reason, it was considered important to attempt expression of the catalytic domain of PKCα as well 
as the full length kinase. However, pBacPAK-GST contains a human rhinovirus protease (HRV) 
 
Figure 3.12 – Schematic of 3-
way ligation 
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cleavage site after the GST tag, allowing for cleavage of the protein from the solid support post-
purification if necessary. 
 
Using the same conditions as before (see Table 3.3), one-step site-directed mutagenesis was 
employed to introduce a XhoI restriction site before at the 5’ end of the required coding region of 
either N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-pcDNA3 or N-His6-PKCα(M417A)-pcDNA3 
and again the XbaI site was moved just after the 3’ end as for the Strep-tagged proteins (Figure 
3.13). All six PCR reactions were successful, the PCR products ligated into pBacPAK-GST and the 
sequences of the transfer plasmids confirmed (see Figure 13.7, Figure 13.8). 
 
5’ primer (catalytic): 5’-GGGCTCGAGTGAAGCTCACGGACTTCAACTTCCTCATGG-3’ 
5’ primer (full length): 5’-GGGCTCGAGACGTCTTCCCGGCCGCCGAGCCGG-3’ 
3’ primer: 5’-GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’ 
 
Figure 3.13 – Oligonucleotides for the generation of GST fusions of full length and catalytic PKCα 
(TCA is the reverse complement of the stop codon, orange text is mutated bases, CTCGAG/CTCGAG is the XhoI 
restriction site, TCTAGA is the XbaI restriction site) 
 
 
Baculovirus Recombination and Protein Expression 
 
In order to generate the complete baculoviruses, all six transfer plasmids were recombined with 
BaculoGold
TM
 in Sf9 (insect) cells. Successful recombination was shown for five out of the six 
transfer plasmids by positive protein expression in a test infection (Figure 3.14A). However, 
recombination with cat.PKCα(M417A)-pBacPAK-GST was not successful after two attempts. After 
amplification, protein expression using the five baculoviruses generated proved successful and GST 
purification yielded high-purity tagged kinases (Figure 3.14B). Since baculoviruses for the 
expression of fusions of the isolated catalytic domain were prepared for use in the event that the full 
length kinases had poor expression, and all three full length kinases expressed well, recombination 
of the plasmid for the generation of cat. PKCα (M417A) was not reattempted. 
 
 
 
 37 
 
 
Figure 3.14 – Expression of baculoviruses in Sf9 cells 
A. Western blot on proteins from infected 3.5 cm plate probing with anti-GST antibody; B. InstantBlueTM stained gels 
of GST-purified proteins from infected 175 cm2 flasks 
 
 
Elution and Tag Removal 
 
The kinases were purified by binding them to solid-supported glutathione. Although the presence of 
this solid support would not inhibit kinase activity, difficulty in transferring accurate and consistent 
quantities of bound kinase required its removal from the solid support. The preferred option was to 
cleave the protein from the GST and therefore His6-tagged HRV-3C was purchased (which could be 
removed post-cleavage by His-purification). However, after optimisation of buffer and kinase to 
protease ratio, no significant cleavage was observed. It was therefore necessary to change strategy 
to glutathione elution, which was successful under standard conditions. The buffer was then 
replaced using a filtration device under centrifugation to remove the high concentration of 
glutathione. 
 
Initial [γ-32P]-ATP Assay to Measure Specific Activities 
 
In order to check that the full length GST-tagged 
kinases were active, their specific activities were 
measured in a kinase assay utilising [γ-32P]ATP to 
allow for subsequent quantitative analysis of 
phosphorylation. Furthermore, protamine sulfate 
was used as this substrate negates the need for lipid-
activation of the kinase, simplifying the assay 
conditions. The results suggested that all three 
kinases had very low activity compared to the 
normal PKCα activity of ca. 5000 U mg-1 (Graph 
 
 
Graph 3.1 – Specific Activities of Kinases 
Results shown are an average of 3 assays, errors 
shown are standard deviations 
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3.1). It was postulated that this may be due to insufficient phosphorylation of the high levels of 
expressed protein by the upstream kinase PDK1 endogenous to insect cells and this was 
investigated further. 
 
Analysis of Protein Phosphorylation 
 
Western blots were carried out using anti-phospho-PKCα antibodies to the three important 
phosphorylation sites (Figure 3.15). This suggested that the full length kinases were phosphorylated, 
at least to some extent. However, the catalytic kinases, which had a much higher expression than 
the full length kinases, showed much lower levels of phosphorylation. 
 
 
 
Figure 3.15 – Analysis of extent of phosphorylation of GST-tagged catalytic and full length PKCα 
and cleaved full length PKCα 
 
A. Coomassie®-stained gel; B. anti-pT497; C. anti-pT638; D. anti-pS657/T658 
 
It is unsurprising that the catalytic kinases were phosphorylated to a lesser extent as, combined with 
their higher expression, they are maintained in an open conformation, making them prone to 
dephosphorylation.
64,80
 However, the extent of phosphorylation of the full length kinases could not 
be quantified as a fully-phosphorylated sample of PKCα was not readily available for comparison, 
and further analysis was therefore necessary. 
 
Aggregation Analysis 
 
It is known that PKCα aggregates when unphosphorylated,62 and therefore the kinases were 
analysed by dynamic light scattering (DLS). The observation of large particles in the solutions 
supported the presence of aggregated protein. However, this was not necessarily a result of the 
absence of phosphorylation; it is known that GST can dimerise and the buffer composition may also 
have an effect on the stability of the protein solution.  
 
At this stage of the research, the baculoviruses were reamplified and expressed on a larger scale by 
the Protein Production Facility (PPF) at Cancer Research UK, providing large protein pellets for 
subsequent optimisation of purification. The PPF also donated a quantity of GST-HRV-3C protease 
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and this was found to successfully cleave the kinase while bound to the solid support; this also had 
the advantage over His6-HRV-3C that the protease remained bound to the solid-support, simplifying 
purification post-cleavage. 
 
Optimisation of the GST purification buffer was therefore attempted using these protein pellets. The 
pH (6.8, 7.4 or 8.0) and salt concentration (50 or 250 mM) were varied prior to cleavage of the GST 
tag with GST-HRV-3C. Analysis of the resulting solutions showed the presence of free kinase in all 
samples, albeit less in the lower pH, which is known to reduce the activity of the protease. However, 
DLS analysis of the samples did not suggest any significant reduction in aggregation. Since neither 
GST-tag removal nor buffer would have any effect on the phosphorylation state of the kinase, this 
supported the hypothesis the kinases were indeed incorrectly phosphorylated. In order to confirm 
this, the wild-type protein was subjected to gel filtration, a technique which separates protein by 
size. A large amount of aggregated protein was detected, with two small peaks at the correct volume 
for the molecular weight of unaggregated protein. A Western blot of all three peaks showed that the 
aggregated protein was indeed not correctly phosphorylated and suggested that the smaller peaks 
may be two different phosphorylation states of unaggregated protein. This finding that the non-
phosphorylated kinase becomes aggregated agrees with the literature.
62
 
 
Since a large quantity of protein had been obtained, it was considered a viable strategy to separate 
the correctly phosphorylated protein for use in the subsequent assays. This required a better 
separation of the phosphorylated protein and it was decided to switch to using ion exchange 
chromatography, which separates proteins based on their net charges. In order for the protein to 
bind effectively to the column for good separation, the pH of the solution must initially be below 
the pI of the protein. However, dialysis into a pH 6.0 buffer resulted in precipitation of the protein, 
and analysis of the remaining solution showed very little soluble protein remained. This was 
therefore not a viable method for the isolation of pure phosphorylated protein. Alternative options 
for the isolation of fully active kinase were considered, and co-expression with the upstream kinase, 
PDK1 was selected since a suitable baculovirus was available. 
 
Co-expression with PDK1 
 
The wild-type protein was thus expressed both 
with and without PDK1, and the relative 
proportion of phosphorylation was analysed 
(Figure 3.16). However, no significant 
difference was shown between the two proteins. 
 
 
Figure 3.16 – Comparison of phosphorylation 
A. Western blot using MC5; B. Western blot using pS657 
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Although it was possible that neither protein was correctly phosphorylated, there had been a 
significant reduction of expression of the kinases from previous attempts due to a decrease in the 
viral titre, suggesting that the endogenous kinases were now capable of maintaining complete 
phosphorylation of the target kinases. 
 
Specific Activity Determination 
 
All three full length kinases were then expressed at this lower level, purified and quantified by the 
PPF. Subsequent in vitro kinase radioassays showed that the three kinases had much higher activity 
than before, although with fairly similar relative activities (Figure 3.17A). However, the specific 
activity for PKCα was much higher than the expected value (ca. 5000 U/mg). This was likely to be 
a result of either an unexpected higher concentration of kinase or lower concentration of cold ATP 
in the assay, the latter presumably resulting from degradation. The concentrations of the kinases 
were therefore checked by the PPF, and this agreed with the previous concentration measurements. 
The radioassay was therefore repeated using a freshly-made solution of ATP and the resulting 
kinase specific activities were lower, approaching the expected values, thus supporting the theory of 
ATP degradation. 
 
 
 
Figure 3.17 – Relative activities and phosphorylation of kinases 
Results shown are an average of 3 assays, errors shown are standard deviations 
 
Although the relative activities of the three kinases were fairly consistent throughout the different 
kinase radioassays, the ratio observed does not correspond to literature results.
67
 However, analysis 
of all three kinases showed the same extent of phosphorylation, eliminating this as a possible cause 
(Figure 3.17B). An alternative hypothesis was that gatekeeper mutation had destabilised the closed 
conformer, leading to partial oxidation of the activation loop cysteine (C499) as has been seen in a 
PKCα (T338A).64 However, preincubation of the kinases with a reducing agent (50 μM DTT for 10 
minutes at 30 °C) did not result in an appreciable difference in relative activities, although an 
approximately two-fold increase in specific activity was observed for all three enzymes. However, 
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the ratio of activities was found to change over time, with the mutant kinase activity decreasing 
when compared to the wild-type activity for proteins that were stored at -20 °C. Since the initial 
specific activities were not measured immediately following protein expression and purification, it 
is probable that the original specific activities of the as-kinases were closer to that of the wild-type 
than observed in the above assays, possibly explaining the discrepancy with the literature results. 
 
These results mirror the literature finding that PKCα (M417A) is more active than PKCα (M417G). 
Furthermore, since it has been reported that PKCα (M417A) should show comparable activity to the 
wild-type kinase, it was decided to proceed with this as-kinase only.
67
 
 
In summary, after multiple switches in strategy and lengthy optimisation, wild-type PKCα and two 
as-kinases, PKCα (M417G) and PKCα (M417A) were successfully expressed and purified. PKCα 
(M417G) was shown to have significantly decreased activity compared with the wild-type kinase, 
and PKCα (M417A) was selected for further investigations. 
 
3.2 Expression of Alternative Kinases 
 
Although the expression of wild-type and as-PKCα was eventually successful, many changes in the 
strategy and significant optimisation were required. Therefore, during this process, the expression 
of other suitable serine/threonine kinases was investigated in the event that expression of PKCα and 
a suitable as-kinase could not be achieved. Protein kinase A and cyclin dependent kinase 2 were 
chosen for this task. 
 
Furthermore, it is known that serine/threonine kinases have a larger gatekeeper residue than many 
tyrosine kinases.
81
 Therefore, even if an inhibitor binds selectively to a serine/threonine as-kinase 
and not the wild-type, it will not necessarily be precluded from inhibiting tyrosine kinases. 
Although there are few tyrosine kinases in the cell compared with serine/threonine kinases, 
obtaining selectivity over tyrosine kinases would result in less background reaction and simplify 
analysis. For this reason, proto-oncogenic tyrosine kinase (c-Src) was chosen as an appropriate 
selectivity control. 
 
3.2.1 Protein Kinase A (cAMP-Dependent Protein Kinase, PKA) 
 
Protein kinase A (PKA) is involved in the regulation of the cell cycle and metabolism. PKA is a 
tetrameric holoenzyme, consisting of a homodimeric regulatory subunit and two catalytic subunits
82
 
for which there are three isoforms of the mammalian regulatory subunit and four of the catalytic 
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subunit (Figure 3.18).
61
 When bound to the regulatory subunits, the catalytic subunits are inactive. 
Upon binding to four molecules of cAMP, the inhibition by the homodimeric regulatory subunit of 
the catalytic subunits is released. 
 
 
 
Figure 3.18 – Structure of PKA61,83 
 
The catalytic domains are further regulated by PDK1-mediated phosphorylation on both T197 and 
S338 in PKAα.84 However, unlike PKC, active protein can be expressed in E. coli, where these sites 
are instead autophosphorylated, although it has been shown that the as-kinase PKAα (M120G) 
needs co-expression with PDK1. 
 
Protein Expression in Bacteria 
 
A construct coding for murine wild-type cat. PKAα in pRSETB was obtained (cat.PKAα-pRSETB),
85
 
and the first task was to incorporate a tag for ease of purification. An N-terminal His6-tag could be 
simply introduced by inserting the coding region for PKAα into pRSETA; this work was carried out 
by a co-worker.
†
 To summarise, PCR was carried out using mutagenic primers (Figure 3.19) and the 
resulting product T-tailed to introduce the required adenosine for ligation into pGEM
®
-T to generate 
N-His6-cat.PKAα-pGEM-T. The sequence was confirmed (see Figure 13.9) and the BamHI/HindIII 
region was subcloned into pRSETA to generate N-His6-cat.PKAα-pRSETA, the sequence of which 
was also confirmed (Figure 13.10). 
 
5’ mutagenic primer: 5’-GGATCCATGGGCAACGCCGCCGC-3’;  
3’ mutagenic primer: 5’-AAGCTTAAAACTCAGTAAACTCCTTGCCACACTTC-3’ 
 
Figure 3.19 – PCR primers used for generating N-His6-cat.PKAα-pGEM-T 
†
 
 (ATG is the start codon, TTA is the reverse complement of the stop codon, GGATCC is the BamHI restriction site, 
AAGCTT is the HindIII restriction site, orange text is mutated bases) 
 
 
Work towards the gatekeeper mutant was carried out using cat.PKAα-pRSETB as the template. The 
same two terminal mutagenic primers were used, along with two mutagenic primers for introduction 
of the gatekeeper mutation and an engineered SnaBI site (Table 3.4). Both rounds of PCR were 
successful under fairly standard conditions, and the two-step PCR product was T-tailed and ligated 
into pGEM
®
-T. Sequencing showed that along with the desired mutation, an additional three base 
                                                 
† Work carried out by Shahidah Ali under the supervision of Dr. Mann 
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pair mutations were also present, two of which resulted in amino acid alterations (V60M and 
V288A), giving N-His6-cat.PKAα(M121A)-pGEM-T*. 
 
Table 3.4 – Conditions for second round of PCR 
 
Round Template/μL Enzyme Timing 
1st 0.5 KOD A 
2nd 0.01 KOD A 
 
A: denaturing: 15 s at 98 C; annealing: 2 s at 44 C; polymerising: 20 s at 72 C; ramp rate 4 °C s-1; 25 cycles 
 
5’ mutagenic primer: 5’-GGATCCATGGGCAACGCCGCCGC-3’;  
3’ mutagenic primer: 5’-AAGCTTAAAACTCAGTAAACTCCTTGCCACACTTC-3’ 
M120G 5’ mutagenic primer: 5’-CAAACCTGTACATGGTCGGGGAGTACGTAGCTGG-3’ 
M120G 3’ mutagenic primer: 5’-CCAGCTACGTACTCCCCGACCATGTACAGGTTTG-3’ 
 
(ATG is the start codon, TTA is the reverse complement of the stop codon, GGATCC is the BamHI restriction site, 
AAGCTT is the HindIII restriction site, orange, red and blue text is mutated bases, GGG/CCC is the codon for the 
gatekeeper residue, TACGTA/TACGTA is the SnaBI restriction site) 
 
 
Rather than repeat the PCR, attempts were made to subclone the error-free EcoRI/Eco91I region 
containing the mutated gatekeeper G120 residue of N-His6-cat.PKAα(M120G)-pGEM-T* into N-
His6-cat.PKAα-pRSETA. However, this was unsuccessful after multiple attempts and the PCR was 
therefore repeated, along with the T-tailing and ligation into pGEM
®
-T. Fortunately, on this 
occasion, the sequence of cat.PKAα(M121A)-pGEM-T was confirmed, with no unintended base pair 
alterations (Figure 13.9). However attempts to subclone the BamHI/HindIII region into pRSETA 
failed, recovering just the parent vector. Linearisation of any remaining parent vector by digestion 
with SacI post-ligation resulted in the absence of any colonies. To increase the chance of success, 
p27-pRSETA was used as a source of the pRSETA vector in order to be able to separate the smaller 
isolated vector from the partially cut, linearised plasmid. However, this strategy also failed, and 
attempts to generate a construct for the expression of the as-kinase were halted until the expression 
of His6-PKAα could be confirmed. 
 
Expression of the N-His6 fusion of cat. PKAα in bacteria was 
attempted by a co-worker at various temperatures.
‡
 However, no 
protein was observed on either a stained gel or by blotting with an 
anti-His6 antibody. An in vitro translation was therefore carried out to 
ensure that the plasmid was capable of expressing the protein, and 
this was successful (Figure 3.20). This confirmed that the construct 
                                                 
‡ Work carried out by Dr. Emma Child 
 
Figure 3.20 – Western 
blot of in vitro translation 
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contained the correct DNA for expression of a His-tagged protein of the correct size. However, the 
reason for the failure of bacterial expression was unknown. Unfortunately, it was not possible to 
confirm expression of the untagged protein using construct cat.PKAα-pRSETB since an antibody for 
PKA was not available. 
 
Considering the difficulties in both expression of cat. PKAα and generation of the construct for the 
expression of the as-kinase, work was ceased on this strand of the project and the expression of 
cdk2-cyclin E was therefore explored. 
 
3.2.2 Cyclin Dependent Kinase 2 (cdk2) 
 
Cyclin dependent kinases (cdks) are involved in cell cycle 
progression (Figure 3.21), regulation of transcription and 
mRNA processing.
87
 At present, 20 distinct kinases have 
been identified in this family,
88
 all of which require 
binding to a cyclin for activity, along with phosphorylation 
of the activation loop (T160 in cdk2).
89
 Cdk activity is 
regulated by the synthesis and degradation of the 
associated cyclins, binding to inhibitory subunits and phosphorylation status.
90
 
 
Protein Expression in Insect Cells 
 
Baculoviruses for the expression of GST-fusions of cdk2 and cdk2 (F80G) were available, along 
with a baculovirus for cyclin E, the binding of which was required for cdk2 activity. Co-expression 
of cdk2 with cyclin E allowed the isolation of the cdk-cyclin complex by GST purification. 
However, since the complex was isolated through cdk2, optimisation was required in order to 
simultaneously achieve high levels of cdk2 expression together with a near-stoichiometric level of 
cyclin E. An example of the difficulties encountered was 
the observation that the addition of a large excess of cyclin 
E baculovirus resulted in a very low yield of protein, either 
due to virus-induced cell death or insufficient cdk2 
expression. The best result obtained gave a reasonable 
yield after GST-purification and elution, albeit with a poor 
ratio of cyclin E to cdk2 for the wild-type kinase (Figure 
3.22A). A brief assay using retinoblastoma protein (which 
migrates slower on an SDS-PAGE gel when 
 
Figure 3.21 – Cell cycle regulation 
by cdks and cyclins
86
 
 
 
Figure 3.22 – Expression and activity 
of cdk2 and cdk2 (F80G) complexes 
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phosphorylated) showed that both kinases were active (Figure 3.22B). However, the presence of a 
large quantity of cyclin-free inactive cdk2 in quantitative inhibition assays was thought to represent 
a potential complicating factor, and therefore further expression optimisation was required. 
However, at this stage, the problems with the expression of PKCα had been resolved, and therefore 
the expression of cdk2-cyclin E was no longer required. 
 
3.2.3 Proto-Oncogenic Tyrosine Kinase (c-Src) 
 
Src-family kinases (SFKs) are involved in cell signalling, regulating cell growth and differentiation 
and all eleven known SFKs are implicated in cancer, with Src being the first oncogenic kinase 
identified. The kinase structure consists of a regulatory domain and a catalytic domain (Figure 3.23). 
Phosphorylation of Y419 is required for activation; and conversely phosphorylation of the Y530 
renders the kinase inactive through a conformational change brought about by binding of pY530 to 
the regulatory SH2 domain. 
 
 
 
Figure 3.23 – Structure of SFKs91 
 
Expression in Bacteria 
 
 A construct for the expression of a GST-fusion of c-Src in pGEX-3X was obtained from Steve 
Dilworth (Imperial College London) (c-Src-pGEX-3X, Figure 13.11). Although it was advised that 
this construct gives poor expression, this is not a 
significant disadvantage as it is known that the expression 
of c-Src on a significant scale is toxic to cells. 
 
Initial expression under standard conditions (DH5α cells, 
18 h, 37 °C) followed by GST purification did not result in 
acceptable quantities of isolated GST-c-Src. It was 
therefore decided to optimise the cell type, the time for 
expression and the temperature. BL21 cells were shown to 
have superior expression to DH5α cells under all 
conditions investigated, with optimal expression of GST-
c-Src after 24 h at 37 °C. However, after isolation, only a 
 
Figure 3.24 – Analysis of GST-c-Src 
expression and isolation 
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small amount of very impure protein was obtained (Figure 3.24). A comparison of the ratio of total 
protein (cells) to soluble protein (lysis) suggested that GST-c-Src was predominantly insoluble and 
was therefore being removed in the centrifugation and filtration of the cell lysate. 
 
It has been reported that only 13% of the GST-v-Src expressed in BL21(DE3)pLysS cells is soluble, 
with the remaining protein contained in inclusion bodies.
92
 It was therefore necessary to attempt to 
identify conditions that would maximise the proportion of soluble protein. Both the lysate and pellet 
were therefore compared for protein expression at lower temperatures (18 and 30 °C) although the 
amount of soluble c-Src did not appear to vary substantially with either temperature or time. The 
two marginally superior results (18 °C for 5 h and 30 °C for 2 h) were used for expression and the 
protein purified. Analysis of the results showed that a sufficient amount of GST-c-Src had been 
expressed, albeit isolated in low purity (Figure 3.25A). Furthermore, elution of the kinase from the 
solid support using glutathione appeared to cause complete degradation (Figure 3.25B).  
 
 
 
Figure 3.25 – Analysis of Src expression, isolation and elution under optimised conditions 
 
The rapid degradation of GST-c-Src suggested the presence of proteases in the purified sample, 
possibly retained through binding to the soluble kinase and therefore it was decided to attempt to 
purify the insoluble protein. The cell pellet from the lysis was isolated and extraction following a 
protocol by Miller
93
 was successful in partially resolubilising GST-c-Src. However, GST 
purification again resulted in the loss of the kinase, as seen in the earlier optimisations (Figure 3.24). 
Since the optimisation of expression of pure GST-c-Src had not proved successful, and Src can be 
obtained commercially, this was considered of low priority and focus therefore returned to other 
areas of research. 
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4 Results and Discussion – C3-Substituted Pyrazolo[3,4-d]pyrimidines 
 
4.1 Optimisation of C3 Substituent 
 
4.1.1 Background and Previous Work 
 
As discussed in Section 1.2.1, C3-substituted pyrazolo[3,4-d]pyrimidines have been successfully 
used as as-kinase selective ATP analogues. A robust 4-step synthesis has been devised by Rees that 
allows variation of the N1- and C3-positions by choice of the hydrazine and acid chloride/anhydride, 
respectively (Scheme 4.1).
94
 It is also possible to carry out the first three transformations in one-pot, 
without detriment to the yield. 
 
 
 
Scheme 4.1 – Rees’ synthesis of pyrazolo[3,4-d]pyrimidines94 
 
Shokat has used Rees’ chemistry to synthesise a range of pyrazolo[3,4-d]pyrimidine analogues, 
with inhibitors 1a (PP1), 1b (1-Na-PP1) and 1c (1-NM-PP1) being the most widely used for 
chemical genetics studies (Table 4.1). The latter two inhibitors have been shown to have high 
potency against cdk2 (F80G) and good selectivity over wild-type tyrosine kinases.
31
 
 
Table 4.1 – Literature IC50 values for 1a (PP1), 1b (1-Na-PP1) and 1c (1-NM-PP1) against wild-
type and mutant kinases
31
 
 
 
  IC50 (μM) at 10 nM ATP 
 kinase 
 
 
  
 
v-Src 2.2 1.0 28 
c-Fyn 0.050 0.60 1.0 
c-Abl 0.30 0.60 3.4 
 
cdk2 22 18 29 
CAMK II 17 22 24 
 
v-Src (I338G) - 0.0015 0.0043 
c-Fyn (T339G) - 0.0065 0.0032 
c-Abl (T315A) - 0.0070 0.12 
 
cdk2 (F80G) - 0.015 0.0050 
CAMK II (F89G) - 0.097 0.0080 
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However, although the gatekeeper residue can be readily identified, some optimisation is required 
to identify the most selective and potent ATP analogue for each as-kinase.
31,95
 It was therefore 
necessary to synthesise a range of pyrazolo[3,4-d]pyrimidines with various C3 substituents to find a 
suitable inhibitor for PKCα (M417A). Application of Rees’ chemistry to make such analogues has 
the disadvantage of early stage introduction of the C3 substituent. Furthermore, pyrazole formation 
can be low-yielding when R
1
 is sterically bulky, observed during the synthesis of 1b (1-Na-PP1).
55*
 
A more divergent synthesis was therefore devised to allow late-stage installation of the C3 
substituent, and 19 compounds were previously made using this method, including 1a (PP1) 
(Scheme 4.2).
55*
 This Suzuki coupling has since been reported using very similar conditions.
96,97
 
 
 
 
Scheme 4.2 – Previously developed divergent synthesis of C3-aryl substituted 
pyrazolo[3,4-d]pyrimidines
55*
 
 
 
4.1.2 Synthesis of Inhibitors 
 
Although a wide range of C3-aryl substituted pyrazolo[3,4-d]pyrimidines were previously 
synthesised using the Suzuki coupling developed, this chemistry had not been extended to non-
aromatic substitution. Since 1c (1-NM-PP1) has been shown to be a highly potent inhibitor of other 
serine/threonine kinases with good selectivity over wild-type tyrosine kinases (Table 4.1), this was 
an important target. The known route for the synthesis of this compound using Rees’ chemistry was 
therefore attempted. Initial reaction between malononitrile and naphthylen-1-yl acetyl chloride was 
successful, giving enol 6 in good yield (Scheme 4.3). However, subsequent enol methylation proved 
problematic, giving a very low yield of enol ether 8, with the predominant product being ester 7. 
 
 
 
Scheme 4.3 – Attempted synthesis of 1c (1-NM-PP1) using Rees’ method 
 
Comparably low yields for the synthesis of 1c (1-NM-PP1) reported in the literature suggest that 
the development of an alternative approach for the synthesis of this inhibitor would be 
worthwhile.
98
 It was therefore hoped that the Suzuki coupling previously optimised could be 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
 49 
applied to the synthesis of 1c (1-NM-PP1). Miyaura borylation of 1-naphthylmethyl chloride 
proved problematic, and isolation of pure boronate ester 9 from by-products did not prove possible 
(Scheme 4.4).
99
 The semi-purified material was thus used in a Suzuki coupling with bromide 5 
(synthesised as described previously) using the conditions previously optimised,
55*
 although no 
conversion was observed. 
 
 
 
Scheme 4.4 – Attempted synthesis of 1c (1-NM-PP1) via Suzuki coupling 
 
Suzuki couplings are attractive due to their versatility and the mild conditions employed.
55,100
 
However, alkylboranes are often inert under standard Suzuki conditions and can require specialised 
and/or rigorous conditions.
101
 Although slightly less functional group tolerant, alkylzinc halides 
have a much greater intrinsic reactivity and Negishi coupling was therefore investigated for the 
synthesis of 1c (1-NM-PP1). A solution of alkylzinc chloride 10 was prepared from the 
corresponding alkyl chloride using Knochel’s direct zinc insertion methodology (Scheme 4.5).102 
Subsequent Negishi coupling was initially attempted using Pd(OAc)2 with S-Phos, although this 
only resulted in low conversion.
102
 In case this was a result of incomplete reduction of the Pd(II) 
precursor to the active Pd(0) species, Pd(PPh3)4 was used, resulting in complete conversion and a 
good yield of 1-NM-PP1, 1c. 
 
 
 
Scheme 4.5 – Synthesis of 1c (1-NM-PP1) via Negishi coupling 
 
 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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4.1.3 Selectivity Assays 
 
In order to determine the optimum inhibitor, it was necessary to assay all the inhibitors synthesised 
against PKCα (M417A). Pyrazolo[3,4-d]pyrimidines are Type I ATP-competitive kinase inhibitors, 
which bind to the active ‘DFG-in’ conformation and therefore their potencies can be measured 
using kinase radioassays.
103
 Kinase inhibitors are generally tested at ATP concentrations close to 
the Km of the kinase. This allows for a compromise between the ideal conditions to find competitive 
inhibitors (decreasing ATP concentrations increase sensitivity) and uncompetitive inhibitors 
(increasing ATP concentrations increase sensitivity).
104
 Since it is known that pyrazolo[3,4-
d]pyrimidines are competitive kinase inhibitors, detection of uncompetitive inhibitors is not 
required. Furthermore, as-kinases can have substantially different Km values for ATP to their wild-
type counterparts (9.3 μM for PKCα, 82.8 μM for PKCα (M417A)67) and therefore the effect of this 
difference can be minimised when searching for competitive as-kinase inhibitors by using a much 
lower ATP concentration.
81
 However, the use of sub-micromolar ATP concentrations results in an 
assay which is does not reflect the cellular environment, where the ATP concentration is in the 
millimolar range.
104
 The assay was therefore performed at 20 μM, a compromise between the 
sensitivity for detection of competitive inhibitors and the cellular relevancy of the assay. 
 
Furthermore, the inclusion of DMSO in the assays was 
necessary for the solubilisation of the inhibitors. However, 
it is known that DMSO has an effect on kinase activity, and 
therefore this would need to be kept at as low a 
concentration as possible. The use of 2.5% DMSO was 
effective for the solubilisation of pyrazolo[3,4-
d]pyrimidines and this concentration was shown to have no 
significant effect on kinase activity (Graph 4.1). 
 
Although the addition of DTT was shown to moderately 
increase the activity of the kinases (Section 3.1.1), this was 
incompatible with any reduction-sensitive functionalities, such as the azides that will be present in 
the final photoaffinity probes and therefore DTT was not included from this point forward.  
 
All 20 C3-aryl substituted inhibitors made previously
55*
 as well as 1c (1-NM-PP1), C3-
unfunctionalised inhibitor 4 and bromide 5 were thus tested for inhibition of PKCα (M417A). 
Assays were carried out initially at 10 μM inhibitor, and all compounds that gave significant 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
 
Graph 4.1 – Effect of DMSO on 
PKCα activity 
 
Results shown are an average of 3 assays, 
errors shown are standard deviations 
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inhibition (>80%) were further tested at lower concentrations. Results are shown in Figure 4.1, with 
the inhibitors ordered by approximate size of the C3 substituent. 
 
 
 
  % Inhibition at x μM 
 R 10 5 1 0.5 0.1 
4 H 14 - - - - 
5 Br 24 - - - - 
1d Ph - - - - 59 
1e (4-F)Ph - - - - 69 
1f (2-Me)Ph - - - - 35 
1g (3-Me)Ph - - - - 21 
1a 
(4-Me)Ph 
(PP1) 
- - - - 39 
1h (4-CF3)Ph - - 59 - - 
1i (2-OMe)Ph 70 - - - - 
1j (3-OMe)Ph - - 64 - - 
1k (4-OMe)Ph - - - 72 - 
1l (3,5-diMe)Ph - 76 - - - 
 
 
  % Inhibition at x μM 
 R 10 5 1 0.5 0.1 
1m (3,5-diCF3)Ph 18 - - - - 
1n (4-CN)Ph 74 - - - - 
1b 
1-naphthyl 
(1-Na-PP1) 
- - - - 39 
1o 2-naphthyl - - - 52 - 
1c 
1-naphthylmethyl 
(1-NM-PP1) 
- - 56 - - 
1p (3-Ph)Ph 40 - - - - 
1q (4-Ph)Ph 42 - - - - 
1r (4-OPh)Ph 63 - - - - 
1s (2-OBn)Ph - 58 - - - 
1t (3-OBn)Ph 33 - - - - 
1u (4-OBn)Ph - 46 - - - 
 
 
 
Figure 4.1 – Inhibition of PKCα (M417A) by C3-substituted pyrazolo[3,4-d]pyrimidines 
Results shown are an average of 3 assays, errors shown are standard deviations 
 
The optimal inhibitors contain small aromatic groups at the C3 position (inhibitors 1d-g, 1a). 
Significant reduction in the size of the C3 substituent resulted in a significant drop in potency 
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(inhibitors 4 (R=H) and 5 (R=Br)), suggesting that this region is important in forming positive 
interactions with the ATP binding site. The largest inhibitors (1p-u) also exhibit a significant loss in 
potency, suggesting that the pocket is not able to accommodate such bulky C3 substituents. The 
intermediate inhibitors (1h-o, 1b, 1c) show a broader spread of potency, giving more information 
regarding the shape and size of this region of the expanded ATP binding site. Inhibitors 1h (R=(4-
CN)Ph) and 1i (R=(4-CF3)Ph) are of similar size to highly potent inhibitor 1a (PP1) (Figure 4.2A-
B), although their potencies are ca. 100-fold and 10-fold lower, respectively. Although it is possible 
to rationalise this reduction based on incremental increases in steric bulk, the subtlety of this effect 
may suggest the influence of repulsive electrostatic interactions with the lone pairs that are not 
present in 1a (PP1). On the other hand, inhibitor 1e (R=(4-F)Ph) shows slightly superior potency to 
1a (PP1). It is difficult to fully rationalise this SAR, although in this case the fluorine lone pairs 
may not project as deep into the pocket. However, this rules out the negative effect of an electron-
poor aromatic ring as an alternative explanation for the poor potency of 1h (R=(4-CN)Ph) and 1i 
(R=(4-CF3)Ph). Methoxy-substituted inhibitors 1j-l show reduced potency compared to the 
corresponding methyl analogues, which again is possible to attribute to either slightly increased 
steric bulk or the presence of the heteroatom. The poor potency of 1m (R=(3,5-diMe)Ph) suggests 
that this substitution pattern cannot be accommodated, also evidenced by the lack of inhibition by 
1n (R=(3,5-diCF3)Ph). Despite their apparently larger sizes, both naphthyl substituted inhibitors (1b 
(1-Na-PP1) and 1o (R=2-naphthyl)) show fairly high potency, with 1b (1-Na-PP1) exhibiting 
comparable inhibition to all three methyl-substituted aromatics (inhibitors 1f-g, 1a)). The aromatic 
substituents on 1a (PP1) and 1b (1-Na-PP1) have very different orientations, suggesting that both 
are accommodated in different regions of the enlarged ATP binding site (Figure 4.2C). It may 
therefore be possible to develop highly potent inhibitors that contain elements of both these 
inhibitors. Despite its high affinity for related as-kinases cdk2 (F80G) and CAMK II (F89G), 1c (1-
NM-PP1) shows only moderate potency compared with both 1a (PP1) and 1b (1-Na-PP1) 
demonstrating the unpredictable nature of as-kinase inhibitor optimisation. 
 
 
 
Figure 4.2 – 1a (PP1) overlayed with 1h (R=(4-CN)Ph), 1i (R=(4-CF3)Ph) and 1a (1-Na-PP1) 
Solvent accessible surfaces shown. Images created using ChemBio3D Ultra 11.0, following MM2 minimisation 
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The six best compounds (1d-g and 1a-b) were assayed for selectivity against wild-type PKCα at 10 
μM (Graph 4.2). Similar selectivity of ca. 100-fold was observed for all six compounds between the 
as-kinase and the wild-type. This selectivity was sufficient for the ensuing work, and is the first 
example of C3-substituted pyrazolo[3,4-d]pyrimidines for the selective inhibition of as-PKCα. 
Further optimisation of the C3 substituent based on these results may allow the identification of 
more potent and potentially more selective inhibitors for PKCα (M417A). 
 
 
 
Graph 4.2 – as-Kinase selectivity of six most potent inhibitors 1d-g and 1a-b 
Results shown are an average of 3 assays, errors shown are standard deviations 
 
The optimal inhibitor of PKCα (M417A) also requires selectivity over tyrosine kinases, which have 
an enlarged ATP binding sites compared with serine/threonine kinases and reported variation in 
their ability to accommodate C3-substituted pyrazolo[3,4-d]pyrimidine inhibitors (see Table 4.1). 
Two of the six compounds (1a (PP1) and 1b (1-Na-PP1)) were already known for their low 
inhibition of tyrosine kinases, and of the remaining four compounds two were substantially smaller, 
which would likely confer lower selectivity over tyrosine kinases. The use of either 1a (PP1) or 1b 
(1-Na-PP1) therefore negated the requirement for selectivity assays to be carried out using a panel 
of tyrosine kinases. IC50 values for both inhibitors against PKCα (M417A) were determined and 
found to be very similar (Figure 4.3). 1b (1-Na-PP1) was therefore selected as this inhibitor has 
been reported to show less inhibition of tyrosine kinases than 1a (PP1) (see Table 4.1).
31
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Figure 4.3 – IC50 values of 1b (1-Na-PP1) and 1a (PP1) against PKCα (M417A) 
IC50 values were determined by fitting data to a standard sigmoid curve using SigmaPlot Results shown are an average 
of 3 assays, errors shown are standard errors of the mean 
 
 
At this stage of the project, concerns were raised over the proposed method of cross-linked 
photoaffinity probe-substrate complex isolation by its affinity for solid-supported PKCα (M417A), 
The strength of this interaction, especially in the presence of high concentrations of ATP, may be 
insufficient for effective isolation and purification and alternative strategies were therefore 
considered. 
 
4.2 C3-Alkynyl Inhibitors 
 
Although the presence of a tag such as biotin on the cross-linked photoaffinity-probe-substrate 
complex would be allow for facile and rapid isolation, this would likely affect binding to the as-
kinase. An alternative would be the incorporation of a much smaller functionality that would allow 
for a bioorthogonal ligation to introduce a tag after the cross-linking has taken place. Huisgen [3+2] 
cycloaddition between an azide and an alkyne has been extensively used in biological systems and 
is suitable for this purpose.
105
 As this strategy would require the introduction of an alkyne into the 
photoaffinity probe, incorporation into the C3 substituent would be elegant solution, allowing the 
use of a simpler photoactivatable group and linker. However, a C3-acetylenyl inhibitor would most 
likely have insufficient steric bulk to confer as-kinase selectivity based on the results shown 
previously (see Figure 4.1), the addition of an alkyne to the phenyl ring was considered too bulky 
and internal alkynes, unless strained, do not undergo cycloadditions with azides at temperatures 
compatible with a biological system. An attractive solution to this would be the introduction of 
alkynes functionalised with trialkylsilanes. These would allow simple variation of the steric bulk to 
achieve good selectivity, and would also allow for silyl group removal post-cross-linking to unmask 
a terminal alkyne. 
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Commercially available trimethylsilylacetylene was used to 
test the Sonogashira coupling with bromide 5. This reaction 
was successful under standard conditions
106
, giving 
inhibitor 1v (R=TMS-alkyne) in high yield (Scheme 4.6). 
This should be applicable to other trialkylsilylacetylenes, 
which could be made from the corresponding 
ethynylmagnesium bromide and the appropriate chlorotrialkylsilane.
107
 
 
After this work was carried out, a similar article was published showing the successful Sonogashira 
reaction of a similar aryl iodide with trimethylsilylacetylene. Subsequent TMS removal and Cu-
catalysed Huisgen [3+2] cycloaddition were also performed, albeit at elevated temperatures in 
organic solvents,
108
 showing some precedent for the proposed transformations. 
 
However, inhibition of PKCα (M417A) by inhibitor 1v 
(R=TMS-alkyne) was shown to be fairly poor compared to 
the most potent C3-substituted pyrazolo[3,4-d]pyrimidines 
(Graph 4.3). Considering the size relative to 1a (PP1) and 
1b (1-Na-PP1), it appears that the TMS group gives too 
much steric bulk to this region of the inhibitor, although the 
size difference is subtle (Figure 4.4A). An alternative 
explanation for the low potency is the absence of a C3-aryl 
substituent, which can partake in hydrophobic interactions 
with many residues as seen for c-Src (T338G) with N
6
-
(benzyl) ATP (Figure 4.4B). 
 
 
Scheme 4.6 – Synthesis of alkyne 1v 
via Sonogashira coupling 
 
 
Graph 4.3 – Inhibition of PKCα 
(M417A) at 5 μM inhibitor 1v 
(R=TMS-alkyne) 
 
Results shown are an average of 3 assays, 
errors shown are standard deviations 
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Figure 4.4 – Potential explanations for the poor binding of inhibitor 1v (R=TMS-alkyne) 
A. Solvent accessible surfaces shown. Inhibitor 1v (R=TMS-alkyne) overlayed with 1a (PP1) and 1b (1-Na-PP1) 
images created using ChemBio3D Ultra 11.0, following MM2 minimisation; B. PDB entry; 1ksw28: N6-(benzyl) ATP 
bound to c-Src (T338G), residues showing hydrophobic interactions with distances highlighted, image created using 
AstexViewerTM 
 
 
Since the free alkyne would likely to be far too small to generate a good interaction and TMS is the 
smallest stable silyl group, it is unlikely that any other alkyne inhibitors of this type would be both a 
good, selective inhibitor of PKCα and be able to undergo cycloaddition post-cross-linking, although 
it does not preclude the possibility that inhibitor 1v (R=TMS-alkyne) would be a suitable inhibitor 
of other as-kinases. 
 
The proposed aryl-substituted inhibitor 1w (R=(4-alkynyl)Ph) 
was previously disregarded for this purpose as being too large 
to bind to PKCα (M417A). However, after full analysis of the 
inhibition of all 24 compounds, 1w (R=(4-alkynyl)Ph) is not 
substantially larger than 1a (PP1) (Figure 4.5). Although it 
was shown that 1h (R=(4-CN)Ph), which is slightly larger 
than 1a (PP1) had much lower potency, this may have been a 
result of the electrostatics rather than sterics. However, further 
investigations were put on hold, to be re-examined should a 
successful method for the purification of the cross-linked 
substrates not be found. 
 
 
Figure 4.5 – 1a (PP1) overlayed 
with 1w (R=(1-alkynyl)Ph) 
 
Solvent accessible surfaces shown. 
Images created using ChemBio3D Ultra 
11.0, following MM2 minimisation 
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4.3 C3-Thiol Containing Inhibitors 
 
An alternative strategy was proposed to allow for the facile purification of cross-linked substrates 
by strengthening the interaction between the kinase and photoaffinity probe. Disulfide bonds have 
been used to allow for transient interactions between small molecules and proteins containing an 
engineered cysteine to persist for longer, the main purpose being to allow for detection of weakly-
binding fragments.
109
 It is known that there are very few kinases that contain cysteine as the 
gatekeeper residue. Therefore, it was postulated that the gatekeeper residue of the kinase could be 
mutated to a cysteine, with concomitant introduction of a pendant thiol-containing chain on an ATP 
analogue to allow for a disulfide bond to form selectively with the as-kinase (Figure 4.6A). Since 
cysteine has a relatively small side chain, this would result in a reduction in size of the gatekeeper, 
thereby retaining a partial steric complementation element in this strategy. Overall, this would 
constitute a novel method for obtaining selective as-kinase inhibitors. Application to a photoaffinity 
probe should allow for facile purification of the cross-linked substrates via isolation using a tag on 
the now covalently bound as-kinase (Figure 4.6B). Disulfide tethering has the added advantage that 
the cross-linked probe-substrate complex could be eluted from the captured as-kinase by the 
addition of a reducing agent. 
 
 
 
Figure 4.6 – Illustration of proposed cysteine tethering 
A. Application of cysteine tethering towards obtaining as-kinase selective inhibitors; B. Application of cysteine 
tethering towards isolation of kinase-substrate pairs. 
 
 
4.3.1 Synthesis of C3-Thiol-Substituted Pyrazolo[3,4-d]pyrimidines 
 
In order to optimise the disulfide tethering, three thiol-
containing inhibitors were initially targeted (Figure 4.7). In 
order to allow for late-stage optimisation of this group, 
installation of the C3 substituent after the construction of 
the pyrazolo[3,4-d]pyrimidine scaffold was preferred. 
 
A variety of approaches from bromide 5 were investigated for the synthesis of thiol 11. 
Nucleophilic substitution with NaSH was unsuccessful,
110
 suggesting that the C3 position of 
pyrazolo[3,4-d]pyrimidines is not activated enough for this type of addition-elimination mechanism 
to occur (Scheme 4.7). Cu-catalysed thiolation with sulfur has been reported to work well only with 
 
Figure 4.7 – Thiol targets for 
cysteine tethering 
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iodides,
111
 and unsurprisingly the reaction was unsuccessful 
on bromide 5. Pd-catalysed thiolation with TIPS-SH also 
showed no conversion to the product.
112
 
 
Synthesis of the corresponding iodide was attempted in the 
hope that this would be a good substrate for Cu-catalysed 
thiolation. However, iodination of C3-unsubstituted pyrazolo[3,4-d]pyrimidine 4 was unsuccessful 
under all conditions attempted. Lithium-halogen exchange on bromide 5 using 3 equivalents of 
n
BuLi followed by an iodine quench returned a mixture of starting material and debrominated 
compound 4. 
 
It was envisaged that thiol 12 could be synthesised from the corresponding aldehyde by thionation 
followed by reduction (Scheme 4.8). Attempts to synthesise aldehyde 14 from bromide 5 by Pd-
catalysed carbonylation
113
 or copper-catalysed cyanation
114
 failed, with no conversion observed for 
either reaction. 
 
 
 
Scheme 4.8 – Attempted syntheses of thiol 12 
 
Although a variety of methods were attempted for the synthesis of the target thiols, none of these 
were successful. Although optimisation or a change in strategy would likely allow for the synthesis 
of these compounds, the speculative nature of the disulfide tethering strategy combined with these 
initial failures resulted in focus being returned to the main strand of the project. If this approach 
were to be developed, it would likely provide a valuable technique for generating high affinity as-
kinase selective inhibitors. 
 
 
Scheme 4.7 – Attempted syntheses 
of thiol 11 
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5 Results and Discussion – Synthesis of Photoaffinity Probes 
 
5.1 First Generation Photoaffinity Probes 
 
C3-Substituted pyrazolo[3,4-d]pyrimidines allow for selective inhibition of as-kinases over their 
wild-type counterparts and other endogenous kinases. Transforming these inhibitors into 
photoaffinity probes would hopefully allow selective cross-linking to the as-kinase substrates and 
the second objective was therefore to optimise this cross-linking (Figure 5.1). 
 
 
 
Figure 5.1 – Schematic of first generation photoaffinity probe 
 
Initial work focussed on C3-unsubstituted probes as at this stage kinase expression was still proving 
problematic and the optimal C3 substituent had therefore not been determined. 
 
It was necessary to identify a target structure that would allow for rapid synthesis as well as late-
stage incorporation of the aryl azide to allow for the most efficient optimisation and to reduce the 
possibility of any potential photo-induced degradation. Functionalisation of the N1 position on the 
preformed pyrazolo[3,4-d]pyrimidine would be the most obvious disconnection. However, forming 
a bond from the N1 position to a quaternary carbon would require a difficult and unprecedented SN1 
displacement as well as selectivity over exocyclic amine functionalisation. Synthesis of core 
pyrazolo[3,4-d]pyrimidines with a functional group handle would solve this problem and still allow 
for late-stage optimisation. However, the design of the linker should avoid the use of any cationic 
functionality since it must be accommodated in the hydrophilic channel that binds to the anionic 
triphosphate of ATP.
65
 Alcohols (16) fit all these criteria as ethers are neutral under biological 
conditions, should give good flexibility in the subsequent photoactivatable group incorporation and 
should be compatible with the proposed synthesis (Scheme 5.1). 
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Scheme 5.1 – Suggested photoaffinity probes and retrosynthetic analysis 
 
Assuming a similar binding orientation to ATP, positioning the azide of the photoaffinity probe 
where the γ-phosphate of ATP normally resides should result in the best chance of cross-linking to 
the substrate. 
 
In order to provide some quantitative measure to aid the design of the probes, both ATP and 
photoaffinity probes of the type 15 were computationally modelled to calculate the approximate 
distances between the ring system and either the γ-phosphate of ATP or cross-linking nitrene of 
photoaffinity probe 15 (Table 5.1). The crystal structure of cdk2 bound with ATP (PDB entry 1hck
5
: 
cdk2 bound to ATP) showed a distance of 8.5 Ǻ between the substituted imidazole amine and the γ-
phosphate phosphorus atom and MM2 minimisation of a similar extended conformation of ATP 
gave an approximate value of 10.0 Ǻ. This variation in bound and free conformation may also occur 
for the photoaffinity probes, and therefore a distance between these two values was considered an 
appropriate, approximate target. MM2 minimisation of several potential probes identified an 
optimum distance between pyrazole N1 and the resultant nitrene where m+n is between 0 and 2. For 
this reason, alcohols where m=0 and m=1 were selected, to be reacted with both aryl and benzyl 
halides to give compounds with n=0 and n=1. This would allow for maximum optimisation of 
cross-linking with the fewest reaction partners. Furthermore, ortho-azides were not investigated as 
these would be less likely to be positioned in a productive manner to allow cross-linking to the 
substrate, and would be more likely to result in cross-linking to the kinase. 
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Table 5.1 – Approximate distance between pyrazole N1 and resulting nitrene in photoaffinity probe 
15 
 
 
 
 
m n Azide orientation Distance/Ǻa 
1 1 para 10.8 
1 1 meta 10.3 
1 0 para 9.0 
1 0 meta 8.3 
0 1 para 8.7 
0 1 meta 8.1 
0 0 para 8.4 
0 0 meta 7.8 
 
a. MM2 minimisations performed using ChemBio3D Ultra 11.0 
 
5.1.1 Synthesis of Alcohol 16a 
 
The synthesis of a protected version of longer chain hydrazine 18 (see Scheme 5.1, m=1) was 
proposed via hydrohydrazination of the corresponding alkene, prenyl alcohol.
115
 This required the 
synthesis of cobalt catalyst 19, which was obtained in high yield (Scheme 5.2). 
 
 
 
Scheme 5.2 – Synthesis of cobalt catalyst 19 
 
Synthesis of hydrazine 20a was then achieved in a comparable 
yield to the literature, and on scale up this hydrohydrazination was 
found to be robust (Scheme 5.3). 
 
Subsequent hydrazine deprotection was attempted 
under standard conditions using either TFA or HCl but 
it was not found to be possible to isolate the 
unprotected hydrazine, either as the free hydrazine or 
as a salt. It was possible that the product was unstable 
 
Scheme 5.3 – Synthesis of 
hydrazine 20a 
 
 
Scheme 5.4 – Synthesis of pyrazole 21a 
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since protected hydrazine 20a was consumed during the reaction. In situ deprotection using HCl 
prior to the pyrazole formation successfully resulted in clean conversion to desired product 21a in a 
moderate yield (Scheme 5.4). 
 
The long deprotection time was likely resulting in degradation and diminishing the yield. However, 
heating the deprotection step resulted in none of pyrazole 21a as cyclisation of intermediate 
hydrazine 18a resulted in clean formation of pyrazolidine 23 in high yield (Scheme 5.5). 
 
 
 
Scheme 5.5 – Unexpected synthesis of pyrazolidine 23 
 
Synthesis of pyrazolo[3,4-d]pyrimidine 16a was 
then attempted using formamide (Scheme 5.6). 
However, this led only to a side product, which 
was not identified at this time, although the 
absence of oxygen in the expected formula 
suggested the loss of the alcohol. It was 
considered that protection of the alcohol may therefore suppress formation of this by-product. Initial 
protection as TIPS ether 24, which was isolated in high yield, resulted in the same unidentified 
compound, most likely a result of deprotection under the harsh reaction conditions of pyrimidine 
formation. 
 
The by-product was later identified by 
crystallography to be triazine 25, although a 
low yield of this product was obtained from 
both reactions (17-21%) (Figure 5.2). The 
product suggests that initial 1,3-diazinane 
formation with the extrusion of water 
prevents pyrimidine ring formation, resulting in two equivalents of formamide condensing with the 
nitrile to form the triazine. Although this latter reaction appears to be unreported in the literature, a 
nitrile has previously been transformed into a triazine using related formamidine.
116
 
 
Alternative protection as a benzyl ether was deemed suitable as this should be stable to the high 
temperature reaction conditions and facile to deprotect post-pyrimidine formation. Furthermore, 
introduction of aryl iodides at this stage would give the option of Cu-catalysed azidation
117
 post-
pyrimidine formation to generate the final probes, albeit diverging at an earlier stage. However, 
 
Scheme 5.6 – Attempted pyrimidine formation 
 
Figure 5.2 – Structure of by-product 25 
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selective O-benzylation proved difficult. Standard benzylation under strongly basic conditions 
afforded mainly N-benzylation (Table 5.2, Entry 1). The regioselectivity of this reaction was 
subsequently confirmed by the synthesis (and further benzylation) of O-benzylated pyrazole 26 by a 
different route. However, no reaction was observed under mildly basic conditions (Entry 2) or 
acidic conditions using benzyl trichloroacetimidate
118
 (Entry 3). Although silver bases are known to 
promote O-alkylation in aromatic amides,
119
 silver (I) oxide
120
 did not promote benzylation, only 
giving a small quantity of N-benzylated aldehyde 29 (Entry 4), and silver (I) iodide resulted in no 
reaction (Entry 5). 
 
Table 5.2 – Attempted O-selective benzylation of alcohol 21a 
 
 
 
  Isolated Yield/% 
Entry Conditions 21a 26 27 28 29 
1 BnBr, NaH, THF, 6 d, rt 20 7 8 33 - 
2 BnBr, pyridine, rt, 3 d No conversion 
3 BTCA, TMSOTf, CH2Cl2, 40 °C, 3 d No conversion 
4 BnBr, Ag2O, CH2Cl2, rt, 3 d nd
a - - - nda 
5 BnBr, AgI, MeCN, 19 h No conversion 
6 Reagent 31, MgO, PhMe, 85 °C, 23 h 36 30 6 10 - 
 
a. Compound observed by 1H-NMR of the crude reaction material but not isolated 
 
Reagent 31 has been shown to be an effective alternative to Mukaiyama’s reagent for benzylation 
reactions in order to prevent competing displacement by the iodide counterion; triflate salts are 
stable to this decomposition (Scheme 5.7).
121,122
 Benzylation of pyrazole 21a using reagent 31 was 
the most successful method attempted, although amine benzylation still competed significantly 
(Entry 6). Despite the use of two equivalents of reagent 31, this reaction only proceeded in low 
conversion, with a large proportion of recovered starting material. 
 
 
 
Scheme 5.7 – Synthesis of reagent 31 and decomposition of Mukaiyama’s reagent 
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Due to the difficulty in benzylating pyrazole 21a selectively, the introduction of the benzyl 
protecting group earlier in the synthesis was therefore necessary. Although benzylation of hydrazine 
20a proved difficult due to the highly hindered nature of the alcohol, prenyl alcohol could be 
benzylated in quantitative yield (Scheme 5.8). Subsequent hydrohydrazination proved much slower 
than in the absence of alcohol protection, giving hydrazine 33 in fairly low yield after 6 days (35%), 
although this could be improved to 58% 
using an increased number of equivalents 
of both the silane and azodicarboxylate. 
 
Subsequent pyrazole formation was found to be 
lower yielding than for corresponding unprotected 
pyrazole 21a, likely a result of the observed slower 
rate of deprotection resulting in greater 
decomposition (Scheme 5.9). However, as expected, 
heating the hydrazine deprotection gave none of pyrazolidine by-product 23, and substantially 
increased the yield of pyrazole 26. It was discovered that the rate of pyrazole formation could be 
similarly increased by heating without detriment to either yield or purity. 
 
Formation of the pyrimidine ring was now effective with formamide, giving pyrazolo[3,4-
d]pyrimidine 34 in high yield, with a trace of 
pyrazolo[3,4-d]pyrimidone 35 (Scheme 5.10). The 
latter compound was presumably formed by the 
presence of trace water performing hydrolysis of 
the nitrile in pyrazole 26 to an amide, prior to 
condensation with formamide. 
 
Deprotection proved more difficult than anticipated, giving only starting material under standard 
hydrogenation conditions (Table 5.3, Entries 1-2). 
 
 
 
 
 
 
 
 
 
 
Scheme 5.8 – Synthesis of hydrazine 33 
 
Scheme 5.9 – Synthesis of pyrazole 26 
 
Scheme 5.10 – Synthesis of 
pyrazolo[3,4-d]pyrimidine 34 
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Table 5.3 – Benzyl deprotection optimisation 
 
 
 
  Isolated yield/% 
Entry Conditions 16a 36 
1 H2, Pd/C, rt no conversion 
2 H2, Pd(OH)2, rt no conversion 
3 BF3.OEt2, Ac2O, rt - 92 
4 BBr3, CH2Cl2, -78 °C nd
a - 
5 BBr3, CH2Cl2, -78 °C; 2 M NaOH, rt 59 - 
 
a. Isolated in low yield 
 
Attempted benzyl deprotection by Lewis-acid mediated acetate formation was unsuccessful, giving 
only acetamide 36 in high yield (Entry 3), although this could subsequently be successfully 
debenzylated in high yield under standard hydrogenation conditions, suggesting that the free amine 
may coordinate and deactivate the catalyst (Scheme 
5.11).
123,124
 Although this route requires two extra 
transformations, it represented a potential back-up 
strategy should all more efficient routes prove 
unsuccessful. 
 
Standard Lewis acid deprotection using BBr3
125
 gave complete conversion, although with poor mass 
recovery (Entry 4). In case boron complexation of product alcohol 16a was resulting in retention in 
the aqueous layer, various boron-chelating agents were included in the work-up procedure.
126
 
NaOH proved moderately successful, giving the product in acceptable yet variable yield (Entry 5). 
However, further extraction after the addition of ethylene glycol or triethanolamine did not result in 
any improvement. 
 
As an aside, pyrazole 26 was briefly 
benzylated using NaH to confirm the 
regiochemistry of dibenzylated product 27, 
also generating tribenzylated product 38. 
 
 
 
Scheme 5.11 – Benzyl deprotection 
 
Scheme 5.12 – Benzylation of pyrazole 26 
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5.1.2 Synthesis of Alcohol 16b 
 
A derivative of shorter chain hydrazine 18 (see Scheme 5.1, m=0) was synthesised via 
organocatalysed α-hydrazination of isobutyraldehyde followed by an in situ reduction (Scheme 
5.13). However, the α-hydrazination was found to be very slow, and was incomplete after 10 days. 
The addition of 2,2,2-trifluoroethanol, reported to solubilise the proline catalyst,
127
 resulted in a 
significant increase in the rate of reaction, giving complete conversion after only 3 days, and this 
reaction was also found to be robust and reproducible on scale up. The subsequent pyrazole 
formation using the same conditions as for hydrazine 20a again proved fairly low yielding. 
However, the yield could be improved by heating the deprotection step, as in this case, ring closure 
to form the analogous 1,2-diazetidine by the same mechanism was less favourable. 
 
 
 
Scheme 5.13 – α-Amination of isobutyraldehyde 
 
The identity of the product from the unsuccessful 
pyrimidine formation of pyrazoles 21a and 24 was 
unknown at this point, and it was therefore not clear as to 
whether pyrazole 21b could form the corresponding by-
product. This reaction was attempted, and pyrazolo[3,4-
d]pyrimidine was obtained in high yield with only a trace 
of by-product 39 corresponding to recently identified 25 (Scheme 5.14). This suggests that 
formation of the imidazolidine ring system is substantially slower than for the corresponding 1,3-
diazinane (see Figure 5.2), resulting in a high yield of desired pyrazolo[3,4-d]pyrimidine 16b. 
 
5.1.3 Synthesis and Installation of Aryl Azides 
 
With alcohols 16a and 16b in hand, derivatisation with both benzyl (n=1) and aryl (n=0) groups 
was desired as this would allow a range of photoactivatable groups to be introduced at this position 
(see Scheme 5.1, n=0,1). The synthesis of aryl azides 17a-d was carried out according to literature 
methods and all were obtained in high yields (Scheme 5.15).  
 
 
Scheme 5.14 – Synthesis of 
pyrazolo[3,4-d]pyrimidine 16b 
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Scheme 5.15 – Synthesis of azides 17a-d 
 
Optimisation of the installation of these azides was initially carried out using iodobenzene and 
benzyl bromide as model reaction partners. Cu-catalysed arylation was attempted using literature 
conditions reported to be highly selective for 
alcohols in the presence of amines (Scheme 
5.16).
128
 However, only starting material was 
recovered from these reaction suggesting that 
alcohols 16a and 16b are unusually unreactive, 
perhaps due to steric hindrance. 
 
Since these were the best conditions known to effect arylation of alcohols over amines, it was 
decided instead to focus on benzylation. Mukaiyama reagent analogue 31 was previously found to 
be the most successful reagent for the benzylation of pyrazole 21a and was therefore tested in the 
benzylation of alcohol 16b. However, low conversion was observed in this reaction, and an 
extremely low yield of tentatively-assigned O-benzylated pyrazolo[3,4-d]pyrimidine was isolated 
(Scheme 5.17). The relatively higher yields of N-benzylated and N-dibenzylated compounds 
support the earlier conclusion that this alcohol is very hindered.  
 
 
 
Scheme 5.17 – Benzylation of alcohol 16b 
 
Although it was known that selective O-benzylation of pyrazole 21a using NaH was problematic, 
there were numerous literature examples for the protection of ATP derivatives on relatively 
sterically hindered alcohols in the presence of the free primary amine of adenosine using such 
conditions.
129-135
 However, it was found that 
selective reaction of the alcohol could not be 
achieved with these conditions, and a complex 
mixture of benzylated products was observed both 
by 
1
H-NMR and LC-MS analysis of the crude 
 
Scheme 5.16 – Arylation of alcohols 16a-b 
 
Scheme 5.18 – Benzylation of alcohol 16a 
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reaction mixture (Scheme 5.18). Furthermore, conditions reported to give selective O-derivatisation 
on a similar ATP analogue due to the greater stability and reactivity of the magnesium alkoxide 
compared with the magnesium amide gave no reaction for alcohol 16b.
136
 
 
None of the methods used to selectively arylate or benzylate alcohols 16a and 16b were sufficiently 
successful due to their low reactivity. One possible alternative synthetic strategy would be to 
acylate both the alcohol and amine, selectively deacylate the alcohol and carry out the arylation or 
benzylation of amide 38 before subsequent deprotection. However, this proposed route is very 
inelegant and would require three additional steps per compound, resulting in the consideration of 
alternative strategies that avoided functionalisation of these unreactive alcohols. 
 
5.2 Second Generation Photoaffinity Probes 
 
Replacing the alcohol functionality of 16 with a more nucleophilic amine would likely resolve the 
issues of low reactivity and poor selectivity over the exocyclic aromatic amine (Figure 5.3A). 
Furthermore, the additional point of attachment of an amine would allow the facile introduction of 
an alkyne as a functional handle, the derivatisation of which would allow for efficient isolation and 
purification post-cross-linking without the need to rely on the affinity of the resultant probe-
substrate pair for the as-kinase (Figure 5.3B). This should allow for a more rapid and effective 
purification than would likely have been achieved with the first generation probes. 
 
 
 
Figure 5.3 – Second generation photoaffinity probes 
A. Schematic of second generation photoaffinity probe; B. Illustration of photoaffinity labelling followed by Huisgen 
[3+2] cycloaddition and purification 
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Amines were initially discounted as they are positively charged in biological systems, and would 
therefore likely have a repulsive interaction with the hydrophilic channel of the kinase that normally 
binds the anionic triphosphate of ATP. However, the use of an amide should not only resolve this 
issue, but it was hoped that the oxygen could have a positive interaction with the kinase to hold the 
probe in a productive conformation for cross-linking to the substrate. 
 
Two possible strategies presented themselves for the synthesis of such amides: synthesis from 
amine 49 or aldehyde 50 (Scheme 5.19). Although the aldehyde could be directly obtained by 
oxidation of alcohols 16a and 16b, the use of amine 49 would potentially allow for an alternative 
route to these pyrazolo[3,4-d]pyrimidines that does not rely on the previously developed, 
problematic synthesis of alcohol 16a. 
 
 
 
Scheme 5.19 – Suggested second generation photoaffinity probes and retrosynthetic analysis 
 
The computational modelling was repeated to check the approximate distance between pyrazole N1 
and the nitrene for these second generation photoaffinity probes (compared to 8.5-10.0 Ǻ for ATP). 
Due to the inclusion of an extra atom in the form of the carbonyl carbon, this suggested an optimum 
length where m+n is between 0 and 1 (Table 5.4). However, since this would require the synthesis 
of four coupling partners, the synthesis of all eight possible compounds was deemed appropriate 
given the difficulty in predicting the true binding conformation. 
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Table 5.4 – Approximate distance between pyrazole N1 and resulting nitrene in 
photoaffinity probe 46 
 
 
 
 
m n Azide orientation Distance/Ǻa  
1 0 para 10.8 
1 0 meta 9.9 
1 1 para 11.5 
1 1 meta 10.8 
0 0 para 9.2 
0 0 meta 8.7 
0 1 para 10.9 
0 1 meta 9.8 
 
a. MM2 minimisations performed using ChemBio3D Ultra 11.0 
 
5.2.1 Strategy 1 
 
As discussed previously, the preferred synthetic route to amine 49 (see Scheme 5.19) would not 
utilise alcohol 16 as an intermediate given the problems encountered in the synthesis of 16a. A free 
amine at this position could not be carried through the synthesis, requiring the use of a suitable 
amine protecting group that would survive both the Boc-deprotection and harsh pyrimidine 
formation conditions, and also be easily removed. Phthalimide was chosen, and was prenylated with 
bromide 51 in good yield (Scheme 5.20). However, subsequent hydrohydrazination of phthalimide 
52 proved problematic due to the hindered nature of the alkene, with low conversion after extended 
reaction times. The addition of further equivalents of catalyst, silane and azodicarboxylate did not 
significantly increase the product yield, and further contributed to the problematic separation of 
hydrazine 53 from the hydrazine by-product resulting from reduction of the azodicarboxylate. 
 
 
 
Scheme 5.20 – Attempted synthesis of hydrazine 53 
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It was decided therefore to introduce the protected amine after the hydrazine had been installed. 
Proline-catalysed α-hydrazination of isobutyraldehyde allowed direct synthesis of aldehyde 54 in 
good yield (Scheme 5.21). However, reductive amination with ammonia (70 eq.)
137
 resulted 
predominantly in formation of secondary amine 56. Increasing the equivalents of ammonia (to 700 
eq.) increased the proportion of primary amine 55 synthesised, although some secondary amine still 
remained and effective purification of the desired primary amine did not prove possible. 
 
 
 
Scheme 5.21 – Synthesis of aldehyde 54 and attempted reductive amination with ammonia 
 
An alternative strategy was briefly explored in an attempt to make 
primary amine 49 in a more selective manner via the corresponding 
azide. However, iodination of alcohol 20b under standard Appel 
conditions resulted in no conversion to the desired product was 
observed, suggesting that the neopentyl-like alcohol was too 
hindered for SN2 displacement (Scheme 5.22). 
 
Given these problems, it was considered that the use of the already optimised synthesis of alcohol 
16 would provide the most efficient route to the desired amine intermediates. Strategy 2 was 
selected for further development as this should allow the synthesis of the photoaffinity probes in 
only three steps from alcohol 16. 
 
5.2.2 Strategy 2 
 
Oxidation of alcohol 16b was attempted using standard Swern conditions (Scheme 5.23).
138
 
Complete conversion to aldehyde 50b was observed, although its low stability made complete 
purification difficult. However, immediate use in the subsequent reductive amination reaction with 
propargylamine successfully gave amine 47b, albeit in fairly low yield over the two steps, also 
returning a small amount of alcohol 16b. 
 
 
 
Scheme 5.23 – Swern oxidation of alcohol 16b and subsequent reductive amination 
 
 
Scheme 5.22 – Attempted 
iodination of alcohol 20b 
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It was proposed that the low yield from this reaction sequence may have resulted from by-products 
of the Swern oxidation interfering with the reductive amination. Dess-Martin periodinane (DMP) 
was used as an alternative oxidant as excess DMP can be removed easily in the work-up.
138
 
Following fairly clean conversion to aldehyde 16b, the subsequent reductive amination gave a 
slightly higher yield of amine 47b over the two steps, along with by-products alcohol 16b and 
nitrile 48b (Scheme 5.24). A postulated mechanism for the formation of nitrile 48 was via 
intermediate iminium 49 followed by retro-ene-type reaction to give nitrile 48 and allene, although 
a test reaction carrying out the reaction without the addition of NaBH3CN did not yield any of 
nitrile 48. 
 
 
 
Scheme 5.24 – DMP oxidation of alcohol 16b and subsequent reductive amination 
 
Although the oxidation and reductive amination sequence was still fairly low yielding, this was 
considered sufficient and was therefore applied to alcohol 16a, which gave a better yield of amine 
47a (Scheme 5.25). On this occasion, neither the corresponding nitrile nor alcohol 16a were 
observed, possibly a result of the less hindered nature of the reacting centre. 
 
 
 
Scheme 5.25 – DMP oxidation of alcohol 16a and subsequent reductive amination 
 
5.2.3 Installation of Aryl Azides 
 
With amines 47a and 47b in hand, selective acylation of the secondary amine was required to allow 
a range of photoactivatable groups to be introduced at this position. NHS ester 51 was synthesised 
from acid 50 as its tempered reactivity would hopefully give selectivity for the more nucleophilic 
secondary amine over the electron deficient exocyclic aromatic amine (Scheme 5.26). However, 
reaction with amine 47b showed no conversion either at rt or 50 °C, or following the addition of 
DMAP. 
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Scheme 5.26 – Synthesis of NHS ester 51 and attempted amide formation 
 
More reactive acid chloride 48a was therefore synthesised in a high yield over two steps and 
subsequent reaction with amine 16b gave photoaffinity probe 46a in reasonable yield (Scheme 
5.27). Although the regioselectivity of amide formation was not definitively confirmed, only one 
amide product was isolated from the reaction (as confirmed by LC-MS analysis and coalescence of 
the rotamers in VT 
1
H-NMR), and amide formation solely with the exocyclic aromatic amine would 
be very unlikely based on the expected relative nucleophilicities of the two amines. Additionally, 
there was very little shift in the pyrazole and pyrimidine protons in the 
1
H-NMR spectra after amide 
formation, in contrast with the ca. 0.5 ppm shift of the corresponding protons of amide 37 
synthesised previously (see Table 5.3). Finally, the IR band at 1646 cm
-1
 correlates better with a 
tertiary (1670-1630 cm
-1
) rather than a secondary (1700-1670 cm
-1
 and 1550-1510 cm
-1
) amide.
139
 
 
 
 
Scheme 5.27 – Synthesis of acid chloride 48a and subsequent amide formation 
 
Since successful conditions for amide formation had been found, three more acid chlorides were 
synthesised to allow for optimisation of the positioning of the aryl azide (Scheme 5.28). These were 
all obtained in high yield over two steps. 
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Scheme 5.28 – Synthesis of acid chlorides 48b-d 
 
These acid chlorides were then reacted with both amines 47a and 47b to give all eight photoaffinity 
probes in moderate to high yields (Table 5.5). These compounds were shown to exhibit restricted 
rotation on an NMR timescale, suggesting high conformational rigidity, especially for the shorter 
chain lengths, potentially hindering binding to the kinase compared with the more flexible longer-
chain probes. 
 
Table 5.5 – Synthesis of photoaffinity probes 46a-h 
 
 
 
Entry Photoaffinity Probe Yield/%  Entry Photoaffinity Probe Yield/% 
1 
 
47  5 
 
82 
2 
 
78  6 
 
77 
3 
 
85  7 
 
88 
4 
 
72  8 
 
75 
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In summary, eight second-generation photoaffinity probes have been successfully synthesised from 
two core pyrazolo[3,4-d]pyrimidines, with late late-stage introduction of the aryl azide. The switch 
in strategy from the first generation probes allowed the incorporation of an alkyne that should 
drastically simplify the isolation of kinase substrates. 
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6 Results and Discussion – Cross-Linking Optimisation 
 
6.1 Inhibition of PKCα by Photoaffinity Probes 46a-h 
 
In order to determine whether the probes could still 
bind to and thus inhibit PKCα, it was necessary to test 
them in kinase radioassays. It was important at this 
stage to ensure that the DTT concentration was low 
(<50 μM140) to avoid reduction of the azide. Initially, 
inhibitor 52 (bisindolylmaleimide I, BIM-I, IC50 10 
nM at 10 μM ATP141) was successfully used as a 
positive control to validate the inhibition assay (Graph 
6.1). In order to gauge the likely inhibitory potential of 
the photoaffinity probes, it was decided to also test C3-
unsubstituted inhibitor 4 since it was shown that small 
C3-substitution does not confer high affinity of the 
inhibitor to PKCα (M417A) (see Figure 4.1) and 
inhibition was observed, albeit at a relatively high concentration. 
 
The eight photoaffinity probes were therefore tested at 100 μM, and most showed some inhibition at 
this concentration, with the two longest, most flexible probes (46g-h) exhibiting the greatest 
potency, comparable to that of C3-unsubstituted inhibitor 4 (Graph 6.2). Since both 46g and 46h 
show good inhibition of the wild-type kinase and have different orientations of the azide, it was 
decided to use both these inhibitors in subsequent experiments since this should give the greatest 
chance of successful cross-linking. 
 
 
 
Graph 6.1 – Inhibition of PKCα by 
inhibitors 52 (BIM I) and 4 
 
Results shown are an average of 4 assays, errors 
shown are standard deviations 
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Graph 6.2 – Inhibition of PKCα by photoaffinity probes 46a-h 
Results shown are an average of 4 assays, errors shown are standard deviations 
 
The successful inhibition of PKCα with some of the photoaffinity probes suggested that the amide-
linked aryl azide does not hinder binding of the pyrazolo[3,4-d]pyrimidine motif to the ATP 
binding site. However, this assay provides no information on the binding orientation of the 
photoaffinity probes and therefore the proximity of the photoactivatable group to the protein 
substrate cannot be inferred. Furthermore, the type of inhibition had not been established. Small C3-
substituted pyrazolo[3,4-d]pyrimidines such 1b (1-Na-PP1) are Type I inhibitors. In Type II 
inhibition, the extra hydrophobic pocket in the ‘DFG-out’ conformation is located off the C3 
position as can be seen when comparing binding of AMP-PNP with inhibitor 53 (Imatinib), a 
known Type II kinase inhibitor and pyrazolo[3,4-d]pyrimidine inhibitor 54, which has been found 
to bind the ‘DFG-out’ kinase conformation (Figure 6.1). Although the extra functionality in the 
photoaffinity probes is located off the N1 position, the binding orientation of the pyrazolo[3,4-
d]pyrimidine moiety may have been altered. Apart from the fact that the photoactivatable group 
would be unlikely to be located in the correct position for successful cross-linking to the substrate in 
this orientation, the ‘DFG-out’ conformation of kinases can also generally not bind protein 
substrates.
142
 Therefore, the reasonable potency of photoaffinity probes 46g and 46h for PKCα gave 
no indication as to the likelihood of success in cross-linking to the kinase substrates. 
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Figure 6.1 – Crystal structures of c-Src bound with Type I and Type II inhibitors 
A. PDB entry 2src27: AMP-PNP; B. PDB entry 2oiq143: Type II inhibitor 53 (Imatinib); C. PDB entry 3el8142: 
pyrazolo[3,4-d]pyrimidine inhibitor 54. Images created using AstexViewerTM 
 
 
6.2 Cross-Linking and Huisgen [3+2] Cycloaddition 
 
Cross-linking and Huisgen [3+2] cycloaddition 
experiments using TAMRA azide (Figure 6.2) were 
therefore carried out using the two highest affinity 
photoaffinity probes 46g and 46h (Figure 6.3). Myelin 
basic protein (MBP) was selected as the substrate and, 
to ensure that any substrate labelling was specific, non-
PKCα substrate bovine serum albumin (BSA) was also used. Furthermore, parallel experiments 
were run in the absence of kinase for determination of non-specific background labelling. 
 
 
 
Figure 6.3 – Cross-linking and Huisgen [3+2] cycloaddition 
 
As expected, non-specific labelling of both MBP and BSA was observed in the absence of PKCα 
but this was not substantially altered in the presence of the kinase. However, the kinase band shows 
comparable fluorescence to both the BSA and MBP bands, suggesting that PKCα, present at 10-fold 
 
Figure 6.2 – Fluorescently-tagged azide 
used for Huisgen [3+2] cycloaddition 
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lower concentration, was preferentially labelled. This supported the inhibition assay results that the 
photoaffinity probes have an interaction with PKCα. The absence of an increase in MBP 
fluorescence in the presence of the kinase suggested one of three problems. Firstly, it was possible 
that PKCα was not correctly lipid-activated, which would have resulted in a kinase that was capable 
of complexing with small molecules in the ATP binding site, but incapable of binding protein 
substrates. Secondly, the azide orientation when bound to PKCα may have been unproductive, only 
allowing cross-linking to the kinase itself. Thirdly, since the probes have fairly poor affinity for 
PKCα and the interaction between the kinase and MBP is weak, any selective labelling may have 
been undetectable above background levels. 
 
The first of these three possibilities was ruled out as the kinase was shown to be active in the 
presence of all the assay components (except the photoaffinity probes) in a subsequent radioassay. 
To investigate the second possibility, the remaining six probes 46a-f were utilised in an attempt to 
observe increased cross-linking to MBP. However, similar results were obtained, suggesting that 
either all eight probes have an unproductive azide orientation or that the substrate cross-linking was 
undetectable above background in all cases. As discussed above, this latter issue was related to the 
inherently low potency of the photoaffinity probes for PKCα. It is known that wild-type PKCα has 
ca. 500-fold lower affinity for C3-unsubstuted inhibitor 4 (see Graph 6.1) than PKCα (M417A) has 
for the most potent C3-substituted pyrazolo[3,4-d]pyrimidine inhibitors (e.g. 1a (PP1) and 1b (1-
Na-PP1) (see Figure 4.3)). The use of PKCα (M417A) with a C3-substituted photoaffinity probe 
would greatly increase the lifetime of the kinase-probe complex and, should the azide have a 
productive orientation, detection of substrate-specific labelling over background fluorescence would 
be more likely. It was therefore necessary to investigate the synthesis of C3-substituted 
photoaffinity probes at an earlier stage than anticipated since these higher affinity probes should 
hopefully allow for identification and optimisation of substrate-selective labelling. 
 
In summary, five of the eight synthesised photoaffinity probes showed moderate inhibition of PKCα 
at 100 μM. Subsequent cross-linking reactions and Huisgen [3+2] cycloadditions proved successful, 
demonstrating that the azide can undergo photoactivation and cross-linking, and that the alkyne is 
suitably accessible for the subsequent [3+2] cycloaddition with the fluorescent tag. Although no 
substrate-specific labelling was observed, possibly due to the poor affinity of these C3-
unsubstituted probes for PKCα, the observed enhanced labelling of the kinase is consistent with the 
results of the earlier inhibition assay. 
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7 Results and Discussion – Incorporation of as-Kinase Selectivity into 
Photoaffinity Probes 
 
7.1 Towards as-Kinase Selective Photoaffinity Probes 
 
7.1.1 Installation of C3 Substituent 
 
In order to increase the interaction between the kinase and photoaffinity probe, it was therefore 
necessary to enable the introduction of the chosen C3 substituent, 1-naphthyl, into the probes. Two 
methods for the synthesis of such probes were possible; either the introduction of the substituent via 
the enol ether at an early stage of the synthesis or late-stage bromination/Pd-catalysed cross-
coupling. However, it was not known whether this substituent would require further optimisation 
due to the potentially altered binding orientation of the photoaffinity probes compared with the 
corresponding inhibitors. Furthermore, late stage introduction of the C3 substituent would enable 
facile application of this technique to multiple as-kinases with differing complementary C3 
substituents without the requirement to fully synthesise each probe independently. 
 
Bromination of alcohol 16a was attempted under the optimised conditions for corresponding 
pyrazolo[3,4-d]pyrimidine 4 (Scheme 7.1). However, incomplete conversion was observed after 24 
hours, a poor yield was obtained, and the product was difficult to purify. The reaction of alcohol 
16a appeared to be much slower, allowing degradation under the fairly harsh reaction conditions. 
Although the use of 2.2 equivalents of NBS resulted in complete conversion, neither yield nor 
product purity were increased. 
 
 
 
Scheme 7.1 – Bromination of pyrazolo[3,4-d]pyrimidines 4 and 16a 
 
Optimisation of bromination of pyrazolo[3,4-d]pyrimidine 4 was therefore attempted in an effort to 
find conditions to increase the rate of reaction. The use of bromine instead of NBS surprisingly did 
not give complete conversion under otherwise identical conditions (Table 7.1, Entries 1-2) and 
switching the solvent to AcOH resulted in no reaction (Entry 3). Addition of FeCl3 appeared to 
significantly speed up the bromination, giving 80% conversion after 3 hours by 
1
H-NMR analysis 
compared to 50% conversion without. Furthermore, this Lewis acid was not detrimental to product 
yield (Entry 4). 
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Table 7.1 – Bromination optimisation 
 
 
 
Entry Conditions Observations Isolated Yield/% 
1 NBS (1.1 eq.), MeCN, 80 °C complete conversion 56-79 
2 Br2 (1.1 eq.), MeCN, 80 °C incomplete conversion - 
3 Br2 (1.1 eq.), AcOH, 80 °C no conversion - 
4 NBS (1.1 eq.), FeCl3 (0.1 eq.), MeCN, 80 °C complete conversion 60 
 
 
However, addition of a Lewis acid to the bromination of alcohol 16a did not appear to speed up this 
reaction, possibly due to coordination of the FeCl3 by the free alcohol, and the reaction was less 
clean (Scheme 7.2). Addition of more equivalents 
of both reagents did not result in any improvement. 
Additionally, the product could not be easily 
separated from a by-product, tentatively assigned as 
resulting from bromination on the exocyclic amine. 
 
Since the presence of a free alcohol appeared to retard the bromination reaction and a clean product 
could not be isolated, it was decided to attempt bromination of benzyl ether 35. Under the standard 
conditions, significant decomposition was observed, most likely due to benzylic and phenyl 
bromination (Table 7.2, Entries 1-2). Addition of toluene in an attempt to stop the benzylic 
bromination was unsuccessful (Entry 3) and neither changing the solvent nor adding a base proved 
effective (Entries 4-6). 
 
Table 7.2 – Bromination optimisation on benzyl ether 35 
 
 
 
Entry Conditions Observations 
1 NBS (1.1 eq.), MeCN, 80 °C degradation 
2 NBS (1.1 eq.), MeCN, rt degradation 
3 NBS (1.1 eq.), PhMe, rt degradation 
4 NBS (1.1 eq.), THF, rt degradation 
5 Br2 (1.1 eq.), Na2CO3 (2.2 eq.), CH2Cl2, -10 °C degradation 
6 NBS (1.1 eq.), Na2CO3 (2.2 eq.), MeCN, 80 °C degradation 
 
 
Scheme 7.2 – Bromination of pyrazolo[3,4-
d]pyrimidine 16a in the presence of FeCl3 
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Alternative protection of the alcohol with a TIPS group was thought to potentially hinder ether-
coordination to NBS and remove the possibility of competing protecting group bromination as seen 
for benzyl ether 35. Protection of alcohol 16a was facile, giving silyl ether 56a in high yield 
(Scheme 7.3). Subsequent bromination with 1.1 eq. NBS did not give complete conversion, but 
increased equivalents resulted in detriment to the yield (Scheme 7.3). Addition of FeCl3 had no 
effect on the rate of reaction or yield. However, the product was again difficult to isolate from an 
unknown impurity, and further optimisation of purification was required. 
 
 
 
Scheme 7.3 – Silylation of alcohol 16a and subsequent bromination 
 
Prior to further optimisation of this bromination, it was considered important to check the 
applicability of this route to more hindered alcohol 56b, 
which may not accommodate a TIPS protecting group. 
However, it was shown to be possible to TIPS-protect 
alcohol 16b, albeit in a lower yield than corresponding 
longer chain alcohol 17a (Scheme 7.4). 
 
Similarly, it was considered prudent at this stage to check the viability of bromide 57 in subsequent 
coupling reactions. Simultaneous test Suzuki couplings were attempted on bromide 57 (impure) and 
unfunctionalised bromide 5, which is known to couple well
55*
 and a similar conversion was 
observed (Scheme 7.5). This preliminary result suggested that late-stage introduction of the C3 
substituent into the photoaffinity probes would be possible. However, bromination and Suzuki 
coupling without alcohol protection would be preferred to avoid the two extra steps that this would 
add to the synthesis and further optimisation of the bromination of free alcohols 16a and 16b is 
therefore required. 
 
 
 
Scheme 7.5 – Test Suzuki couplings 
 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
 
Scheme 7.4 – Silylation of alcohol 56b 
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Due to the problems with C3-bromination of the more 
functionalised pyrazolo[3,4-d]pyrimidines, it was 
hoped that a method could be found for direct 
arylation to avoid the need for pre-functionalisation. 
Various literature conditions shown to be successful 
on similar albeit more electron-rich systems were 
attempted on test substrate 4 (Scheme 7.6).
144,145
 However, none of these reactions gave any 
measurable conversion and it was clear that considerable further optimisation would be required, 
making the bromination/coupling strategy more practical. 
 
In summary, late-stage introduction of the C3 substituent into the photoaffinity probes was shown 
to be a viable strategy to allow synthesis of as-kinase selective photoaffinity probes for use in intact 
cells. However, further optimisation of the problematic C3 bromination is required. 
 
 
Scheme 7.6 – Attempted direct arylation 
of pyrazolo[3,4-d]pyrimidine 4 
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8 Results and Discussion – Hydrazine Synthesis 
 
Two functionalised hydrazines were used in the synthesis of the photoaffinity probes, each made by 
a different method. However, to allow for further optimisation of the photoaffinity probes, a general 
synthesis was sought that would allow facile variation of the hydrazine. Electrophilic amination was 
considered a suitable approach for the synthesis of such hydrazines given the vast array of amines 
accessible by current synthetic methods. 
 
8.1 Current Reagents for Electrophilic N-Amination 
 
Chloramine (NH2Cl) can be used to make 
mono- and di-substituted hydrazines via a 
modified Raschig synthesis.
146
 Although 
chloramine can disproportionate to a potentially 
explosive material, an in situ synthesis under 
phase transfer conditions has been devised and applied to the amination of pyrroles (Figure 8.1).
147
 
 
Oxaziridines have also been developed for N-amination, 
the first of which was cyclohexylspiro-3’-oxaziridine, 59 
(Figure 8.2A).
148
 Although amination was achieved on 
both primary and secondary amines, the reagent is 
unstable and therefore has to be prepared in situ.
152
 More 
stable aryl oxaziridines 62 and 63 were developed that 
incorporated protection on the nitrogen, giving Nβ-
protected hydrazines (Figure 8.2B). Reaction with 
primary amines was problematic, however, due to 
reaction with the ketone by-product to form imines.
149,150
 Boc-protected oxaziridine 65 has since 
been developed, which minimises imine formation but requires lengthy reaction times for amination 
(Figure 8.2C).
151
 Furthermore, this reagent has not currently been 
utilised for the synthesis of sterically demanding hydrazines. 
 
A range of O-substituted hydroxylamines has also been used for 
amination, predominantly of heterocyclic amines (Figure 8.3A).
153
 
There have been a few examples of the use of the mesityl 
derivative in the amination of primary and secondary amines, but 
this has not been explored to a significant extent.
154-157
 
 
 
 
Figure 8.1 - Use of chloramine for N-amination 
 
 
Figure 8.2 – Oxaziridine-mediated N-
amination
148-151
 
 
 
  
Figure 8.3 – Hydroxylamines 
for amination reactions 
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Furthermore, this technique generates unprotected hydrazines, which are frequently unstable and 
difficult to isolate. N-Protected hydroxylamines have also been used to generate N-protected 
hydrazines, but again, very little exploration of this area has been carried out (Figure 8.3B).
158
 
 
N-Protected, O-substituted hydroxylamines have been 
investigated much more in amination reactions, mainly for 
aziridination and C-amination (Figure 8.3C).
160-168
 A variety 
of derivatives have been used, with various leaving groups 
and protecting groups, although few attempts have been 
made at N-amination with these reagents. However, similar 
reagents with amide instead of carbamate functionality have reportedly been used for the synthesis 
of protected hydrazines (Figure 8.4).
159
  
 
8.2 Electrophilic Amination using Oxaziridine 65 
 
8.2.1 Hydrazine Formation 
 
As discussed above, oxaziridine 65 has been successfully used to synthesise Boc-protected mono-
substituted hydrazines from a range of aromatic and aliphatic amines.
151
 However, this research 
required the synthesis of hindered hydrazines containing hydroxyl functionality and no such 
examples had been reported. Therefore, it was hoped that the scope of this amination could be 
extended to these types of amines. 
 
Oxaziridine 65 was synthesised using the methods of Begtrup and Armstrong (Scheme 8.1).
169,170
 
Diazotisation of N-Boc hydrazine using sodium nitrate in aqueous acid gave azide 67, which was 
subsequently reacted without concentration with PPh3, giving iminophosphorane 68 in moderate 
yield over two steps. Aza-Wittig reaction with diethylketomalonate gave imine 69, which could be 
oxidised using mCPBA to give a fairly low yield of oxaziridine 65, although comparable to the 
literature. 
 
 
 
Scheme 8.1 – Synthesis of oxaziridine 65 
 
 
 
Figure 8.4 – N-amination with 
amide hydroxylamine derivatives
159
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The successful synthesis and good purity of oxaziridine 65 
was confirmed by amination of thioanisole to give sulfimide 
70 with high conversion and in good isolated yield (Scheme 
8.2). 
 
Amination of 2-phenethylamine was then attempted as this was the substrate used in the literature 
for the optimisation (Scheme 8.3).
151
 A comparably low yield of hydrazine 66a was isolated (34%), 
along with significantly increased quantities of both triazane 71 (24%) and imine 72 (18%). 
 
 
 
Scheme 8.3 – Amination of 2-phenethylamine using oxaziridine 65 
Values shown in brackets are literature yields151 
 
It was postulated that the formation of both triazane 71 and imine 72 would be more likely when 
aminating unhindered amines such as 2-phenethylamine. Given that this research required bulky 
substituents on hydrazines, the reaction may 
therefore be more successful using the required 
hindered amines. Amination of test substrate tert-
butylamine resulted in a significantly higher yield of 
hydrazine 66b with neither the corresponding 
triazane nor imine observed (Table 8.1, Entry 1). 
Two examples of hindered amines containing 
hydroxyl groups were also successfully aminated in 
slightly higher yields and again neither of the 
aforementioned by-products was observed (Entries 
2 and 3). 
 
8.2.2 One-Pot Pyrazole Formation 
 
Following on from the successful hydrazine formation, a three-step, one-pot synthesis of pyrazoles 
from the corresponding amines was envisaged. A two-step, one-pot deprotection/pyrazole formation 
of Boc-protected hydrazines had already been developed (see Scheme 5.4, Scheme 5.9) and good 
yields from this synthesis were dependent on efficient deprotection, which often required elevated 
 
Scheme 8.2 – Amination of 
thioanisole with oxaziridine 65 
 
Table 8.1 – Amination using oxaziridine 65 
 
 
Entry Amine Hydrazine Yield / % 
1 
 
 
68 
2 
 
 
71 
3 
 
 
71 
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temperatures. Therefore, amination of tert-butylamine was repeated in EtOH, giving only a slightly 
decreased yield of hydrazine 66a (55%) and the corresponding three-step, one-pot 
amination/deprotection/pyrazole formation gave pyrazole 3 in good yield (Scheme 8.4). 
 
 
 
Scheme 8.4 – One-pot amination, deprotection and pyrazole formation from tert-butylamine 
 
This novel one-pot pyrazole formation provides a rapid and flexible route to a wide range of N1-
substituted pyrazoles, potentially allowing facile optimisation of the linker region in the synthesis of 
further photoaffinity probes. However, the difficult synthesis of oxaziridine 65, combined with the 
slow amination reaction and significant by-product formation when synthesising unhindered 
hydrazines, suggested that the development of an alternative aminating agent would be of value. 
 
8.3 Electrophilic Amination using Hydroxylamine Derivatives 
 
As mentioned previously, Furukawa used N-protected, O-substituted hydroxylamines to generate 
hydrazides (Figure 8.4).
159
 It was conceived that replacement of the amide functionality on the 
amination reagent with a carbamate should allow the generation of Boc-protected hydrazines via 
this method and tosylate 74 was therefore synthesised in two steps in good yield (Scheme 8.5). 
 
 
 
Scheme 8.5 – Synthesis of tosylate 74 
 
Initial amination was attempted using 1.4 equivalents of 2-phenethylamine, but only a trace amount 
of hydrazine 66a was isolated along with a moderate yield of urea 75a (Scheme 8.6). It was 
discovered at this stage that Furukawa’s results had been subsequently challenged, with evidence 
that they had in fact also isolated the corresponding urea.
171
 
 
 
 
Scheme 8.6 – Attempted amination of 2-phenethylamine using tosylate 74 
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The mechanism for urea formation from hydroxylamine derivatives is thought to involve base-
catalysed nitrene formation followed by Lossen rearrangement to give isocyanate 77, which is then 
trapped with the amine (Scheme 8.7). Previous reports exist for base-catalysed rearrangement of 
both tosylate 74 and the corresponding nosylate.
160,165,171,172
 Furthermore, this reactivity has recently 
been exploited to make a range of substituted N-hydroxyureas.
173
 
 
 
 
Scheme 8.7 – Mechanism for formation of urea 37 
 
It has been stated that amines with a pKaH<6 react with tosylate 74 to give the expected hydrazines, 
whereas amines with a pKaH>9 react to give the corresponding ureas.
160
 This is consistent with the 
observations that pyridine (pKaH=5.5
174
), used in the reaction to synthesise tosylate 74, did not 
result in Lossen rearrangement, whereas the presence of 2-phenethylamine (pKaH=9.8
175
) promoted 
formation of urea 75a. However, it has been shown that tosylate 74 can be metallated without 
rearrangement with both lithium and sodium-containing bases, suggesting that some kind of 
coordination with the metal can stabilise the anion.
160,176
 Additionally, one synthesis of the tosyl 
derivative uses an equivalent of Et3N (pKaH=10.7
174
), which should have resulted in Lossen 
rearrangement of the product.
177
 However, this reaction occurred at 0 °C, suggesting that the rate of 
isocyanate formation may decrease with decreasing temperature. One further example includes the 
base-induced formation of a nitrene from the corresponding nosylate, which did not appear to 
rearrange before it reacted with [60]fullerene to give 55-60% yield of the desired aziridine.
178
 
 
The propensity of the tert-butyl carbamates to undergo Lossen rearrangement (seen more 
commonly in the corresponding amides) is surprising as they are generally used in aminations since 
they are considered to not undergo this type of rearrangement. The inconsistency of the literature 
reports of the reactivity of these compounds suggested that further investigation could potentially 
identify conditions for the selective formation of hydrazines. 
 
8.3.1 Optimisation of Amination 
 
The original amination conditions only gave a trace of hydrazine 66a and 46% urea 75a (Table 8.2, 
Entry 1). It was therefore decided to carry out a solvent screen in the hope that this would influence 
the product ratio in favour of hydrazine 66a, although no improvement was observed (Entries 2-8). 
Although the most polar solvents increased the rate of consumption of tosylate 74, this did not 
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translate into increased yields of either hydrazine 66a or urea 75a. Increasing the number of 
equivalents of the amine gave a slightly larger quantity of both hydrazine 66a and urea 75a (Entry 
9), as did increasing the temperature to 40 °C (Entry 10). However, combining increases in both 
amine equivalents and temperature did not improve the yield of hydrazine 66a further (Entry 11). 
 
Table 8.2 – Optimisation of amination using various reagents 
 
 
 
Entry 
Aminating 
reagent 
R LG Solvent Eq. amine T / °C Time / ha 
Yield / % 
66 75 
1 74 
tBu OTs CH2Cl2 1.4 rt 24 trace 46 
2 74 
tBu OTs MeOH 1.4 rt 2 - 30 
3 74 
tBu OTs Et2O 1.4 rt 72 trace 38 
4 74 
tBu OTs THF 1.4 rt 72 - 41 
5 74 
tBu OTs PhMe 1.4 rt 72 trace 20 
6 74 
tBu OTs MeCN 1.4 rt 72 - 41 
7 74 
tBu OTs DMF 1.4 rt 2 - 49 
8 74 
tBu OTs EtOAc 1.4 rt 72 - 53 
9 74 
tBu OTs CH2Cl2 4 rt 1 6 51 
10 74 
tBu OTs CH2Cl2 1.4 40 1 4 59 
11 74 
tBu OTs CH2Cl2 4 40 1 6 57 
12 78 
tBu OMs CH2Cl2 4 rt 1 6 65 
13 80 Bn OTs CH2Cl2 4 rt 1 13 28 
14 83 PMB OTs CH2Cl2 4 rt 1 9 24 
 
a. Reactions left for three days, unless complete conversion observed within this time 
 
Since no significant improvement in the ratio of hydrazine 66a to 
urea 75a had been observed, it was decided to attempt to tune the 
leaving group in order to alter the rate of deprotonation and 
subsequent Lossen rearrangement without significantly 
decreasing the rate of the desired nucleophilic attack by the amine. 
Mesylate 78 was synthesised in the same manner as tosylate 74 (Scheme 8.8), although amination 
using this reagent did not show an improvement in the yield of hydrazine 66a (Entry 12). 
 
Focus turned at this stage to altering the amine protecting group to hopefully generate derivatives 
that do not undergo Lossen rearrangement. Ethoxycarbonyl
165,179-182
, benzyloxycarbonyl (Cbz)
182
, 
  
 
Scheme 8.8 – Synthesis of 
mesylate 78 
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and substituted allyloxycarbonyl (Alloc)
163,168
 derivatives have been used in the literature and have 
not been shown to undergo rearrangement. It is possible that the greater electron-donating ability of 
the tert-butyl group over the ethoxy, benzyl 
and allyl groups allows the stabilisation of a 
positive charge on the migrating oxygen atom 
during the migration, as is seen in the Baeyer-
Villiger rearrangement (Scheme 8.9). 
 
The Cbz group was selected for further investigations since this allowed facile deprotection of the 
resulting hydrazine. An alternative, similar protecting group p-methoxybenzyloxycarbonyl (Moz) 
was also selected as this should allow in situ deprotection under acidic conditions prior to 
subsequent pyrazole formation (see Scheme 5.4).
183
 Tosylates of both these compounds were 
synthesised in the same manner as previous derivatives (Scheme 8.10). On reaction with 2-
phenethylamine, Cbz tosylate 80 gave an increased yield of 13% hydrazine 66b (Entry 13), which 
was much more promising than the corresponding trace amount using Boc tosylate 74 (Entry 9), 
and Moz tosylate 83 gave a slightly lower yield of hydrazine 66c of 9% (Entry 14). 
 
 
 
Scheme 8.10 – Synthesis of Cbz and Moz tosylates 80 and 83 
 
Although an increase in the selectivity of the reaction was observed, it is unlikely that further 
optimisation would give sufficient selectivity to give higher yields than were obtained using 
oxaziridine 65. 
 
 
Scheme 8.9 – Illustration of postulated build-up 
of positive charge during Lossen rearrangement 
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9 Conclusions and Future Work 
 
Constructs for the expression of both His6- and Strep-fusions of PKCα, PKCα (M417G) and 
(M417A) in mammalian cells were generated, although lengthy optimisation did not result in a 
suitable system to obtain sufficient quantities of protein. Baculoviruses were therefore constructed 
for the expression of GST fusions of all three kinases in insect cells and good expression was 
obtained, although optimisation was required to obtain fully phosphorylated kinases. PKCα 
(M417G) was shown to have reduced activity compared with both PKCα and PKCα (M417A).  
 
A new synthesis of 1c (1-NM-PP1) was devised and this compound, along with a panel of 22 
previously synthesised 3-substituted pyrazolo[3,4-d]pyrimidines, was tested for inhibition of PKCα 
(M417A) (Figure 9.1). Six compounds showed good inhibition at 100 nM, each with ca. 100-fold 
selectivity over the wild-type kinase. 1b (1-Na-PP1) was selected as the optimal inhibitor due to its 
known selectivity over various tyrosine 
kinases. Modelling the structures of the most 
potent inhibitors suggested scope to combine 
features of the corresponding C3 substituents 
to improve the potency and possibly the 
selectivity. 
 
Inclusion of an alkyne in the C3 substituent was proposed to 
allow for isolation of the cross-linked substrates via Huisgen 
[3+2] cycloaddition (Figure 9.2). However, the low potency 
observed with inhibitor 1v suggested that this initial strategy was 
not viable. Modelling suggested that inhibitor 1w might be a 
suitable alternative. 
 
Disulfide bond tethering was proposed as a new method of kinase-ATP engineering, generating an 
orthogonal as-kinase-ATP analogue pair with the ability to form a reversible covalent attachment 
for ease of purification. However, preliminary investigations into the synthesis of the required thiols 
were unsuccessful, and further optimisation would be required to assess the feasibility of this novel 
approach. 
 
Towards the first generation photoaffinity probes, a strategy was devised to allow for late stage 
optimisation of the photoactivatable group (Scheme 9.1). The synthesis of longer-chain alcohol 16a 
(m=1) required multiple strategy changes due to problems with various steps in the devised 
approach, and was obtained in moderate yield over the 5 steps (27%). However, synthesis of 
 
Figure 9.1 – 1c (1-NM-PP1) and most potent and 
selective PKCα (M417A) inhibitor 1b (1-Na-PP1) 
 
 
Figure 9.2 – Inhibitor 1v and 
postulated inhibitor 1w 
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shorter-chain alcohol 16b (m=0) proved much more straightforward, and this key intermediate 
could be obtained in much higher yield over 3 steps (54%). However, introduction of either aryl or 
benzyl azides did not prove possible, resulting in a switch in strategy to the second generation 
photoaffinity probes, with the incorporation of an alkyne to aid purification. Amines 47a and 47b 
were synthesised to allow the introduction of the photoactivatable group in the last step, and all 
eight photoaffinity probes were synthesised in moderate yield from alcohols 16a and 16b in 3 steps 
(17-44%). 
 
 
 
Scheme 9.1 – Synthesis of photoaffinity probe 46 
 
Five out of eight probes showed comparable inhibition of PKCα with unfunctionalised inhibitor 4, 
with probes containing longer chain lengths showing better inhibition. Cross-linking and Huisgen 
[3+2] cycloadditions were successful, although no substrate-specific labelling could be observed 
over background fluorescence. However, kinase-selective labelling was observed, confirming the 
interaction of the photoaffinity probes with PKCα. The use of an as-kinase along with C3-
substituted photoaffinity probes will likely be required to allow for detection of substrate-specific 
labelling. To this end, the synthesis of these probes was preliminarily investigated, with initial 
results for bromination and Suzuki coupling of a derivative of alcohol 16a proving moderately 
successful. This late-stage optimisation of the C3 substituent should allow application to the 
synthesis of multiple probes for optimisation with any as-kinase. 
 
An alternative method for the synthesis of 
protected hydrazines was sought to allow for 
further optimisation of positioning of the 
photoactivatable group. However, use of N-
protected, O-substituted hydroxylamines 
resulted predominantly in Lossen 
rearrangement to the corresponding ureas, and 
optimisation was unsuccessful in developing 
suitable conditions to limit this side-reaction (Scheme 9.2). However, the scope of amination using 
oxaziridine 65 was extended successfully to hindered amines and amino alcohols. Furthermore, it 
proved possible to carry out a one-pot amination, deprotection and pyrazole formation in good yield. 
 
Scheme 9.2 – Amination with hydroxylamine 
derivatives 74, 78, 80 and 83 and oxaziridine 75 
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10 Chemistry – Experimental 
 
General methods: All reactions were carried out under an argon atmosphere at rt using oven-dried 
glassware, unless otherwise specified. 
 
Solvents: Petrol refers to the fraction of light petroleum-ether boiling between 40-60 °C. Anhydrous 
solvents were obtained as follows: 
CH2Cl2 was purified by Innovative Technology Inc. PureSolv
TM
 Solvent Purification System or 
distilled from CaH2 immediately prior to use 
Et2O, MeOH, THF and PhMe were purified by Innovative Technology Inc. PureSolv
TM
 Solvent 
Purification System 
EtOH was distilled from magnesium ethoxide and stored over 4 Å molecular sieves 
 
Reagents: Chemicals were purchased from Acros Organics, Aldrich Chemical Co., Alfa Aesar, 
Avocado Chemical Co., Fisher Scientific, Fluka, Fluorochem, Maybridge, Lancaster Synthesis, 
Sigma Chemical Co. and Strem and handled in accordance with COSHH regulations. Solutions of 
n
BuLi were titrated against diphenylacetic acid. CH2Cl2 solutions of mCPBA were purified by 
extraction with pH 7.5 phosphate buffer (× 2), H2O (× 2) and brine and dried (MgSO4) before 
iodometric titration was completed to determine the concentration. MgO was dried at 140 °C in 
vacuo and stored under Ar. 2-Phenethylamine was distilled and stored over 4 Å molecular sieves. 
Isobutyraldehyde was distilled and stored under Ar. Otherwise, all reagents were used as 
commercially supplied. 
 
Chromatography: Flash chromatography was performed on silica gel (Merck Kieselgel 60 F254 
230-400 mesh) according to the method of W. C. Still.
184
 TLC was performed on glass-backed 
plates pre-coated with silica (0.2 mm, 60 F254) which were developed using standard visualising 
agents: UV fluorescence (254 and 366 nm) and KMnO4, cerium ammonium nitrate or ninhydrin 
with appropriate heating. 
 
1
H-NMR spectroscopy: 
1
H-NMR spectra were recorded on Bruker AV-400 or DRX-400 
instruments at 400 MHz; chemical shifts (δH) are quoted to the nearest 0.01 ppm downfield from 
TMS by referencing to the appropriate residual solvent peak (CHCl3, δ = 7.24 ppm; DMSO-d5, δ = 
2.50 ppm; CHD2OD, δ = 3.31 ppm) with coupling constants (J) reported to the nearest 0.1 Hz. 
 
13
C-NMR spectroscopy: 
13
C-NMR spectra were recorded on Bruker AV-400 or DRX-400 
instruments at 101 MHz; chemical shifts (δC) are quoted to the nearest 0.1 ppm downfield from 
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TMS by referencing to the appropriate solvent peak (CDCl3, δ = 77.0 ppm; DMSO-d6, δ = 39.5 ppm; 
CD3OD, δ = 49.2 ppm). 
 
31
P-NMR spectroscopy: 
31
P-NMR spectra were recorded on a Bruker AV-400 instrument at 162 
MHz; chemical shifts (δP) are quoted to the nearest 0.1 ppm downfield from 85% H3PO4 as an 
external standard. 
 
MS: Low resolution mass spectra (m/z) were recorded on VG Platform II or VG AutoSpec 
spectrometers, with only molecular ions (e.g. MH
+
), and major peaks being reported with intensities 
quoted as percentages of the base peak. High resolution mass spectra were recorded on a VG 
AutoSpec spectrometer. 
 
IR spectroscopy: IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR Spectrometer; 
absorbancies (υmax) are quoted to the nearest 1 cm
-1
. 
 
Melting Points: Melting points were determined on a Reichert microscope melting point apparatus 
 
Nomenclature: Compounds are named according to IUPAC nomenclature. Skeleton 
carbon/nitrogen atoms in compounds containing the pyrazolo[3,4-d]pyrimidine ring system are 
numbered according to IUPAC conventions. 
 
 
 
Ethoxymethylenemalononitrile, 2
185
 
 
According to the method of Quinn,
185
 triethyl orthoformate (30 mL, 182 mmol) was added to a 
solution of malononitrile (8.00 g, 121 mmol) in Ac2O (40 mL) and the solution heated to reflux (5 
h), whereupon it was cooled and the solvent removed in vacuo. The resulting solid was 
recrystallised (Et2O) to give the title compound as pale yellow amorphous crystals (12.2 g, 83%), 
mp 66-67 °C; δH (400 MHz, CDCl3) 7.55 (1H, s, CH), 4.38 (2H, q, J 7.2, CH2), 1.45 (3H, t, J 7.2, 
CH3). Data is in agreement with the literature.
185
 
 
 
 
 
 
 95 
5-Amino-1-tert-butyl-1H-pyrazole-4-carbonitrile, 3
186
 
 
According to the method of Rees,
94
 Et3N (10.3 mL, 73.7 mmol) and tert-butylhydrazine 
hydrochloride (3.06 g, 24.6 mmol) were added to a solution of enol ether 2 (3.00 g, 24.6 mmol) in 
EtOH (100 mL), and the solution heated to reflux (15 h), whereupon the solution was cooled and 
the solvent removed in vacuo. The resulting residue was dissolved in water (100 mL), which was 
extracted with EtOAc (3 × 75 mL), the organic layer extracted with brine (2 × 30 mL), dried 
(MgSO4), filtered and the solvent removed in vacuo. Recrystallisation (EtOAc) gave the title 
compound as off-white prisms (3.58 g, 89%), mp 103-104 °C (EtOAc); δH (400 MHz, CDCl3) 7.40 
(1H, s, Ar-H), 4.32 (2H, br s, NH2), 1.61 (9H, s, C(CH3)3). Data is in agreement with the 
literature.
186
 
 
1-tert-Butyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 4
55
 
 
According to the method of Rees,
94
 a solution of pyrazole 3 (1.75 g, 10.7 mmol) in formamide (17.5 
mL) was heated at 180 °C (14 h), whereupon it was cooled, poured into brine (50 mL) and extracted 
with EtOAc (4 × 50 mL). The organic layer was extracted with brine (3 × 50 mL), dried (MgSO4), 
filtered and the solvent removed in vacuo. The resulting solid was suspended in H2O and filtered to 
give the title compound as off-white amorphous crystals (1.90 g, 93%), mp 192-194 °C; δH (400 
MHz, CDCl3) 8.32 (1H, s, pyrimidine-H), 7.80 (1H, s, pyrazole-H), 5.52 (2H, br s, NH2), 1.78 (9H, 
s, C(CH3)3). Data is in agreement with the literature.
55
 
 
3-Bromo-1-tert-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 5
55
 
 
According to the method of McCague,
55*
 a solution of pyrazolo[3,4-d]pyrimidine 4 (1.00 g, 5.23 
mmol) and NBS (1.02 g, 5.75 mmol) in MeCN (10 mL) was heated at 80 °C (17 h). Upon cooling, 
the solvent was removed in vacuo. Purification by column chromatography, eluting with 
ether/petrol (gradient, 1:2 → 2:1) gave the title compound as pale yellow amorphous crystals (805 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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mg, 57%), mp 194-196 °C; Rf 0.36 (1:1 EtOAc/hexane); δH (400 MHz, CDCl3) 8.28 (1H, s, 
pyrimidine-H), 5.93 (2H, br s, NH2), 1.74 (9H, s, C(CH3)3). Data is in agreement with the 
literature.
55
 
 
2-(1-Hydroxy-2-naphthalen-1-yl-ethylidene)-malononitrile, 6 
 
According to the method of Rees,
94
 malononitrile (132 mg, 2.00 mmol) was added dropwise to a 
slurry of NaH (60% dispersion in mineral oil, 160 mg, 4.00 mmol) in THF (4 mL) at 0 °C. 
Naphthalen-1-yl acetyl chloride (409 mg, 2.00 mmol) was then added dropwise at 0 °C and the 
solution stirred at rt (2.5 h), whereupon it was acidified with 1 M HCl to pH 2, and H2O (20 mL) 
was added. The aqueous layer was extracted with EtOAc (3 × 30 mL), the organic layer dried 
(MgSO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with MeOH/EtOAc (gradient, 0:1 → 1:9), gave the title compound as colourless amorphous 
crystals (412 mg, 88%), mp 228-230 °C; Rf 0.41 (1:9 MeOH/EtOAc); υmax (thin film)/cm
-1
 3410, 
2208, 2180, 1539; δH (400 MHz, CD3OD) 8.09 (1H, d, J 8.4, Ar-H), 7.86-7.82 (1H, m, Ar-H), 7.77-
7.72 (1H, m, Ar-H), 7.53-7.48 (1H, m, Ar-H), 7.48-7.43 (1H, m, Ar-H), 7.43-7.39 (2H, m, Ar-H), 
4.15 (2H, s, CH2); δC (101 MHz, CD3OD) 195.6, 135.4, 134.4, 133.9, 129.6, 129.0, 128.4, 127.1, 
126.7, 126.6, 125.4, 123.3, 121.1, 51.1, 43.0. 
 
Naphthalen-1-yl-acetic acid methyl ester, 7
187
 and 2-(1-Methoxy-2-naphthalen-1-yl-
ethylidene)-malononitrile, 8
98
 
 
According to the method of Rees,
94
 NaHCO3 (717 mg, 8.53 mmol) was added in portionwise to a 
solution of enol 6 (250 mg, 1.07 mmol) in dioxane/H2O (3.5 mL, 6:1). Me2SO4 (707 μL, 7.47 mmol) 
was added to the resulting suspension, the reaction mixture heated to reflux (4.5 h), whereupon the 
solution was cooled to rt and H2O (20 mL) was added. The aqueous layer was extracted with ether 
(5 × 20 mL) and the organic layer dried (MgSO4), filtered and the solvent removed in vacuo. 
Purification by column chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:2), gave the 
following compounds: 
 
Ester 7
187
 as a pale yellow oil (69 mg, 32%), Rf 0.48 (1:3 EtOAc/hexane); υmax (thin film)/cm
-1
 2951, 
1733; δH (400 MHz, CDCl3) 8.01 (1H, d, J 8.5, Ar-H), 7.89-7.85 (1H, m, Ar-H), 7.81 (1H, dd, J 7.5, 
1.7, Ar-H), 7.58-7.53 (1H, m, Ar-H), 7.53-7.48 (1H, m, Ar-H), 7.47-7.40 (2H, m, Ar-H), 4.09 (2H, 
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s, CH2), 3.68 (3H, s, CH3); δC (101 MHz, CDCl3) 172.2, 134.0, 132.3, 130.7, 128.9, 128.3, 128.2, 
126.6, 126.0, 125.7, 123.9, 68.0, 52.3, 39.2; m/z (CI) 219 (31%), 218 (MNH4
+
, 100), 200 (17), 141 
(12). Found: MNH4
+
, 218.1192. C13H16NO2 requires 218.1181. Data is in agreement with the 
literature.
187
 
 
Enol ether 8
98
 as pale yellow amorphous crystals (15 mg, 6%), Rf 0.20 (1:3 EtOAc/hexane); υmax 
(thin film)/cm
-1
 2229, 1576; δH (400 MHz, CDCl3) 7.93-7.89 (2H, m, Ar-H), 7.85 (1H, d, J 8.2, Ar-
H), 7.64-7.59 (1H, m, Ar-H), 7.59-7.54 (1H, m, Ar-H), 7.49-7.44 (1H, m, Ar-H), 7.27-7.24 (1H, m, 
Ar-H), 4.44 (2H, s, CH2), 3.93 (3H, s, CH3); δC (101 MHz, CDCl3) 186.7, 134.2, 131.2, 129.5, 
129.3, 127.9, 127.4, 126.7, 125.8, 125.3, 122.5, 113.5, 111.7, 68.0, 59.7, 34.6; m/z (CI) 267 (38%), 
266 (MNH4
+
, 100), 248 (MH
+
, 15), 52 (16), Found: MNH4
+
, 266.1302. C16H16N3O requires 
266.1293. Data is in agreement with the literature.
98
 
 
1-Naphthylmethylzinc chloride, 9 
 
According to the method of Knochel,
102
 anhydrous LiCl (932 mg, 22.0 mmol) was dried in vacuo 
(250 °C, 30 min) before the addition of Zn dust (1.96 g, 30.0 mmol), and the mixture was heated 
further in vacuo (250 °C, 30 min). Upon cooling, THF (10 mL), 1,2-dibromoethane (86 µL, 1.00 
mmol) and TMS-Cl (127 µL, 1.00 mmol) were added, followed by 1-naphthylmethyl chloride (2.99 
mL, 20.0 mmol) and the solution stirred (rt, 20 h). The reaction mixture was allowed to settle and 
the solution of the title compound was separated from the remaining Zn dust as a pale yellow 
solution. Iodometric titration indicated a concentration of 0.70 M.
188
 
 
1-tert-Butyl-3-naphthalen-1-ylmethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 1c
29,189
 
 
According to the method of Knochel,
102
 zinc reagent 10 (0.70 M in THF, 793 µL, 0.555 mmol) was 
added to a solution of bromide 5 (100 mg, 0.370 mmol) and Pd(PPh3)4 (21 mg, 0.019 mmol) in 
THF (600 µL) and the reaction was heated to reflux (14 h). Upon cooling, the reaction was 
quenched with sat aq. NH4Cl (25 mL), the aqueous layer extracted with EtOAc (3 × 25 mL), the 
organic layer dried (MgSO4), filtered and the solvent removed in vacuo. Purification by column 
chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:1) gave the title compound as 
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colourless rods (99 mg, 81%), mp 165-167 °C; Rf 0.27 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 
3461, 3068, 1638, 1585, 1557; δH (400 MHz, CDCl3) 8.23 (1H, s, pyrimidine-H), 8.20-8.17 (1H, m, 
Ar-H), 7.90-7.86 (1H, m, Ar-H), 7.78 (1H, d, J 8.2, Ar-H), 7.56-7.49 (2H, m, Ar-H), 7.39-7.34 (1H, 
m, Ar-H), 7.19-7.15 (1H, m, Ar-H), 4.87 (2H, br s, NH2), 4.73 (2H, s, CH2) 1.82 (9H, s, C(CH3)3); 
δC (101 MHz, CDCl3) 157.8, 154.9, 154.8, 140.8, 134.2, 134.1, 132.1, 129.1, 128.4, 126.8, 126.4, 
126.0, 125.8, 123.7, 101.4, 60.2, 32.9, 29.4; m/z (CI) 333 (22%), 332 (MH
+
, 100), 197 (24). Found: 
MH
+
, 332.1885. C20H22N5 requires 332.1875. Data is in agreement with the literature.
29,189
 
 
1-tert-Butyl-3-trimethylsilanylethynyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 1v 
 
According to the method of Taylor,
106
 bromide 5 (50 mg, 0.185 mmol), ethynyltrimethylsilane (52 
μL, 0.370 mmol), Et3N (387 μL, 2.78 mmol), CuI (11 mg, 0.06 mmol), and Pd(PPh3)4 (21 mg, 
0.019 mmol) were dissolved in DMF (2 mL) and the solution heated at 105 °C (4.5 h) before being 
cooled to rt. Purification by column chromatography, eluting with ether/hexane (gradient, 1:2 → 1:1) 
gave the title compound as pale yellow needles (49 mg, 92%), mp 163-164 °C; Rf 0.64 (Et2O); υmax 
(thin film)/cm
-1
 3464, 2165; 1252; δH (400 MHz, CDCl3) 8.28 (1H, s, pyrimidine-H), 6.02 (2H, br s, 
NH2), 1.75 (9H, s, C(CH3)3), 0.28 (9H, s, Si(CH3)3); δC (101 MHz, CDCl3) 158.1, 155.4, 153.2, 
124.5, 103.6, 100.7, 97.0, 61.4, 29.2, -0.1; m/z (CI) 289 (22%), 288 (MH
+
, 100), 52 (16). Found: 
MH
+
, 288.1637. C14H22N5Si requires 288.1644. 
 
[N-Salicylidene-2-amino-isobutyrato]-[2-amino-isobutyrato]-cobalt (III), 19
115
 
 
According to the method of Carreira,
115
 a suspension of salicylaldehyde (2.14 mL, 20.1 mmol) and 
2-aminoisobutyric acid (2.07 g, 20.1 mmol) in water (20 mL) was stirred for ca. 5 min at rt before 
the addition of Co(OAc)2.4H2O (5.00 g, 20.1 mmol). The reaction mixture was heated to reflux (2 
h), the reaction mixture was cooled, the precipitate filtered, washed with H2O and dried in vacuo 
(12 h). 2-Isoaminobutyric acid (0.32 g, 3.14 mmol) was added to a suspension of a portion of the 
isolated solid (1.00 g, 3.14 mmol) in EtOH/H2O (42 mL, 15:6) under air and stirred at rt (6 h). The 
mixture was filtered and the solvent removed in vacuo. The residues were co-evaporated with 
CH2Cl2 (2 × 20 mL), dissolved in EtOH, filtered, the solvent removed in vacuo and the isolated 
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solid dried in vacuo (6 h, 80 °C). Purification by column chromatography, eluting with 
MeOH/CH2Cl2 (gradient, 0:1 → 1:1) gave the title compound as deep red-brown amorphous 
crystals as a mixture of two isomers (2:1) (1.195 g, 95%), δH (400 MHz, CD3OD) 8.63 (0.33Hminor, 
s, N=CH), 8.32 (0.67Hmajor, s, N=CH), 7.55 (0.33Hminor, dd, J 7.9, 1.5, Ar-H), 7.50 (0.67Hmajor, dd, J 
7.9, 1.5, Ar-H), 7.30-7.20 (1H, m, Ar), 7.10 (1H, d, J 8.5, Ar-H), 6.72-6.63 (1H, m, Ar-H), 1.84 
(1Hminor, s, CH3), 1.82 (1Hminor, s, CH3), 1.80 (2Hmajor, s, CH3), 1.71 (1Hminor, s, CH3), 1.68 (2Hmajor, 
s, CH3), 1.62 (1Hminor, s, CH3), 1.33 (2Hmajor, s, CH3), 1.27 (2Hmajor, s, CH3); m/z (ES
+
) 367 ((M-
OMe
-
)
+
, 38%), 324 (27), 323 (100), 302 (22). Data is in agreement with the literature.
115
 
 
N-(3-Hydroxy-1,1-dimethyl-propyl)-N’-(tert-butoxycarbonyl)hydrazinecarboxylic acid tert-
butyl ester, 20a
115
 
 
According to the method of Carreira,
115
 prenyl alcohol (203 μL, 2.00 mmol) and phenylsilane (247 
μL, 2.00 mmol) were added to a solution of Co catalyst 19 (40 mg, 0.100 mmol) in EtOH (10 mL) 
before the addition of di-tert-butyl azodicarboxylate (690 mg, 3.00 mmol). The resulting solution 
was stirred at rt (8 h), the reaction quenched with H2O (1 mL). Brine (5 mL) was added, the mixture 
extracted with EtOAc (3 × 10 mL), the organic layer dried (MgSO4) and the solvent removed in 
vacuo. Purification by column chromatography, eluting with EtOAc/hexane (gradient, 1:7 → 1:2) 
gave the title compound as colourless amorphous crystals (472 mg, 74%), mp 107-108 °C; Rf 0.12 
(1:5 EtOAc/hexane); δH (400 MHz, CDCl3, 52 °C) 6.24 (1H, br s, NH), 3.83-3.68 (2H, m, CH2OH), 
3.00 (1H, br s, OH), 2.26 (1H, br s, CHHCN), 1.87 (1H, br s, CHHCN), 1.46 (9H, s, C(CH3)3), 1.45 
(9H, s, C(CH3)3), 1.40 (3H, s, CH3CN), 1.31 (3H, s, CH3CN). Data is in agreement with the 
literature.
115
 
 
5-Amino-1-(3-hydroxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 21a 
 
Adapted from the method of Nudelman
190
, a solution of HCl in EtOH (1 M, 9.5 mL) was prepared 
by the addition of AcCl (676 μL, 9.50 mmol) to EtOH (9.5 mL) at 0 °C, whereupon hydrazine 20a 
(500 mg, 1.57 mmol) was added and the solution stirred at rt (17 h). The solution was cooled to 
0 °C before the addition of Et3N (1.97 mL, 14.1 mmol) and enol ether 2 (192 mg, 1.57 mmol) and 
the solution stirred at rt (6 h), whereupon the solvent was removed in vacuo. H2O (10 mL) and brine 
(20 mL) were added and extracted with EtOAc (3 × 30 mL), the organic layer dried (MgSO4), 
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filtered and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:0) gave the title compound as off-white amorphous crystals (170 
mg, 56%), mp 40-41 °C; Rf 0.38 (EtOAc); υmax (thin film)/cm
-1
 3347, 3242, 2219, 1646, 1635, 1530; 
δH (400 MHz, CDCl3) 7.41 (1H, s, pyrazole-H), 4.64 (2H, br s, NH2), 3.61 (2H, t, J 6.2, CH2OH), 
2.59 (1H, br s, OH), 2.13 (2H, t, J 6.2, CH2CH2OH), 1.63 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 
151.1, 138.9, 114.6, 78.4, 62.3, 58.8, 43.4, 28.1; m/z (CI) 196 (23%), 195 (MH
+
, 100). Found: MH
+
, 
195.1248. C9H15N4O requires 195.1246. 
 
2-(3,3-Dimethyl-pyrazolidin-1-ylmethylene)-malononitrile, 23 
 
Adapted from the method of Nudelman
190
, a solution of HCl in EtOH (1 M, 1.47 mL) was prepared 
by the addition of AcCl (104 μL, 1.47 mmol) to EtOH (1.47 mL), whereupon hydrazine 20a (78 mg, 
0.245 mmol) was added and the solution heated to reflux (7 h). The solution was cooled to 0 °C 
before the addition of Et3N (307 μL, 2.20 mmol) and enol ether 2 (30 mg, 0.245 mmol) and the 
solution stirred at rt (2 h), whereupon the solvent was removed in vacuo. H2O (10 mL) and brine 
(20 mL) were added and extracted with EtOAc (3 × 20 mL), the organic layer dried (MgSO4), 
filtered and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:0) gave the title compound as a pale yellow oil (31 mg, 72%), Rf 
0.47 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 3216, 2971, 2209, 2195, 1623; δH (400 MHz, CDCl3, 
mixture of rotamers, major/minor 3:2) 7.51 (0.6Hmajor, s, CH), 7.51 (0.4Hminor, s, CH), 4.69 (0.6H, 
br s, NH), 4.23 (0.4Hminor, br s, NH), 3.90 (1.2Hmajor, t, J 7.6, CH2N), 3.78 (0.8Hminor, t, J 7.6, CH2N), 
2.02 (1.2Hmajor, t, J 7.6, CH2CH2N), 1.92 (0.8Hminor, t, J 7.6, CH2CH2N), 1.24 (2.4Hminor, s, 2 × CH3), 
1.15 (3.6Hmajor, s, 2 × CH3); δC (101 MHz, CDCl3, mixture of rotamers) 155.0, 151.8, 118.1, 117.1, 
115.9, 115.8, 61.7, 59.5, 53.7, 49.5, 49.0, 46.9, 40.8, 39.1, 25.3, 24.4; m/z (CI) 195 (16%), 194 
(MNH4
+
, 79), 178 (22), 177 (MH
+
, 100), 58 (41). Found: MH
+
, 177.1139. C9H13N4 requires 
177.1140. 
 
5-Amino-1-(1,1-dimethyl-3-triisopropylsilanyloxy-propyl)-1H-pyrazole-4-carbonitrile, 24 
 
Adapted from the method of Smith,
191
 a solution of alcohol 21a (25 mg, 0.129 mmol), TIPS-Cl (41 
μL, 0.193 mmol), Et3N (54 μL, 0.386 mmol) and DMAP (12 mg, 0.010 mmol) in CH2Cl2 (500 μL) 
was stirred at rt (16 h). The reaction was quenched with H2O (10 mL), CH2Cl2 (10 mL) was added 
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and the organic layer separated. The aqueous layer was extracted with EtOAc (3 × 10 mL), the 
organic layer dried (MgSO4), filtered and the solvent removed in vacuo. Purification by column 
chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:3) gave the title compound as a 
colourless oil (38 mg, 84%), Rf 0.4 (1:3 EtOAc/hexane); υmax (thin film)/cm
-1
 3342, 2217, 1633; δH 
(400 MHz, CDCl3) 7.39 (1H, s, pyrazole-H), 4.60 (2H, br s, NH2), 3.64 (2H, t, J 6.0, CH2O), 2.10 
(2H, t, J 6.0, CH2CH2O), 1.65 (6H, s, NC(CH3)2), 1.10-0.92 (21H, m, 3 × CH(CH3)2, 3 × 
CH(CH3)2); δC (101 MHz, CDCl3) 151.1, 138.7, 114.7, 78.3, 62.2, 59.9, 43.8, 28.4, 18.1, 12.0; m/z 
(CI) 352 (25%), 351 (MH
+
, 100), 307 (8). Found: MH
+
, 351.2581. C18H35N4OSi requires 351.2580. 
 
2-[7,7-Dimethyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidin-3-yl]-1,3,5-triazine, 25 
 
According to the method of Rees,
94
 a solution of pyrazole 24 (50 mg, 0.257 mmol) in formamide 
(0.5 mL) was heated at 180 °C (20 h), whereupon it was cooled, poured into brine (10 mL) and 
extracted with EtOAc (4 × 15 mL). The organic layer was extracted with brine (2 × 10 mL) and 
H2O (2 × 15 mL), dried (MgSO4), filtered and the solvent removed in vacuo. Purification by 
column chromatography, eluting with MeOH/EtOAc (gradient, 0:1 → 1:9) gave the title compound 
as colourless amorphous crystals (10 mg, 21%), mp 96-100 °C; Rf 0.61 (1:9 MeOH/EtOAc); υmax 
(thin film)/cm
-1
 1606, 1554; δH (400 MHz, CDCl3) 8.79 (2H, s, triazine-H), 7.93 (1H, s, pyrazole-
H), 6.81 (1H, br s, NH), 3.53-3.48 (2H, m, NHCH2), 2.05-2.00 (2H, m, NHCH2CH2), 1.54 (6H, s, 2 
× CH3); δC (101 MHz, CDCl3) 167.4, 165.2, 147.7, 139.2, 99.2, 55.1, 36.5, 35.7, 28.3; m/z (CI) 232 
(27%), 231 (MH
+
, 100), 204 (18), 177 (16), 148 (14). Found: MH
+
, 231.1365. C11H15N6 requires 
231.1358. 
 
Benzylation of 5-Amino-1-(3-hydroxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 21a 
with Benzyl Bromide 
 
According to the method of Woerpel,
192
 BnBr (29 μL, 0.244 mmol) and alcohol 21a (50 mg, 0.257 
mmol) were added to a suspension of NaH (60% dispersion in mineral oil, 13 mg, 0.335 mmol) in 
THF (1.2 mL) at 0 °C. The reaction was warmed to rt and stirred (6 d) before being quenched with 
H2O (10 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL), the organic layer dried 
(MgSO4) and the solvent removed in vacuo. Purification by column chromatography, eluting with 
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EtOAc/hexane (gradient, 1:3 → 1:0) gave recovered starting material (10 mg, 20%) along with the 
following compounds: 
 
5-Amino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 26 as colourless 
amorphous crystals (5.5 mg, 7%), mp 40-41 °C; Rf 0.44 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 
3343, 3239, 2215, 1646, 1632, 1530; δH (400 MHz, CDCl3) 7.39 (1H, s, pyrazole-H), 7.34-7.20 (5H, 
m, Ar-H), 4.48 (2H, br s, NH2), 4.36 (2H, s, OCH2Ar), 3.41 (2H, t, J 6.1, CH2CH2O), 2.16 (2H, t, J 
6.1, CH2CH2O), 1.62 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 151.2, 138.7, 137.8, 128.7, 128.0, 
127.9, 114.7, 78.5, 73.4, 66.6, 62.1, 40.9, 28.3; m/z (CI) 286 (29%), 285 (MH
+
, 100). Found: MH
+
, 
285.1707. C16H21N4O requires 285.1715. 
 
5-Benzylamino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 27 as a colourless 
oil (8 mg, 8%), Rf 0.73 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 3410, 2210, 1558, 1541; δH (400 
MHz, CDCl3) 7.45 (1H, s, pyrazole-H), 7.35-7.25 (8H, m, Ar-H), 7.21-7.17 (2H, m, Ar-H), 4.79 
(1H, t, J 5.4, NH), 4.52 (2H, d, J 5.4, CH2NH), 4.30 (2H, s, OCH2Ar), 3.42 (2H, t, J 6.0, CH2CH2O), 
2.15 (2H, t, J 6.0, CH2CH2O), 1.62 (6H, s, 2 × CH3), δH (400 MHz, CH3OD) 7.38 (1H, s, pyrazole-
H), 7.35-7.18 (10H, m, Ar-H), 6.12 (1H, t, J 5.8, NH), 4.60 (2H, d, J 5.8, CH2NH), 4.32 (2H, s, 
OCH2Ar), 3.35 (2H, t, J 6.4, CH2CH2O), 2.25 (2H, t, J 6.4, CH2CH2O), 1.62 (6H, s, 2 × CH3); δC 
(101 MHz, CD3OD, mixture of rotamers) 152.4, 152.3, 140.9, 140.3, 139.5, 129.7, 129.5, 128.9, 
128.8, 128.5, 128.4, 117.3, 76.3, 74.1, 67.5, 62.7, 49.5, 49.3, 40.4, 28.5; m/z (ES
+
) 376 (27%), 375 
(MH
+
, 100). Found: MH
+
, 375.2179. C23H27N4O requires 375.2185. 
 
5-Benzylamino-1-(3-hydroxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 28 as a colourless 
oil (24.5 mg, 33%), Rf 0.57 (EtOAc); υmax (thin film)/cm
-1
 3403, 2943, 2213, 1569, 1546; δH (400 
MHz, CDCl3) 7.46 (1H, s, pyrazole-H), 7.39-7.28 (5H, m, Ar-H), 4.68 (2H, d, J 5.6, CH2NH), 4.64-
4.57 (1H, m, NH), 3.63-3.57 (2H, m, CH2OH), 2.11 (2H, t, J 6.2, CH2CH2OH), 2.08-2.04 (1H, m, 
OH), 1.61 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 151.0, 140.3, 137.8, 129.2, 128.3, 128.1, 116.0, 
77.0, 62.0, 58.9, 50.2, 43.6, 28.4; m/z (CI) 391 (8%) 286 (19), 285 (MH
+
, 100), 189 (9). Found: 
MH
+
, 285.1717. C16H21N4O requires 285.1715. 
 
2-Benzyloxy-pyridine, 30
193
 
 
According to the method of Dudley,
121
 a suspension of benzyl alcohol (5.17 mL, 50.0 mmol), 2-
chloropyridine (5.20 mL, 55.0 mmol) and ground KOH (9.26 g, 165 mmol) in PhMe (100 mL) were 
heated at 140 °C (1 h) with azeotropic removal of H2O (Dean-Stark apparatus). Upon cooling, H2O 
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(40 mL) and EtOAc (50 mL) were added, separated and the aqueous layer was extracted with 
EtOAc (2 × 40 mL), the organic layer dried (MgSO4), filtered and the solvent removed in vacuo. 
Purification by column chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:9) gave the 
title compound as a colourless oil (7.68 g, 83%), Rf 0.31 (1:19 EtOAc/hexane); δH (400 MHz, 
CDCl3) 8.20-8.16 (1H, m, pyridine H-6), 7.57 (1H, ddd, J 8.4, 7.3, 2.0, pyridine H-4), 7.49-7.44 
(2H, m, Ar-H), 7.40-7.35 (2H, m, Ar-H), 7.34-7.28 (1H, m, Ar-H), 6.89-6.85 (1H, m, pyridine H-5), 
6.81 (1H, dt, J 8.3, 0.8, pyridine H-3), 5.39 (2H, s, CH2); m/z (CI) 187 (27%), 186 (MH
+
, 100), 185 
(10); Found: MH
+
, 186.0922. C12H12NO requires 186.0919. Data is in agreement with the 
literature.
193
 
 
2-Benzyloxy-1-methylpyridinium triflate, 31
122
 
 
According to the method of Dudley,
122
 MeOTf (119 μL, 1.05 mmol) was added to a solution of 2-
benzyloxypyridine, 30 (185 mg, 1.00 mmol) in PhMe (1 mL) at 0 °C. The solution was stirred at rt 
(50 min) and the solvent removed in vacuo to give the title compound as colourless rods (351 mg, 
100%), mp 89-92 °C; δH (400 MHz, CDCl3) 8.47-8.44 (1H, m, pyridine H-6), 8.29 (1H, m, pyridine 
H-4), 7.63 (1H, d, J 8.8, pyridine H-5), 7.49-7.44 (2H, m, Ar-H), 7.41-7.34 (4H, m, 3 × Ar-H, 
pyridine H-3), 5.52 (2H, s, CH2), 4.03 (3H, s, CH3); m/z (ES
+
) 201 (15%), 200 ((M-OTf
-
)
+
, 100); 
Found: (M-OTf
-
)
+
, 200.1072. C13H14NO requires 200.1075. Data is in agreement with the 
literature.
122
 
 
Benzylation of 5-Amino-1-(3-hydroxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 21a 
with Reagent 31 
 
According to the method of Dudley,
122
 a mixture of alcohol 21a (50 mg, 0.257 mmol), pyridinium 
triflate 31 (95 mg, 0.515 mmol) and MgO (21 mg, 0.515 mmol) in PhMe (1 mL) was heated at 
85 °C (23 h). Upon cooling, the reaction mixture was filtered (Celite
®
), washed through with 
EtOAc, and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:0) gave the following compounds: 
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5-Amino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 26 as colourless 
amorphous crystals (22 mg, 30%). Data matches that obtained from BnBr benzylation of alcohol 
21a. 
 
5-Benzylamino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 27 as a colourless 
oil (6 mg, 6%). Data matches that obtained from BnBr benzylation of alcohol 21a. 
 
5-Benzylamino-1-(3-hydroxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 28 as a colourless 
oil (7 mg, 10%). Data matches that obtained from BnBr benzylation of alcohol 21a. 
 
(3-Methyl-but-2-enyloxymethyl)-benzene, 32
192
 
 
According to the method of Woerpel,
192
 BnBr (1.17 mL, 9.85 mmol) and prenyl alcohol (1 mL, 
9.85 mmol) were added to a suspension of NaH (60% dispersion in mineral oil, 512 mg, 12.8 
mmol) in THF (30 mL) at 0 °C. The reaction was warmed to rt and stirred (24 h) before being 
quenched with H2O (20 mL). The aqueous layer was extracted with hexane (3 × 20 mL) and the 
organic layer extracted with brine (2 × 20 mL), dried (MgSO4) and the solvent removed in vacuo. 
Purification by column chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:49) gave 
the title compound as a colourless oil (1.73 g, 100%), Rf 0.13 (1:49 EtOAc/hexane); δH (400 MHz, 
CDCl3) 7.36-7.24 (5H, m, Ar-H), 5.42-5.36 (1H, m, CH), 4.49 (2H, s, CH2Ph), 3.99 (2H, d, J 6.9, 
CH2CH), 1.74 (3H, s, CH3), 1.64 (3H, s, CH3). Data is in agreement with the literature.
192
 
 
N-(3-Benzyloxy-1,1-dimethyl-propyl)-N’-(tert-butoxycarbonyl)hydrazinecarboxylic acid tert-
butyl ester, 33 
 
According to the method of Carreira,
115
 alkene 32 (1.76 g, 10.0 mmol) and phenylsilane (1.62 mL, 
15.0 mmol) were added to a solution of Co catalyst 19 (200 mg, 0.50 mmol) in EtOH (50 mL) 
before the addition of di-tert-butyl azodicarboxylate (5.18 g, 22.5 mmol). The resulting solution 
was stirred at rt (5 d) before the reaction was quenched with brine (100 mL) and the aqueous layer 
extracted with EtOAc (3 × 100 mL), the organic layer dried (MgSO4) and the solvent removed in 
vacuo. Purification by column chromatography, eluting with EtOAc/hexane (gradient, 1:5 → 1:1) 
gave the title compound as a colourless oil (2.35 g, 58%), Rf 0.50 (1:3 EtOAc/hexane); υmax (thin 
film)/cm
-1
 3357, 2984, 1743, 1705, 1366; δH (400 MHz, CDCl3, 52 °C, mixture of rotamers, 
major/minor 2:1) 7.30-7.19 (5H, m), 6.17 (0.67Hmajor, br s, NH), 5.89 (0.33Hminor, br s, NH), 4.42 
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(2H, s, CH2Ph), 3.60-3.45 (2H, m, CH2CH2O), 2.36-2.26 (1H, m, CH2CHHO), 1.84-1.74 (1H, m, 
CH2CHHO), 1.47 (3H, s, CH3CN), 1.42 (9H, s, C(CH3)3), 1.36 (9H, s, C(CH3)3), 1.24 (3H, s, 
CH3CN); δC (101 MHz, CDCl3, 52 °C) 156.2, 155.0, 138.8, 128.6, 128.0, 127.8, 80.7, 73.4, 67.5, 
60.9, 39.2, 28.5, 28.5, 28.2, 26.8; m/z (CI) 426 (MNH4
+
, 38%), 410 (38), 409 (MH
+
, 100), 309 (59), 
208 (20). Found: MH
+
, 409.2698. C22H37N2O5 requires 409.2702. 
 
5-Amino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 26 
 
Adapted from the method of Nudelman
190
, a solution of HCl in EtOH (1 M, 14.7 mL) was prepared 
by the addition of AcCl (1.0 mL, 14.7 mmol) to EtOH (14.7 mL) at 0 °C, whereupon hydrazine 33 
(1.00 g, 2.45 mmol) was added and the solution heated to reflux (4 h). The solution was cooled to 
0 °C before the addition of Et3N (3.1 mL, 2.20 mmol) and enol ether 2 (299 mg, 2.45 mmol) and the 
solution stirred at rt (1.5 h), whereupon the solvent was removed in vacuo. H2O (50 mL) and brine 
(10 mL) were added and extracted with EtOAc (3 × 40 mL), the organic layer dried (MgSO4), 
filtered and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:2) gave the title compound as colourless amorphous crystals (627 
mg, 90%). Data matches that obtained from BnBr benzylation of alcohol 21a. 
 
1-(3-Benzyloxy-1,1-dimethyl-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 34 and 1-(3-
Benzyloxy-1,1-dimethyl-propyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one, 35 
 
According to the method of Rees,
94
 a solution of pyrazole 26 (1.30 g, 4.57 mmol) in formamide (13 
mL) was heated at 180 °C (19 h), whereupon it was cooled, poured into brine (50 mL) and extracted 
with EtOAc (3 × 50 mL). The organic layer was extracted with brine (2 × 50 mL), dried (MgSO4), 
filtered and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:0) gave the following compounds: 
 
Pyrimidine 34 as colourless amorphous crystals (1.25 g, 88%), mp 120-122 °C; Rf 0.48 (EtOAc); 
υmax (thin film)/cm
-1
 3336, 3186, 1643, 1594, 1556; δH (400 MHz, CDCl3) 8.30 (1H, s, pyrimidine-
H), 7.79 (1H, s, pyrazole-H), 7.28-7.11 (5H, m, Ar-H), 5.72 (2H, s, NH2), 4.31 (2H, s, CH2Ph), 3.33 
(2H, t, J 6.7, CH2CH2O), 2.52 (2H, t, J 6.8, CH2CH2O), 1.81 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 
157.7, 154.5, 153.7, 138.5, 128.9, 128.4, 127.6, 127.6, 102.1, 73.0, 66.8, 62.3, 40.4, 27.9; m/z (CI) 
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313 (19%), 312 (MH
+
, 100), 116 (38), 52 (89). Found: MH
+
, 312.1820. C17H22N5O requires 
285.1824. 
 
Pyrimidone 35 as colourless plates (63 mg, 4%), mp 70-72 °C; Rf 0.54 (EtOAc); υmax (thin 
film)/cm
-1
 2870, 1679, 1595; δH (400 MHz, CDCl3) 12.20 (1H, br s, OH), 8.04 (1H, s, pyrimidine-
H), 7.90 (1H, s, pyrazole-H), 7.29-7.16 (5H, m, Ar-H), 4.32 (2H, s, CH2Ph), 3.35 (2H, t, J 6.7, 
CH2CH2O), 2.49 (2H, t, J 6.7, CH2CH2O), 1.80 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 160.5, 
152.2, 144.3, 138.4, 133.2, 128.5, 127.7, 127.7, 107.6, 73.1, 66.7, 63.0, 40.7, 28.1; m/z (CI) 314 
(29%), 313 (MH
+
, 100), 213 (8), 52 (7). Found: MH
+
, 313.1663. C17H21N4O2 requires 313.1665. 
 
N-[1-(3-Benzyloxy-1,1-dimethyl-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-acetamide, 36 
 
According to the method of Gatta,
194
 a solution of BF3.OEt2 (24 μL, 0.193 mmol) was added to a 
solution of pyrazolo[3,4-d]pyrimidine 34 (75 mg, 0.241 mmol) in Ac2O (200 μL) and stirred at rt (6 
d). The solvent was removed in vacuo, the residue dissolved in CH2Cl2 (15 mL), washed with sat. 
aq. NaHCO3 (15 mL), the aqueous layer extracted with CH2Cl2 (2 × 15 mL), the organic layer dried 
(MgSO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with EtOAc/hexane (gradient, 0:1 → 1:2) gave the title compound as colourless crystals (78 
mg, 92%), mp 88-90 °C; Rf 0.69 (EtOAc); υmax (thin film)/cm
-1
 1727, 1603, 1548, 1498; δH (400 
MHz, CDCl3) 10.07 (1H, br s, NH), 8.53 (1H, s, pyrimidine-H), 8.46 (1H, s, pyrazole-H), 7.26-7.15 
(3H, m, Ar-H), 7.15-7.10 (2H, m, Ar-H), 4.28 (2H, s, CH2Ph), 3.35 (2H, t, J 6.7, CH2CH2O), 2.55 
(2H, t, J 6.7, CH2CH2O), 2.28 (3H, s, COCH3), 1.83 (6H, s, C(CH3)2); δC (101 MHz, CDCl3) 168.6, 
154.8, 152.9, 151.4, 138.4, 134.8, 128.4, 127.7, 127.6, 105.2, 73.1, 66.8, 62.5, 40.3, 27.9, 24.8; m/z 
(CI) 354 (MH
+
, 100%), 234 (44), 153 (52), 52 (38). Found: MH
+
, 354.1927. C19H24N5O2 requires 
354.1930. 
 
N-[1-(3-Hydroxy-1,1-dimethyl-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-acetamide, 37 
 
According to the method of Porcheddu,
195
 a solution of pyrazolo[3,4-d]pyrimidine 36 (50 mg, 0.141 
mmol) and 10% Pd/C (15 mg) in MeOH (2.5 mL) was stirred under an atmosphere of H2 (4 d). The 
reaction mixture was filtered (Celite
®
), washed through with MeOH and the solvent removed in 
vacuo. Purification by column chromatography, eluting with MeOH/EtOAc/hexane (gradient, 0:0:1 
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→ 1:9:0) gave the title compound as a white powder (37 mg, 99%), mp 127-129 °C; Rf 0.43 
(EtOAc); υmax (thin film)/cm
-1
 3344, 1695, 1603, 1553, 1514; δH (400 MHz, CDCl3) 8.55 (1H, s, 
pyrimidine-H), 8.43 (1H, s, pyrazole-H), 3.39 (2H, t, J 7.4, CH2CH2O), 2.49 (2H, t, J 7.4, 
CH2CH2O), 2.28 (3H, s, COCH3), 1.83 (6H, s, C(CH3)2); δC (101 MHz, CDCl3) 171.9, 155.9, 154.8, 
153.6, 135.6, 106.4, 63.4, 59.2, 44.1, 28.2, 24.2; m/z (CI) 265 (13%), 264 (MH
+
, 77), 223 (15), 222 
(100). Found: MH
+
, 264.1462. C12H18N5O2 requires 264.1461. 
 
3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butan-1-ol, 16a 
 
Adapted from the methods of Bierer and De Brabander,
126,196
 a solution of BBr3 (1 M in CH2Cl2, 
482 μL, 0.48 mmol) was added to a solution of pyrazolo[3,4-d]pyrimidine 36 (100 mg, 0.32 mmol) 
in CH2Cl2 (3.2 mL) at -78 °C and the solution allowed to warm to rt over 2 h. The reaction was 
quenched with 2 M NaOH (6 mL) and stirred vigorously (1 h) before the addition of H2O (46 mL). 
The aqueous layer was extracted with EtOAc (8 × 40 mL), the organic layer dried (MgSO4), filtered 
and the solvent removed in vacuo. Purification by column chromatography, eluting with 
MeOH/EtOAc (gradient, 0:1 → 1:4) gave the title compound as colourless rods (42 mg, 59%), mp 
155-156 °C; Rf 0.31 (1:19 MeOH/EtOAc); υmax (thin film)/cm
-1
 3338, 3198, 1651, 1597, 1557; δH 
(400 MHz, CD3OD) 8.15 (1H, s, pyrimidine-H), 8.01 (1H, s, pyrazole-H), 4.88 (3H, br s, OH, NH2), 
3.38 (2H, t, J 7.4, CH2CH2O), 2.44 (2H, t, J 7.4, CH2CH2O), 1.81 (6H, s, 2 × CH3); δC (101 MHz, 
CD3OD) 159.9, 155.6, 154.5, 131.6, 103.1, 63.0, 59.3, 44.3, 28.2; m/z (CI) 259 (11%), 223 (12), 
222 (MH
+
, 100), 136 (9), 52 (15). Found: MH
+
, 222.1350. C10H16N5O requires 222.1355. 
 
Benzylation of 5-Amino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 26 
with Benzyl Bromide 
 
According to the method of Woerpel,
192
 BnBr (85 μL, 0.716 mmol) and pyrazole 26 (185 mg, 0.651 
mmol) were added to a suspension of NaH (60% dispersion in mineral oil, 39 mg, 0.976 mmol) in 
THF (2 mL) at 0 °C. The reaction was warmed to rt and stirred (2 d) before being quenched with 
H2O (10 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL), the organic layer dried 
(MgSO4) and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 0:1 → 2:3) gave the following compounds: 
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5-Benzylamino-1-(3-benzyloxy-1,1-dimethyl-propyl)-1H-pyrazole-4-carbonitrile, 27 as a colourless 
oil (77 mg, 32%). Data matches that obtained from BnBr benzylation of alcohol 21a. 
 
1-(3-Benzyloxy-1,1-dimethyl-propyl)-5-dibenzylamino-1H-pyrazole-4-carbonitrile, 38 as a 
colourless oil (108 mg, 36%), Rf 0.78 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 2861, 2225, 1531; 
δH (400 MHz, CDCl3) 7.67 (1H, s, pyrazole-H), 7.35-7.18 (15H, m, Ar-H), 4.30 (2H, s, PhCH2O), 
4.23 (4H, br s, 2 × CH2N), 3.12 (2H, t, J 6.6, CH2CH2O), 2.15 (2H, t, J 6.6, CH2CH2O), 1.50 (6H, s, 
2 × CH3); δC (101 MHz, CDCl3) 155.0, 140.5, 138.3, 136.2, 129.7, 128.8, 128.5, 128.1, 127.7, 
127.7, 114.4, 89.3, 73.1, 66.3, 64.6, 58.6, 41.9, 28.5; m/z (ES
+
) 466 (37%), 465 (MH
+
, 100). Found: 
MH
+
, 465.2660. C30H33N4O requires 465.2654. 
 
N-(2-Hydroxy-1,1-dimethyl-ethyl)-N’-(tert-butoxycarbonyl)hydrazinecarboxylic acid tert-
butyl ester, 20b 
 
Adapted from the methods of Armstrong, List and Bräse
79,127,197
, a solution of isobutyraldehyde 
(1.37 mL, 15.0 mmol), L-proline (576 mg, 5.00 mmol), di-tert-butyl azodicarboxylate (2.30 g, 10.0 
mmol) and 2,2,2-trifluoroethanol (1.00 mL, 25.0 mmol) in CH2Cl2 (100 mL) was stirred at rt. On 
the disappearance of the yellow colour of the reaction mixture, indicating the complete consumption 
of all the di-tert-butyl azodicarboxylate, the solution was cooled (0 °C), EtOH (100 mL) and NaBH4 
(400 mg, 10.5 mmol) were added and the reaction stirred at rt (1 h). The excess NaBH4 was 
quenched with sat. aq. NH4Cl (150 mL), H2O (80 mL) was added, the aqueous layer extracted with 
EtOAc (3 × 200 mL), the organic layer dried (MgSO4), filtered and the solvent removed in vacuo. 
Purification by column chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:1) gave the 
title compound as colourless rods (2.97 g, 65%), mp 133 °C; Rf 0.23 (1:3 EtOAc/hexane); υmax (thin 
film)/cm
-1
 3330, 2980, 1708; δH (400 MHz, CDCl3) 6.28 (1H, br s, NH), 4.12 (1H, br s, OH), 4.08 
(1H, d, CHHOH, J 11.6), 3.28 (1H, d, CHHOH, J 11.6), 1.45 (9H, s, C(CH3)3), 1.43 (9H, s, 
C(CH3)3), 1.36 (3H, s, CH3CN), 1.24 (3H, s, CH3CN); δC (101 MHz, CDCl3) 157.7, 154.6, 82.0, 
81.6, 68.2, 64.1, 28.4, 24.5, 24.3; m/z (CI) 305 (MH
+
, 12%), 249 (28), 210 (23), 205 (69), 193 (12), 
166 (20), 149 (100), 117 (37), 104 (18). Found: MH
+
, 305.2080. C14H29N2O5 requires 305.2076. 
 
 
 
 
 
 
 109 
5-Amino-1-(2-hydroxy-1,1-dimethyl-ethyl)-1H-pyrazole-4-carbonitrile, 21b 
 
Adapted from the method of Nudelman
190
, a solution of HCl in EtOH (1 M, 15 mL) was prepared 
by the addition of AcCl (3.38 mL, 47.5 mmol) to EtOH (20 mL) at 0 °C, whereupon hydrazine 20b 
(2.41 g, 7.92 mmol) was added and the solution heated to reflux (2 h). The solution was cooled to 
0 °C before the addition of Et3N (9.93 mL, 71.3 mmol) and enol ether 2 (967 mg, 7.92 mmol) and 
the solution heated to reflux (2 h) whereupon the mixture was cooled and the solvent was removed 
in vacuo. H2O (100 mL) was added and extracted with EtOAc (3 × 100 mL), the organic layer dried 
(MgSO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with EtOAc/hexane (gradient, 0:1 → 1:0) gave the title compound as colourless cubes (1.29 
g, 90%), mp 103-105 °C; Rf 0.23 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 3163, 2215, 1630, 1552, 
1534; δH (400 MHz, CDCl3) 7.40 (1H, s, pyrazole-H), 4.85 (2H, br s, NH2), 3.84 (2H, s, CH2O), 
1.54 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 151.3, 139.1, 114.7, 77.5, 70.9, 63.4, 23.4; m/z (CI) 
181 (MH
+
, 13%), 123 (13), 106 (100). Found: MH
+
, 181.1091. C9H13N4O requires 181.1089. 
 
2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propan-1-ol, 16b 
 
According to the method of Rees,
94
 a solution of pyrazole 21b (1.13 g, 6.27 mmol) in formamide 
(11 mL) was heated at 180 °C (13 h), whereupon it was cooled, poured into brine (75 mL) and 
extracted with EtOAc (4 × 50 mL). The organic layer was extracted with brine (2 × 20 mL), dried 
(MgSO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with EtOAc/hexane (gradient, 0:1 → 1:0) and subsequent recrystallisation (EtOAc) gave the 
title compound as colourless amorphous crystals (1.02 g, 78%), mp 196-198 °C; Rf 0.28 (EtOAc); 
υmax (thin film)/cm
-1
 3335, 3187, 2978, 1666, 1641, 1549, 1557, 1308; δH (400 MHz, CD3OD) 8.15 
(1H, s, pyrimidine-H), 8.04 (1H, s, pyrazole-H), 4.04 (2H, s, CH2O), 1.67 (6H, s, 2 × CH3); δC (101 
MHz, CD3OD) 160.0, 155.7, 154.0, 132.3, 102.8, 69.4, 65.4, 24.8; m/z (CI) 216 (10%), 209 (13), 
208 (MH
+
, 100), 120 (15), 52 (28). Found: MH
+
, 208.1197. C9H14N5O requires 208.1198. 
 
General Procedure A: Azidation of Amines 
According to the method of Sechi,
198
 NaNO2 (1.5 eq.) was added portionwise to a 0.5 M solution of 
amine (1.0 eq.) in 5 M HCl at 0 °C, followed by NaN3 (4 eq.) and the reaction stirred at 0 °C (2 h). 
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The reaction was quenched with ice and basified to pH 8.5 with sat. aq. NaHCO3. The aqueous 
layer was extracted with EtOAc, the organic layer dried (MgSO4), filtered and the solvent removed 
in vacuo to give the title compound. 
 
General Procedure B: Bromination of Alcohols 
According to the method of Sechi,
198
 a solution of PBr3 (0.4 eq.) in CH2Cl2 (0.3 M) was added to a 
solution of alcohol (1.0 eq.) in CH2Cl2 (0.4 M) at 0 °C, whereupon the solution was warmed to rt 
and stirred (5 h). The reaction was quenched with 
i
PrOH/CH2Cl2 (1:5) and 1 M NaHCO3. The 
organic layer was separated and the aqueous layer was extracted with CH2Cl2, the organic layer 
dried (MgSO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with EtOAc/hexane (gradient, 0:1 → 1:19) gave the title compound. 
 
1-Azido-4-iodo benzene, 17a
199
 
 
Synthesised according to General Procedure A on a 2.28 mmol scale of 4-iodoaniline. Purification 
by column chromatography, eluting with hexane gave the title compound as pale yellow plates (492 
mg, 88%), Rf 0.45 (hexane); δH (400 MHz, CDCl3) 7.62 (2H, d, J 8.7, Ar-H), 6.77 (2H, d, J 8.7, Ar-
H); m/z (EI) 245 (M
+
, 63%), 217 (100), 90 (22), 63 (14). Data is in agreement with the literature.
199
 
 
1-Azido-3-iodo benzene, 17b
199
 
 
Synthesised according to General Procedure A on a 2.28 mmol scale of 3-iodoaniline. Purification 
by column chromatography, eluting with hexane gave the title compound as a yellow oil (493 mg, 
88%), Rf 0.46 (hexane); δH (400 MHz, CDCl3) 7.45 (1H, dt, J 7.8, 1.2, Ar-H), 7.36 (1H, s, J 1.9, Ar-
H), 7.05 (1H, t, J 7.9, Ar-H), 6.99-6.95 (1H, m, Ar-H); m/z (EI) 245 (M
+
, 37%), 217 (55), 90 (100), 
63 (35). Data is in agreement with the literature.
199
 
 
4-Azidobenzylalcohol, 40a
198
 
 
Synthesised according to General Procedure A on a 4.06 mmol scale of 4-aminobenzyl alcohol to 
give the title compound as beige needles (600 mg, 99%), mp 29-31 °C; Rf 0.43 (1:1 
EtOAc/hexane); δH (400 MHz, CDCl3) 7.33 (2H, d, J 8.3, Ar-H), 7.00 (2H, d, J 8.4, Ar-H), 4.65 
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(2H, s, CH2O), 1.71 (1H, br s, OH); m/z (EI) 149 (M
+
, 41%), 121 (68), 84 (58), 66 (100), 49 (63). 
Data is in agreement with the literature.
198
 
 
1-Azido-4-bromomethyl-benzene, 17c
198
 
 
Synthesised according to General Procedure A on a 1.68 mmol scale of alcohol 40a to give the title 
compound as a pale yellow semi-solid (303 mg, 85%), Rf 0.43 (1:19 EtOAc/hexane); δH (400 MHz, 
CDCl3) 7.36 (2H, d, J 8.5, Ar-H), 6.98 (2H, d, J 8.5, Ar-H), 4.46 (2H, s, CH2). Data is in agreement 
with the literature.
198
  
 
3-Azidobenzylalcohol, 40b
200
 
 
Synthesised according to General Procedure A on a 1.62 mmol scale of 3-aminobenzyl alcohol to 
give the title compound as a yellow oil (242 mg, 100%), Rf 0.43 (1:1 EtOAc/hexane); υmax (thin 
film)/cm
-1
 2105, 1608, 1590, 1557; δH (400 MHz, CDCl3) 7.31 (1H, d, J 7.8, Ar-H), 7.10 (1H, d, J 
7.9, Ar-H), 7.03 (1H, s, Ar-H), 6.94 (1H, dd, J 7.9, 1.9, Ar-H), 4.66 (2H, s, CH2O), 1.91 (1H, br s, 
OH); δC (101 MHz, CDCl3) 143.1, 140.5, 130.1, 123.4, 118.4, 117.5, 64.9; m/z (EI) 149 (M
+
, 25%), 
121 (63), 91 (61), 86 (51), 84 (78), 34 (32), 51 (38), 49 (100). Found: MH
+
, 149.0582. C7H7N3O 
requires 149.0589. 
 
1-Azido-3-bromomethyl-benzene, 17d
201
 
 
Synthesised according to General Procedure A on a 1.17 mmol scale of alcohol 40b to give the title 
compound as a pale yellow oil (195 mg, 78%), Rf 0.42 (1:19 EtOAc/hexane); δH (400 MHz, CDCl3) 
7.31 (1H, t, J 7.8, Ar-H), 7.15 (1H, d, J 7.7, Ar-H), 7.03 (1H, t, J 1.9, Ar-H), 6.95 (1H, m, Ar-H), 
4.43 (2H, s, CH2). Data is in agreement with the literature.
201
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Benzylation of 2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propan-1-ol, 16b with 
Reagent 31 
 
According to the method of Dudley,
122
 a mixture of alcohol 16b (53 mg, 0.257 mmol), pyridinium 
triflate 31 (95 mg, 0.515 mmol) and MgO (21 mg, 0.515 mmol) in PhMe (1 mL) was heated at 
85 °C (23 h). Upon cooling, the reaction mixture was filtered (Celite
®
), washed through with 
EtOAc, and the solvent removed in vacuo. Purification by column chromatography, eluting with 
EtOAc/hexane (gradient, 1:3 → 1:0) gave the following compounds: 
 
1-(2-Benzyloxy-1,1-dimethyl-ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 42 as a colourless 
gum (1 mg, 1%), Rf 0.61 (1:19 MeOH/EtOAc); υmax (thin film)/cm
-1
 3336, 3204, 2935, 1653, 1594, 
1557; δH (400 MHz, CDCl3) 8.27 (1H, br s, pyrimidine-H), 7.86 (1H, s, pyrazole-H), 7.37-7.18 (5H, 
m, Ar-H), 5.34 (2H, br s, NH2), 4.41 (2H, d, J 5.9, PhCH2O), 3.99 (2H, s, OCH2CN), 1.79 (6H, s, 2 
× CH3); m/z (CI) 299 (19%), 298 (MH
+
, 100), 153 (90), 136 (23). Found: MH
+
, 298.1669. 
C16H20N5O requires 298.1668. 
 
Benzyl-[1-(2-benzyloxy-1,1-dimethyl-ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine, 43 as 
colourless amorphous crystals (3 mg, 3%), mp 125-128 °C; Rf 0.79 (1:19 MeOH/EtOAc); υmax (thin 
film)/cm
-1
 3357, 2935, 1650, 1580; δH (400 MHz, CDCl3) 7.96 (1H, s, pyrimidine-H), 7.76 (1H, s, 
pyrazole-H), 7.36-7.19 (10H, m, Ar-H), 5.23 (2H, s, PhCH2O), 5.01 (1H, t, J 7.4, NH), 4.72 (2H, s, 
OCH2CN), 3.93 (2H, d, J 7.4, CH2NH), 1.61 (6H, s, 2 × CH3); m/z (CI) 388 (MH
+
, 38%), 298 
(100), 208 (45), 106 (74), 52 (54). Found: MH
+
, 388.2141. C23H26N5O requires 388.2137. 
 
2-(4-Benzylamino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propan-1-ol, 44 as colourless 
amorphous crystals (8 mg, 10%), mp 134-137 °C; Rf 0.71 (1:19 MeOH/EtOAc); υmax (thin film)/cm
-
1
 3287, 2935, 1611, 1563; δH (400 MHz, CDCl3) 8.34 (1H, br s, pyrimidine-H), 7.82 (1H, s, 
pyrazole-H), 7.37-7.28 (5H, m, Ar-H), 6.14 (1H, br t, J 5.7, NH), 4.83 (2H, d, J 5.7, CH2NH), 4.00 
(2H, d, J 5.8, CH2OH), 1.62 (6H, s, 2 × CH3); m/z (CI) 299 (39%), 298 (MH
+
, 100), 205 (21), 52 
(15). Found: MH
+
, 298.1676. C16H20N5O requires 298.1668. 
 
2-(4-Dibenzylamino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propan-1-ol, 45 as a colourless gum 
(6 mg, 6%), Rf 0.38 (1:19 MeOH/EtOAc); υmax (thin film)/cm
-1
 2938, 1644, 1575; δH (400 MHz, 
CDCl3) 7.79 (1H, br s, pyrimidine-H), 7.36 (1H, s, pyrazole-H), 7.37-7.11 (10H, m, Ar-H), 5.18 
(2H, s, CH2N), 4.43 (2H, s, CH2N), 3.87 (2H, s, CH2OH), 1.72 (6H, s, 2 × CH3); m/z (CI) 389 
(26%), 388 (MH
+
, 100), 298 (69), 52 (61). Found: MH
+
, 388.2136. C23H26N5O requires 388.2137. 
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1-Bromo-3-methyl-but-2-ene, 51
202
 
 
According to the method of Scott,
203
 PBr3 (940 μL, 10.0 mmol) was added to a solution of prenyl 
alcohol (2.03 mL, 20.0 mmol) in ether (100 mL) at 0 °C. The reaction was stirred (1.5 h) before 
being quenched with brine (100 mL). The aqueous layer was extracted with ether (2 × 75 mL), 
dried (MgSO4) and the solvent removed in vacuo to give the title compound as a colourless liquid 
(1.42 g, 48%), δH (400 MHz, CDCl3) 5.54-5.47 (1H, m, CH), 3.99 (2H, d, J 8.4, CH2), 1.76 (3H, s, 
CH3), 1.71 (3H, s, CH3). Data is in agreement with the literature.
202
 
 
2-(3-Methyl-but-2-enyl)-isoindole-1,3-dione, 52
204
 
 
According to the method of Coxon,
205
 a mixture of bromide 51 (1.40 g, 9.39 mmol) and potassium 
phthalimide (2.61 g, 14.1 mmol) in DMF (15 mL) was heated at 160 °C (16 h). Upon cooling, the 
solution was poured onto ice (20 g), the aqueous layer extracted with CHCl3 (3 × 20 mL), the 
organic layer washed with 0.1 M NaOH (20 mL), H2O (2 × 20 mL), dried (MgSO4), filtered and the 
solvent removed in vacuo. Recrystallisation (EtOH) gave the title compound as colourless prisms 
(1.76 g, 87%), mp 105-106 °C; Rf 0.37 (1:9 EtOAc/hexane); δH (400 MHz, CDCl3) 7.80 (2H, dd, J 
5.4, 3.0, Ar-H), 7.67 (2H, dd, J 5.5, 3.1, Ar-H), 5.28-5.22 (1H, m, CH), 4.24 (2H, d, J 7.2, CH2), 
1.80 (3H, s, CH3), 1.68 (3H, s, CH3); m/z (CI) 234 (21%), 233 (MNH4
+
, 76), 217 (27), 216 (MH
+
, 
100), 120 (22), 52 (21). Found: MH
+
, 216.1031. C13H14NO2 requires 216.1025. Data is in 
agreement with the literature.
204
 
 
N-(1,1-Dimethyl-2-oxo-ethyl)-N’-(tert-butoxycarbonyl)hydrazinecarboxylic acid tert-butyl 
ester, 54 
 
Adapted from the methods of Armstrong, List and Bräse
79,127,197
, a solution of isobutyraldehyde 
(1.08 mL, 15.0 mmol), L-proline (576 mg, 5.00 mmol), di-tert-butyl azodicarboxylate (2.3 g, 10.0 
mmol) and 2,2,2-trifluoroethanol (1.82 mL, 25.0 mmol) in CH2Cl2 (100 mL) was stirred at rt (3 d). 
Sat. aq. NH4Cl (50 mL) and H2O (50 mL) were then added, the aqueous layer extracted with EtOAc 
(2 × 100 mL), the organic layer dried (MgSO4), filtered and the solvent removed in vacuo to give 
the title compound as colourless needles (3.03 g, 67%), mp 132-134 °C; Rf 0.23 (1:5 
EtOAc/hexane); υmax (thin film)/cm
-1
 3310, 2979, 1736, 1667, 1365; δH (400 MHz, CDCl3, 52 °C) 
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9.40 (1H, s, CHO), 6.40 (1H, br s, NH), 1.42 (9H, s, C(CH3)3), 1.38 (9H, s, C(CH3)3), 1.26 (3H, s, 
CH3CN), 1.19 (3H, s, CH3CN); δC (101 MHz, CDCl3, 52 °C) 198.5, 156.0, 154.8, 82.9, 81.6, 67.0, 
28.3, 28.2, 20.6, 20.5; m/z (ES
+
) 367 (19%), 366 (100), 341 (22), 325 (MNa
+
, 73). Found: MNa
+
, 
325.1734. C14H26N2O5Na requires 325.1739. 
 
2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propionaldehyde, 50b 
 
Method 1: According to the method of Tojo,
138
 oxalyl chloride (510 μL, 6.03 mmol) was added 
dropwise to a solution of DMSO (857 μL, 12.1 mmol) in CH2Cl2 (35 mL) at -78 °C and the solution 
stirred (50 min). A solution of alcohol 16b (500 mg, 2.41 mmol) in CH2Cl2/DMSO (11 mL, 10:1) 
was added dropwise and stirred for a further 1 h before the addition of Et3N (3.4 mL, 24.1 mmol). 
The solution was stirred for an additional 30 min before being warmed to 0 °C, quenched with sat. 
aq. NaHCO3 (50 mL) and allowed to warm to rt. The layers were separated and the aqueous layer 
was extracted with EtOAc (3 × 40 mL), the combined organic layers were dried (MgSO4), filtered 
and the solvent removed in vacuo to give the crude title compound as a pale yellow solid (ca. 70% 
pure by 
1
H-NMR), Rf 0.38 (1:19 MeOH/EtOAc); δH (400 MHz, CDCl3) 9.74 (1H, s, CHO), 8.18 
(1H, s, pyrimidine-H), 7.93 (1H, s, pyrazole-H), 6.49 (1H, br s, NH2), 1.74 (6H, s, 2 × CH3); m/z 
(CI) 207 (23%), 206 (MH
+
, 100), 52 (9). Found: MH
+
, 206.1038. C9H12N5O requires 206.1042. The 
product was used without further purification. 
 
Method 2: According to the method of Tojo,
138
 a solution of alcohol 16b (500 mg, 2.41 mmol) and 
DMP (2.05 g, 4.83 mmol) in CH2Cl2/DMSO (25 mL, 9:1) was stirred (30 min), whereupon the 
reaction was quenched with sat. aq. Na2S2O3 (50 mL) and sat. aq. NaHCO3 (50 mL) and stirred (15 
min). The layers were separated and the aqueous layer was extracted with EtOAc (3 × 40 mL), the 
combined organic layers were dried (MgSO4), filtered and the solvent removed in vacuo to give the 
crude title compound as a pale yellow oil. Data matches that obtained from alternative oxidation. 
The product was used crude without further purification. 
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1-(1,1-Dimethyl-2-prop-2-ynylamino-ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 47b, 2-
(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propan-1-ol, 16 and 2-(4-Amino-
pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propionitrile, 48 
 
According to the method of McBride,
206
 propargylamine (265 μL, 4.14 mmol) was added to a 
solution of crude aldehyde 50b prepared by oxidation with DMP (425 mg, 2.07 mmol) in MeOH 
(15 mL) before the addition of AcOH (356 μL, 6.21 mmol), whereupon the solution was stirred at rt 
(50 min). NaBH3CN (390 mg, 6.21 mmol) was added and the solution stirred for a further 16 h. The 
reaction was quenched with 0.5 M HCl (30 mL), stirred (15 min), neutralised with sat. aq. NaHCO3 
and the aqueous layer extracted with EtOAc (3 × 40 mL). The organic layer was dried (MgSO4), 
filtered and the solvent removed in vacuo. Purification by column chromatography, eluting with 
Et3N/MeOH/EtOAc/hexane (gradient, 0:0:1:1 → 5:5:90:0) gave the following compounds: 
 
Amine 47b as colourless amorphous crystals (210 mg, 36% over 2 steps from alcohol 16b), mp 
143-145 °C; Rf 0.41 (1:19 MeOH/EtOAc); υmax (thin film)/cm
-1
 3305, 3190, 1646, 1596, 1557; δH 
(400 MHz, CDCl3) 8.30 (1H, s, pyrimidine-H), 7.83 (1H, s, pyrazole-H), 5.75 (2H, br s, NH2), 3.35 
(2H, d, J 2.3, CH2C CH), 3.31 (2H, s, CH2C(CH3)2), 2.15 (1H, t, J 2.3, C CH), 1.77 (6H, s, 2 × 
CH3); δC (101 MHz, CDCl3) 157.8, 154.7, 153.7, 129.3, 102.0, 82.5, 71.4, 63.5, 57.7, 38.9, 25.9; 
m/z (CI) 246 (32%), 245 (MH
+
, 100), 220 (23), 203 (20). Found: MH
+
, 245.1520. C12H17N6 requires 
245.1515. 
 
Alcohol 16b as colourless amorphous crystals (59 mg, 12% over 2 steps from alcohol 16b). Data 
matches that obtained from formation of pyrazole 21b. 
 
Nitrile 48 as colourless needles (55 mg, 11% over 2 steps from alcohol 16b), mp 181-183 °C; Rf 
0.47 (EtOAc); υmax (thin film)/cm
-1
 3330, 3166, 1648, 1595, 1566; δH (400 MHz, CDCl3) 8.36 (1H, 
s, pyrimidine-H), 7.94 (1H, s, pyrazole-H), 2.17 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 157.9, 
155.6, 153.8, 131.3, 120.1, 102.2, 55.5, 27.3; m/z (CI) 204 (26%), 203 (MH
+
, 100), 136 (12). Found: 
MH
+
, 203.1049. C9H11N6 requires 203.1045. 
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3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butyraldehyde, 50a and 1-(1,1-Dimethyl-
3-prop-2-ynylamino-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 47a 
 
According to the method of Tojo,
138
 a solution of alcohol 16a (50 mg, 0.226 mmol) and DMP (192 
mg, 0.452 mmol) in CH2Cl2/DMSO (2.5 mL, 9:1) was stirred (1.5 h), whereupon the reaction was 
quenched with sat. aq. Na2S2O3 (8 mL) and sat. aq. NaHCO3 (8 mL) and stirred (15 min). The 
layers were separated and the aqueous layer was extracted with EtOAc (2 × 15 mL), the combined 
organic layers were dried (MgSO4), filtered and the solvent removed in vacuo to give the crude 
aldehyde 50a as a white solid (ca. 80% pure by 
1
H-NMR), Rf 0.32 (1:19 MeOH/EtOAc); δH (400 
MHz, CDCl3) 9.44 (1H, br s, CHO), 8.26 (1H, s, pyrimidine-H), 7.88 (1H, s, pyrazole-H), 6.68 (2H, 
br s, NH2), 3.15 (2H, d, J 2.2, CH2), 1.82 (6H, s, 2 × CH3); m/z (CI) 221 (20%), 220 (MH
+
, 100), 
206 (MH
+
, 100), 196 (17), 163 (20), 91 (36), 74 (19). Found: MH
+
, 220.1200. C10H14N5O requires 
220.1198. 
 
According to the method of McBride,
206
 propargylamine (29 μL, 0.452 mmol) was added to a 
solution of crude aldehyde 50a in MeOH (3.5 mL) before the addition of AcOH (41 μL, 0.678 
mmol), whereupon the solution was stirred at rt (50 min). NaBH3CN (41 mg, 0.678 mmol) was 
added and the solution stirred for a further 17 h. The reaction was quenched with 0.5 M HCl (15 
mL), stirred (15 min), neutralised with sat. aq. NaHCO3 and the aqueous layer extracted with 
EtOAc (3 × 20 mL). The organic layer was dried (MgSO4), filtered and the solvent removed in 
vacuo. Purification by column chromatography, eluting with Et3N/MeOH/EtOAc/hexane (gradient, 
0:0:1:1 → 5:5:90:0) gave amine 47a as a white gum (29 mg, 50% over 2 steps from alcohol 16a), Rf 
0.29 (1:9 MeOH/EtOAc); υmax (thin film)/cm
-1
 3298, 3186, 1647, 1594, 1556; δH (400 MHz, CDCl3) 
8.25 (1H, s, pyrimidine-H), 7.82 (1H, s, pyrazole-H), 6.19 (2H, br s, NH2), 3.26 (2H, d, J 2.4, 
CH2C CH), 2.50-2.44 (2H, s, CHCH2N), 2.38-2.32 (2H, s, CH2CH2N), 2.07 (1H, t, J 2.4, C CH), 
1.75 (6H, s, 2 × CH3); δC (101 MHz, CDCl3) 158.0, 154.6, 153.6, 129.3, 102.1, 81.9, 71.6, 62.3, 
44.1, 40.6, 38.1, 27.8; m/z (CI) 260 (18%), 259 (MH
+
, 100), 224 (11), 204 (10), 196 (8). Found: 
MH
+
, 259.1678. C13H19N6 requires 259.1671. 
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4-Azidobenzoic acid, 50a
207,208
 
 
Synthesised according to General Procedure A on a 3.65 mmol scale of 4-aminobenzoic acid to give 
the title compound as pale yellow plates (594 mg, 100%), mp 188.5-190.5 °C; δH (400 MHz, 
CDCl3) 12.96 (1H, br s, CO2H), 7.98-7.94 (2H, m, Ar-H), 7.24-7.20 (2H, m, Ar-H); m/z (CI) 181 
(MNH4
+
, 25%), 172 (23), 156 (24), 155 (100), 152 (26), 137 (21), 120 (18), 52 (58). Found: 
MNH4
+
, 181.0724. C7H9N3O2 requires 181.0726. Data is in agreement with the literature.
207,208
 
 
4-Azido-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester, 51
209
 
 
According to the method of Pflum,
43
 EDC.HCl (413 mg, 1.99 mmol) was added to a solution of 
acid 50a (250 mg, 1.53 mmol), NHS (176 mg, 1.53 mmol) and Et3N (641 μL, 4.60 mmol) in 
CH2Cl2/DMF (1:1, 10 mL) at -78 °C, whereupon the solution was warmed up to rt and stirred (20 h) 
before removal of CH2Cl2 in vacuo. Addition of cold H2O precipitated the product, which was 
washed with cold H2O and dried in vacuo to give the title compound as white amorphous crystals 
(323 mg, 86%), mp 173-177 °C; υmax (thin film)/cm
-1
 2131, 1767, 1738, 1602; δH (400 MHz, CDCl3) 
8.12-8.08 (2H, m, Ar-H), 7.13-7.09 (2H, m, Ar-H), 2.89 (4H, s, 2 × CH2); δC (101 MHz, CDCl3) 
169.4, 161.3, 147.2, 132.7, 121.5, 119.5, 25.9; m/z (CI) 278 (MNH4
+
, 55%), 252 (59), 155 (100), 
137 (48), 120 (94), 52 (78). Found: MNH4
+
, 278.0894. C11H12N5O4 requires 278.0889. Data is in 
agreement with the literature.
209
 
 
General Procedure C: Acid Chloride Formation from Acids 
According to the method of Bauer,
210
 oxalyl chloride (1.2 eq.) was added to a solution or 
suspension of acid (1.0 eq.) in CH2Cl2 (0.6 M) and the reaction mixture stirred at rt (30 min). DMF 
(1 drop per mL of CH2Cl2) was added and the solution stirred at rt (1 h) before the solvent was 
removed in vacuo. 
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4-Azido-benzoyl chloride, 48a 
 
Synthesised according to General Procedure C on a 1.53 mmol scale of acid 50a to give the title 
compound as pale orange amorphous crystals (273 mg, 98%), mp 55.5-56.5 °C; υmax (thin film)/cm
-
1
 2127, 1775, 1741; δH (400 MHz, CDCl3) 8.12-8.08 (2H, m, Ar-H), 7.13-7.09 (2H, m, Ar-H); δC 
(101 MHz, CDCl3) 167.3, 147.7, 133.6, 129.7, 119.5. 
 
3-Azido-benzoic acid, 50b
211
 
 
Synthesised according to General Procedure A on a 3.65 mmol scale of 3-aminobenzoic acid to give 
the title compound as pale yellow crystals (499 mg, 84%), mp 163.5-165 °C; δH (400 MHz, CDCl3) 
13.23 (1H, br s, CO2H), 7.76-7.73 (1H, m, Ar-H), 7.58-7.56 (1H, m, Ar-H), 7.54 (1H, t, J 7.7, Ar-
H), 7.40-7.36 (1H, m, Ar-H). Data is in agreement with the literature.
211
 
 
3-Azido-benzoyl chloride, 48b 
 
Synthesised according to General Procedure C on a 1.53 mmol scale of acid 50b to give the title 
compound as pale yellow plates (276 mg, 99%), mp 159-162 °C; υmax (thin film)/cm
-1
 2117, 1770, 
1750, 1647; δH (400 MHz, CDCl3) 7.86 (1H, d, J 7.8, Ar-H), 7.68 (1H, s, Ar-H), 7.48 (1H, t, J 7.8, 
Ar-H), 7.30 (1H, d, J 7.8, Ar-H); δC (101 MHz, CDCl3) 167.6, 141.4, 134.8, 130.4, 127.7, 125.6, 
121.2. 
 
(4-Azido-phenyl)-acetic acid, 50c
212
 
 
Synthesised according to General Procedure A on a 3.31 mmol scale of 4-aminophenylacetic acid to 
give the title compound as beige rods (517 mg, 88%), mp 91-93 °C; υmax (thin film)/cm
-1
 2118, 
2093, 1691; δH (400 MHz, CDCl3) 11.60 (1H, br s, OH), 7.25 (2H, d, J 6.8, Ar-H), 6.98 (2H, d, J 
6.8, Ar-H), 3.61 (2H, s, CH2); δC (101 MHz, CDCl3) 178.3, 139.4, 131.0, 130.0, 119.4, 40.5; m/z 
(CI) 195 (MNH4
+
, 36%), 169 (100), 152 (32), 52 (24). Found: MNH4
+
, 195.0885. C8H11N4O2 
requires 195.0882. Data is in agreement with the literature.
212
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(4-Azido-phenyl)-acetyl chloride, 48c 
 
Synthesised according to General Procedure C on a 1.41 mmol scale of alcohol 50c to give the title 
compound as a deep red liquid (274 mg, 99%), υmax (thin film)/cm
-1
 2106, 1790; δH (400 MHz, 
CDCl3) 7.26-7.21 (2H, m, Ar-H), 7.04-6.99 (2H, m, Ar-H), 4.11 (2H, s, CH2); δC (101 MHz, CDCl3) 
172.0, 140.3, 131.1, 128.0, 119.7, 52.5. 
 
(3-Azido-phenyl)-acetic acid, 50d
213
 
 
Synthesised according to General Procedure A on a 3.31 mmol scale of 3-aminophenylacetic acid to 
give the title compound as beige amorphous crystals (579 mg, 99%), mp 65-67 °C; υmax (thin 
film)/cm
-1
 2111, 1701; δH (400 MHz, CDCl3) 12.02 (1H, br s, OH), 7.31 (1H, t, J 7.9, Ar-H), 7.06 
(1H, d, J 7.5, Ar-H), 6.98-9.63 (2H, m, Ar-H), 3.64 (2H, s, CH2); δC (101 MHz, CDCl3) 178.0, 
140.5, 135.2, 130.1, 126.1, 120.2, 118.2, 40.9; m/z (CI) 195 (MNH4
+
, 68%), 169 (100), 152 (43), 
108 (43), 52 (28). Found: MNH4
+
, 195.0883. C8H11N4O2 requires 195.0882. Data is in agreement 
with the literature.
213
 
 
(3-Azido-phenyl)-acetyl chloride, 48d 
 
Synthesised according to General Procedure C on a 1.41 mmol scale of alcohol 50d to give the title 
compound as a deep red liquid (268 mg, 97%), υmax (thin film)/cm
-1
 2106, 1790; δH (400 MHz, 
CDCl3) 7.34 (1H, t, J 7.9, Ar-H), 7.05-6.98 (2H, m, Ar-H), 6.91-6.85 (1H, m, Ar-H), 4.11 (2H, s, 
CH2); δC (101 MHz, CDCl3) 171.6, 140.9, 133.2, 130.5, 126.2, 120.3, 118.9, 52.8. 
 
General Method D: Amide Formation with Amine 47 and Acid Chloride 48 
 
According to the method of Wischart,
214
 Et3N (91 μL, 0.655 mmol) was added to a solution of 
amine 47 (0.164 mmol) in CH2Cl2 (2.5 mL) at 0 °C before the addition of acid chloride 48 (0.180 
mmol) in CH2Cl2 (2.5 mL). The reaction was allowed to warm to rt and stirred (ca. 17 h) before the 
 120 
addition of sat. aq. NaHCO3 (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL) 
and the organic layer dried (MgSO4), filtered and the solvent removed in vacuo. Purification by 
column chromatography, eluting with MeOH/EtOAc/hexane (gradient, 0:1:1 → 4:96:0) gave the 
title compound. 
 
N-[2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propyl]-4-azido-N-prop-2-ynyl-
benzamide, 46a 
 
White powder (30 mg, 47%), mp >240 °C; Rf 0.43 (EtOAc); υmax (thin film)/cm
-1
 3411, 3292, 3090, 
2135, 2100, 1646, 1602, 1560; δH (400 MHz, CDCl3, peaks broadened by restricted rotation) 8.35 
(1H, s, pyrimidine-H), 7.88 (1H, s, pyrazole-H), 7.36 (2H, s, Ar-H), 6.99 (2H, m, Ar-H), 5.44 (2H, 
br s, NH2), 4.38 (2H, s, CH2C CH), 3.31 (2H, s, CH2C(CH3)2), 2.01 (1H, t, J 2.4, C CH), 1.86 (6H, 
s, 2 × CH3); δH (400 MHz, DMSO-d6, peaks broadened by restricted rotation) 8.15 (1H, s, 
pyrimidine-H), 8.07 (1H, s, pyrazole-H), 7.63 (2H, br s, NH2), 7.32 (2H, s, Ar-H), 7.13 (2H, s, Ar-
H), 4.18 (2H, s, CH2C CH), 3.34 (2H, s, CH2C(CH3)2), 3.11 (1H, s, C CH), 1.77 (6H, s, 2 × CH3); 
δC (101 MHz, DMSO-d6, peaks broadened by restricted rotation) 170.8, 158.1, 154.9, 153.5, 140.8, 
132.0, 130.9, 128.4, 119.1, 101.6, 78.7, 75.2, 63.0, 54.9, 25.5; m/z (ES
+
) 453 (31%), 391 (27), 390 
(MH
+
, 100), 224 (28). Found: MH
+
, 390.1786. C19H20N9O requires 390.1791. 
 
N-[2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propyl]-3-azido-N-prop-2-ynyl-
benzamide, 46b 
 
Colourless amorphous crystals (50 mg, 78%), mp >240 °C; Rf 0.44 (EtOAc); υmax (thin film)/cm
-1
 
3309, 3204, 2110, 1632, 1593, 1560; δH (400 MHz, CDCl3, peaks broadened by restricted rotation) 
8.31 (1H, s, pyrimidine-H), 7.87 (1H, s, pyrazole-H), 7.30 (1H, s, Ar-H), 7.16-6.93 (3H, m, Ar-H), 
5.95 (2H, br s, NH2), 4.35 (2H, s, CH2C CH), 3.25 (2H, s, CH2C(CH3)2), 2.05 (1H, s, C CH), 1.90 
(6H, s, 2 × CH3); δC (101 MHz, CDCl3, peaks broadened by restricted rotation) 171.7, 157.8, 154.9, 
154.3, 140.7, 137.5, 130.2, 129.9, 123.1, 120.5, 117.4, 102.3, 78.1, 73.2, 64.2, 51.8, 40.0, 26.1; m/z 
(ES
+
) 453 (25%), 431 (14), 391 (25), 390 (MH
+
, 100). Found: MH
+
, 390.1783. C19H20N9O requires 
390.1791. 
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N-[2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propyl]-2-(4-azido-phenyl)-N-prop-2-
ynyl-acetamide, 46c 
 
Colourless amorphous crystals (56 mg, 85%), mp 152-153 °C; Rf 0.43 (EtOAc); υmax (thin film)/cm
-
1
 3291, 3116, 2112, 2079, 1655, 1594, 1554; δH (400 MHz, CDCl3, mixture of rotamers, 
major/minor 3:1) 8.32 (0.25H, s, pyrimidine-H), 8.30 (0.75Hmajor, s, pyrimidine-H), 7.87 (0.25Hminor, 
s, pyrazole-H), 7.84 (0.75Hmajor, s, pyrazole-H), 7.17 (1.5Hmajor, d, J 8.3, Ar-H), 7.10 (0.5Hminor, d, J 
8.3, Ar-H), 6.94 (1.5Hmajor, d, J 8.3, Ar-H), 6.92 (0.5Hminor, d, J 8.3, Ar-H), 5.65 (0.5Hminor, br s, 
NH2), 5.62 (1.5Hmajor, br s, NH2), 4.21 (1.5Hmajor, s, CH2Ar), 4.07 (0.5Hminor, s, CH2Ar), 3.92 
(0.5Hminor, d, J 2.1, CH2C CH), 3.71 (1.5Hmajor, s, CH2C(CH3)2), 3.48 (0.5Hminor, s, CH2C(CH3)2), 
3.37 (1.5Hmajor, d, J 2.1, CH2C CH), 2.08 (0.75Hmajor, t, J 2.1, C CH), 2.02 (0.25Hminor, t, J 2.1, 
C CH), 1.90 (1.5Hminor, s, 2 × CH3), 1.79 (4.5Hmajor, s, 2 × CH3); δH (400 MHz, DMSO-d6, mixture 
of rotamers, major/minor 2:1) 8.17 (1H, s, pyrimidine-H), 8.17 (0.33Hminor, s, pyrazole-H), 8.08 
(0.67Hmajor, s, pyrazole-H), 7.66 (2H, br s, NH2), 7.22-7.17 (1.33Hmajor, d, J 8.3, Ar-H), 7.12-7.08 
(0.67Hminor, s, Ar-H), 7.06-7.00 (2H, s, Ar-H), 4.04 (2H, s, CH2Ar), 3.72 (1.33Hmajor, s, 
CH2C(CH3)2), 3.58 (0.67Hminor, s, CH2C(CH3)2), 3.53 (1.33Hmajor, s, CH2C CH), 3.43 (0.67Hminor, s, 
CH2C CH), 3.15 (1.33Hmajor, t, J 2.2, C CH), 2.92 (0.67Hminor, t, J 2.1, C CH), 1.84 (2Hminor, s, 2 × 
CH3), 1.68 (4Hmajor, s, 2 × CH3); δC (101 MHz, DMSO-d6, mixture of rotamers) 171.9, 171.3, 158.7, 
155.6, 155.4, 154.1, 154.0, 138.0, 133.0, 131.6, 131.4, 131.3, 131.2, 119.3, 102.1, 102.0, 79.7, 79.5, 
75.3, 74.1, 63.6, 63.2, 54.4, 52.6, 39.0, 38.3, 38.2, 35.3, 26.0, 25.9; m/z (ES
+
) 467 (31%), 405 (24), 
404 (MH
+
, 100). Found: MH
+
, 404.1949. C20H22N9O requires 404.1947. 
 
N-[2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methyl-propyl]-2-(3-azido-phenyl)-N-prop-2-
ynyl-acetamide, 46d 
 
Colourless plates (47 mg, 72%), mp 96-99 °C; Rf 0.46 (EtOAc); υmax (thin film)/cm
-1
 3308, 3200, 
2113, 1639, 1592, 1557; δH (400 MHz, CDCl3, mixture of rotamers, major/minor 3:1) 8.30 (0.25H, 
s, pyrimidine-H), 8.28 (0.75Hmajor, s, pyrimidine-H), 7.87 (0.25Hminor, s, pyrazole-H), 7.84 
(0.75Hmajor, s, pyrazole-H), 7.27-7.19 (1H, m, Ar-H), 6.94 (0.75Hmajor, d, J 7.6, Ar-H), 6.88-6.82 
(2H, m, Ar-H), 6.75 (0.25Hminor, s, Ar-H), 5.99 (0.5Hminor, br s, NH2), 5.93 (1.5Hmajor, br s, NH2), 
4.20 (1.5Hmajor, s, CH2Ar), 4.06 (0.5Hminor, s, CH2Ar), 3.93 (0.5Hminor, d, J 2.1, CH2C CH), 3.72 
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(1.5Hmajor, s, CH2C(CH3)2), 3.46 (0.5Hminor, s, CH2C(CH3)2), 3.38 (1.5Hmajor, d, J 2.1, CH2C CH), 
2.10 (0.75Hmajor, t, J 2.1, C CH), 2.05 (0.25Hmajor, t, J 2.1, C CH), 1.90 (1.5Hminor, s, 2 × CH3), 
1.79 (4.5Hmajor, s, 2 × CH3); δC (101 MHz, CDCl3, mixture of rotamers) 172.1, 171.5, 157.9, 157.8, 
155.0, 154.8, 154.2, 154.2, 140.4, 136.7, 130.2, 130.1, 130.1, 129.9, 125.9, 125.7, 119.9, 119.6, 
117.8, 117.8, 102.2, 102.2, 78.6, 78.2, 72.9, 72.3, 64.5, 63.6, 55.0, 53.6, 40.5, 39.8, 38.6, 36.3, 26.3, 
26.0; m/z (ES
+
) 467 (30%), 405 (27), 404 (MH
+
, 100). Found: MH
+
, 404.1948. C20H22N9O requires 
404.1947. 
 
N-[3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butyl]-4-azido-N-prop-2-ynyl-
benzamide, 46e 
 
Colourless plates (54 mg, 82%), mp 85-87 °C; Rf 0.44 (EtOAc); υmax (thin film)/cm
-1
 3317, 3209, 
2128, 2104, 1626, 1603, 1558; δH (400 MHz, CDCl3, mixture of rotamers, major/minor 3:2, peaks 
broadened by restricted rotation) 8.28 (1H, s, pyrimidine-H), 7.90 (0.33Hminor, s, pyrazole-H), 7.75 
(0.67Hmajor, s, pyrazole-H), 7.47 (0.67Hminor, s, Ar-H), 7.17 (1.33Hmajor, s, Ar-H), 7.02 (0.67Hminor, s, 
Ar-H), 6.82 (1.33Hmajor, s, Ar-H), 6.26 (2H, br s, NH2), 4.31 (1.33Hmajor, s, CH2C CH), 3.93 
(0.67Hminor, s, CH2C CH), 3.44 (0.67Hminor, s, CH2CH2N), 3.20 (1.33Hmajor, s, CH2CH2N), 2.63 
(0.67Hminor, s, CH2CH2N), 2.49 (1.33Hmajor, s, CH2CH2N), 2.21 (1H, t, J 2.4, CH2C CH), 1.84 
(2Hminor, s, 2 × CH3), 1.73 (4Hmajor, s, 2 × CH3); δC (101 MHz, CDCl3, peaks broadened by 
restricted rotation) 170.7, 157.9, 154.7, 153.5, 141.7, 131.9, 129.6, 128.6, 118.8, 102.0, 78.6, 72.5, 
61.6, 44.5, 38.8, 34.2, 27.5; m/z (ES
+
) 467 (22%), 405 (25), 404 (MH
+
, 100). Found: MH
+
, 
404.1947. C20H22N9O requires 404.1947. 
 
N-[3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butyl]-3-azido-N-prop-2-ynyl-
benzamide, 46f 
 
Colourless plates (51 mg, 77%), mp 57-59 °C; Rf 0.40 (EtOAc); υmax (thin film)/cm
-1
 3317, 3194, 
2107, 1625, 1590, 1556; δH (400 MHz, CDCl3, mixture of rotamers, major/minor 5:4, peaks 
broadened by restricted rotation) 8.27 (0.44Hminor, s, pyrimidine-H), 8.21 (0.56Hmajor, s, pyrimidine-
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H), 7.87 (0.44Hminor, s, pyrazole-H), 7.69 (0.56Hmajor, s, pyrazole-H), 7.36-6.80 (4H, m, Ar-H), 6.13 
(2H, br s, NH2), 4.27 (1.1Hmajor, s, CH2C CH), 3.85 (0.9Hminor, s, CH2C CH), 3.42 (0.9Hminor, s, 
CH2CH2N), 3.13 (1.1Hmajor, s, CH2CH2N), 2.61 (0.9Hminor, s, CH2CH2N), 2.40 (1.1Hmajor, s, 
CH2CH2N), 2.16 (1H, t, J 2.4, CH2C CH), 1.81 (2.7Hminor, s, 2 × CH3), 1.66 (3.3Hmajor, s, 2 × CH3); 
δC (101 MHz, CDCl3, mixture of rotamers, peaks broadened by restricted rotation) 170.5, 170.1, 
157.9, 154.7, 153.7, 153.4, 140.7, 140.4, 137.3, 137.2, 130.2, 129.7, 129.4, 123.3, 122.8, 120.8, 
120.2, 117.6, 117.2, 102.1, 101.9, 78.5, 43.2, 72.5, 62.1, 61.4, 44.5, 41.6, 39.4, 39.0, 37.4, 34.2, 
27.6, 27.4; m/z (ES
+
) 467 (23%), 405 (28), 404 (MH
+
, 100). Found: MH
+
, 404.1935. C20H22N9O 
requires 404.1934. 
 
N-[3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butyl]-2-(4-azido-phenyl)-N-prop-2-
ynyl-acetamide, 46g 
 
Colourless plates (60 mg, 88%), mp 50-52 °C; Rf 0.42 (EtOAc); υmax (thin film)/cm
-1
 3320, 3205, 
2116, 1635, 1594, 1557; δH (400 MHz, CDCl3, mixture of rotamers, major/minor 2:1) 8.29 
(0.67Hmajor, s, pyrimidine-H), 8.28 (0.33Hminor, s, pyrimidine-H), 7.84 (0.67Hmajor, s, pyrazole-H), 
7.83 (0.33Hminor, s, pyrazole-H), 7.16 (0.67Hminor, d, J 8.4, Ar-H), 6.98 (1.33Hmajor, d, J 8.4, Ar-H), 
6.92 (0.67Hminor, d, J 8.4, Ar-H), 6.86 (1.33Hmajor, d, J 8.4, Ar-H), 5.98 (1.33Hmajor, br s, NH2), 5.90 
(0.67Hminor, s, NH2), 4.15 (1.33Hmajor, d, J 2.4, CH2C CH), 3.91 (0.67Hminor, d, J 2.3, CH2C CH), 
3.66 (0.67Hminor, s, CH2Ar), 3.47 (1.33Hmajor, s, CH2Ar), 3.31-3.26 (0.67Hminor, m, CH2CH2N), 3.23-
3.17 (1.33Hmajor, m, CH2CH2N), 2.54-2.46 (2H, m, CH2CH2N), 2.18 (0.33Hminor, t, J 2.3, C CH), 
2.09 (0.67Hmajor, t, J 2.4, C CH), 1.77 (4Hmajor, s, 2 × CH3), 1.75 (2Hminor, s, 2 × CH3); δH (400 MHz, 
DMSO-d6, 110 °C) 8.16 (1H, s, pyrimidine-H), 8.08 (1H, s, pyrazole-H), 7.18 (2H, br s, NH2), 
7.17-7.12 (2H, m, Ar-H), 7.02-6.98 (2H, m, Ar-H), 4.09 (2H, d, J 2.5, CH2C CH), 3.56 (2H, s, 
CH2Ar), 3.28-3.23 (2H, m, CH2CH2N), 2.85 (1H, br s, C CH), 2.49-2.43 (2H, m, CH2CH2N), 1.76 
(6H, s, 2 × CH3); δC (101 MHz, CDCl3, mixture of rotamers) 170.7, 170.6, 157.9, 157.9, 155.0, 
154.7, 153.8, 153.7, 138.9, 138.7, 131.6, 131.5, 130.6, 130.3, 129.7, 129.6, 119.4, 119.3, 102.1, 
102.1, 78.9, 78.6, 72.9, 72.1, 62.1, 61.6, 43.4, 42.8, 40.1, 39.5, 39.2, 37.9, 37.8, 34.7, 27.7, 27.7; 
m/z (ES
+
) 481 (24%), 440 (15), 419 (27), 418 (MH
+
, 100). Found: MH
+
, 418.2097. C21H24N9O 
requires 418.2090. 
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N-[3-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-3-methyl-butyl]-2-(3-azido-phenyl)-N-prop-2-
ynyl-acetamide, 46h 
 
Colourless plates (51 mg, 75%), mp 44-46 °C; Rf 0.42 (EtOAc); υmax (thin film)/cm
-1
 3320, 3205, 
2116, 1635, 1594, 1557; δH (400 MHz, CDCl3, mixture of rotamers, major/minor 2:1) 8.29 
(0.67Hmajor, s, pyrimidine-H), 8.28 (0.33Hminor, s, pyrimidine-H), 7.86 (0.67Hmajor, s, pyrazole-H), 
7.83 (0.33minor, s, pyrazole-H), 7.24 (0.33Hminor, t, J 7.8, Ar-H), 7.18 (0.67Hmajor, t, J 7.8, Ar-H), 
6.95 (0.33Hminor, d, J 7.6, Ar-H), 6.89-6.77 (2H, m, Ar-H), 6.68 (0.67Hmajor, t, J 1.8, Ar-H), 5.98 
(1.33Hmajor, br s, NH2), 5.92 (0.67Hminor, s, NH2), 4.15 (1.33Hmajor, d, J 2.4, CH2C CH), 3.91 
(0.67Hminor, d, J 2.2, CH2C CH), 3.67 (0.67Hminor, s, CH2Ar), 3.49 (1.33Hmajor, s, CH2Ar), 3.32-3.26 
(0.67Hminor, m, CH2CH2N), 3.25-3.18 (1.33Hmajor, m, CH2CH2N), 2.54-2.47 (4H, m, CH2CH2N), 
2.19 (0.33Hminor, t, J 2.2, C CH), 2.10 (0.67Hmajor, t, J 2.4, C CH), 1.77 (4Hmajor, s, 2 × CH3), 1.75 
(2Hminor, s, 2 × CH3); δC (101 MHz, CDCl3, mixture of rotamers) 170.3, 170.3, 157.9, 157.8, 155.0, 
154.7, 153.8, 153.7, 140.5, 140.4, 136.9, 136.8, 130.1, 130.0, 129.8, 129.6, 125.9, 125.5, 119.8, 
119.5, 117.8, 117.7, 102.1, 102.1, 78.9, 78.6, 72.9, 72.1, 62.1, 61.6, 43.5, 42.9, 40.5, 40.0, 39.2, 
37.9, 37.7, 34.8, 27.7, 27.7; m/z (ES
+
) 481 (30%), 440 (29), 419 (36), 418 (MH
+
, 100). Found: MH
+
, 
418.2104. C21H24N9O requires 418.2090. 
 
1-(1,1-Dimethyl-3-triisopropylsilanyloxy-propyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 56a 
 
Adapted from the method of Smith,
191
 a solution of alcohol 16a (100 mg, 0.452 mmol), TIPS-Cl 
(193 μL, 0.904 mmol), Et3N (252 μL, 1.81 mmol) and DMAP (4 mg, 0.034 mmol) in CH2Cl2 (2 
mL) was stirred at rt (44 h). The reaction was quenched with H2O (30 mL), CH2Cl2 (20 mL) was 
added and the organic layer separated. The aqueous layer was extracted with EtOAc (3 × 20 mL), 
the organic layer dried (MgSO4), filtered and the solvent removed in vacuo. Purification by column 
chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:1) gave the title compound as a 
white powder (154 mg, 90%), mp 116-119 °C; Rf 0.24 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 
3319, 3156, 1643, 1096; δH (400 MHz, CDCl3) 8.29 (1H, s, pyrimidine-H), 7.81 (1H, s, pyrazole-
H), 5.95 (2H, br s, NH2), 3.52 (2H, t, J 7.0, CH2CH2O), 2.44 (2H, t, J 6.9, CH2CH2O), 1.80 (6H, s, 
NC(CH3)2), 0.92 (21H, s, 3 × CH(CH3)2); δC (101 MHz, CDCl3) 157.8, 154.5, 153.6, 128.8, 102.1, 
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62.3, 59.8, 43.7, 27.9, 18.1, 12.0; m/z (ES
+
) 419 (17%), 379 (28), 378 (MH
+
, 100). Found: MH
+
, 
378.2682. C19H36N5OSi requires 378.2689. 
 
1-(1,1-Dimethyl-2-triisopropylsilanyloxy-ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine, 56b 
 
Adapted from the method of Smith,
191
 a solution of alcohol 16b (100 mg, 0.483 mmol), TIPS-Cl 
(310 μL, 1.44 mmol), Et3N (269 μL, 1.93 mmol) and DMAP (6 mg, 0.048 mmol) in CH2Cl2 (2 mL) 
was stirred at rt (42 h). The reaction was quenched with H2O (20 mL), CH2Cl2 (15 mL) was added 
and the organic layer separated. The aqueous layer was extracted with EtOAc (2 × 20 mL), the 
organic layer dried (MgSO4), filtered and the solvent removed in vacuo. Purification by column 
chromatography, eluting with EtOAc/hexane (gradient, 0:1 → 1:0) gave the title compound as 
white amorphous crystals (110 mg, 60%), mp 139-142 °C; Rf 0.32 (1:1 EtOAc/hexane); υmax (thin 
film)/cm
-1
 3318, 3064, 2942, 2865, 1661, 1599, 1551, 1108; δH (400 MHz, CDCl3) 8.26 (1H, s, 
pyrimidine-H), 7.82 (1H, s, pyrazole-H), 6.17 (2H, br s, NH2), 4.16 (2H, s, CH2O), 1.76 (6H, s, 
NC(CH3)2), 0.96-0.92 (21H, m, 3 × CH(CH3)2); δC (101 MHz, CDCl3) 157.9, 154.3, 153.7, 129.0, 
102.0, 69.2, 64.4, 24.4, 17.9, 12.0; m/z (CI) 366 (15%), 365 (40), 364 (MH
+
, 100), 320 (15), 136 
(13). Found: MH
+
, 364.2531. C18H34N5OSi requires 364.2533. 
 
tert-Butyl triphenylphosphoranylidenecarbamate, 68
151
 
 
According to the method of Calí,
169
 a solution of NaNO2 (2.87 g, 41.6 mmol) in H2O (5 mL) was 
added in portions over ca. 5 min to a solution of tert-butyl carbazate (5.00 g, 37.8 mmol) in acetic 
acid/H2O (45 mL, 1:1) at 0 °C. After stirring at rt (2 h), the solution was extracted with ether (3 × 
25 mL), the organic layer washed with H2O (50 mL), sat. aq. NaHCO3 (40 mL) and brine (40 mL) 
and dried (MgSO4) to give a solution of azide 67, which was used without further purification in the 
subsequent reaction. 
 
The solution of azide 67 was cooled to 0 °C and cannulated over ca. 20 min into a stirred solution 
of PPh3 (7.94 g, 30.3 mmol) in ether (30 mL) at 0 °C. The reaction was warmed to rt and stirred for 
a further 1 h before the resulting precipitate was filtered, washed with ether and dried in vacuo. 
Recrystallisation (EtOAc) gave the title compound as colourless crystals (7.55 g, 67%), mp 155-
156 °C; δH (400 MHz, CDCl3) 7.74-7.67 (6H, m, Ar-H), 7.54-7.48 (3H, m, Ar-H), 7.45-7.39 (6H, m, 
 126 
Ar-H), 1.34 (9H, s, C(CH3)3); δP (162 MHz, CDCl3) 20.3; m/z (CI) 380 (28%), 378 (MH
+
, 100), 322 
(6), 304 (8), 52 (9). Found: MH
+
, 378.1636. C23H24N2O2P requires 378.1623. Data is in agreement 
with the literature.
151
 
 
Oxaziridine-2,3,3-tricarboxylic acid 2-tert-butyl ester 3,3-diethyl ester, 65
170
 
 
According to the method of Armstrong,
151
 a solution of phosphorimine 68 (5.00 g, 13.2 mmol) and 
diethylketomalonate (2.31 g, 13.2 mmol) in THF (10 mL) was heated at reflux for 24 h before being 
cooled to rt and the solvent removed in vacuo. The resulting residue was warmed to solution in 
PhMe (4 mL) cooled to rt, hexane (10 mL) added, the solution filtered and the solvent removed in 
vacuo to give imine 69 as a colourless oil, which was used without further purification in the 
subsequent reaction. 
 
n
BuLi (2.15 M in hexane, 4.6 mL, 9.9 mmol) was added dropwise to a stirred solution of mCPBA 
(0.55 M in CH2Cl2, 19.3 mL, 10.6 mmol) in CH2Cl2 (19.7 mL) at -78 °C and stirred for a further 30 
min before a solution of intermediate imine 69 in CH2Cl2 (5 mL) was added dropwise. After stirring 
for 2 h, the reaction was quenched with sat. aq. NaHCO3 (6 mL) and warmed to rt. The aqueous 
layer was extracted with CH2Cl2 (2 × 15 mL), the organic layer extracted with sat. aq. NaHCO3 (3 × 
50 mL), dried (MgSO4) and the solvent removed in vacuo. Purification by column chromatography, 
eluting with ether/petrol (gradient, 0:2 → 1:4) gave the title compound as a pale yellow oil (491 mg, 
26% over 2 steps), Rf 0.52 (1:1 ether/petrol); δH (400 MHz, CDCl3) 4.39-4.30 (4H, m, 2 × CH2), 
1.51 (9H, s, C(CH3)3), 1.33 (3H, t, J 7.1, CH2CH3), 1.33 (3H, t, J 7.1, CH2CH3). Data is in 
agreement with the literature.
170
 
 
N-tert-Butoxycarbonyl methyl phenyl sulfimine, 70
215
 
 
According to the method of Armstrong,
170
 a solution of thioanisole (39 μL, 0.329 mmol) in CH2Cl2 
(2 mL) was added to a solution of oxaziridine 65 (100 mg, 0.346 mmol) in CH2Cl2 (2 mL) at -40 °C 
and the resulting solution allowed to warm up to rt over ca. 30 min whereupon the solvent was 
removed in vacuo. Purification by column chromatography, eluting with MeOH/EtOAc (1:19) gave 
the title compound as a white solid (47 mg, 60%), mp 85-86 °C; Rf 0.26 (1:49 MeOH/EtOAc); δH 
(400 MHz, CDCl3) 7.70-7.66 (2H, m, Ar-H), 7.47-7.41 (3H, m, Ar-H), 2.71 (3H, s, SCH3), 1.37 
 127 
(9H, s, C(CH3)3); m/z (ES) 501 (18%), 240 (MH
+
, 11), 185 (10), 184 (100), 123 (7). Found: MH
+
, 
240.1064. C12H17NO2S requires 240.1058. Data is in agreement with the literature.
215
 
 
General Procedure for Amination using Oxaziridine 65 
 
According to the method of Armstrong,
151
 a solution of oxaziridine 65 (72 mg, 0.250 mmol) and 
amine (0.250 mmol) in CH2Cl2 (3 mL) was stirred for 3 d, whereupon the solvent was removed in 
vacuo. Purification by column chromatography, eluting with ether/hexane (gradient, 1:4 → 1:1) 
gave the title compounds. 
 
N'-Phenethylhydrazinecarboxylic acid tert-butyl ester, 66a
151
, 1,3-Triazanedicarboxylic acid, 
2-(2-phenylethyl)-, 1,3-bis(1,1-dimethylethyl) ester, 71
151
 and 2-Phenethylimino-malonic acid 
diethyl ester, 72 
 
Hydrazine 66a as a white solid (20 mg, 34%), mp 90-92 °C; Rf 0.39 (1:1 ether/petrol); υmax (thin 
film)/cm
-1
 3308, 2980, 2931, 1705; δH (400 MHz, CDCl3) 7.30-7.24 (2H, m, Ar-H), 7.22-7.15 (3H, 
m, Ar-H), 6.06 (1H, br s, NH), 3.12 (2H, t, J 7.3, CH2NH), 2.78 (2H, t, J 7.3, CH2Ar), 1.43 (9H, s, 
C(CH3)3). Data is in agreement with the literature.
151
 
 
Triazane 71 as a white solid (21.5 mg, 24%), mp 136-137 °C; Rf 0.53 (1:1 ether/petrol); δH (400 
MHz, CDCl3) 7.29-7.14 (5H, m, Ar-H), 7.12 (2H, br s, 2 × NH), 3.52-3.46 (2H, m, CH2NH), 2.83-
2.77 (2H, t, J 7.3, CH2Ph), 1.43 (18H, s, 2 × C(CH3)3). Data is in agreement with the literature.
151
 
 
Imine 72 as a colourless oil (12.5 mg, 18%), Rf 0.47 (1:1 ether/petrol); υmax (thin film)/cm
-1
 2921, 
1743; δH (400 MHz, CDCl3) 7.31-7.24 (2H, m, Ar-H), 7.21-7.16 (3H, m, Ar-H), 4.37 (2H, q, J 7.1, 
CH2CH3), 4.31 (2H, q, J 7.1, CH2CH3), 3.88-3.79 (2H, m, CH2N), 3.07-3.00 (2H, m, CH2Ar), 1.36 
(3H, t, J 7.1, CH2CH3), 1.30 (3H, t, J 7.1, CH2CH3); m/z (CI) 281 (16%), 280 (100), 278 (12), 180 
(21), 106 (36), 58 (15), 52 (88), 43 (16), 44 (18). Found: MNH4
+
, 278.1395. C15H20NO4 requires 
278.1392. 
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N'-tert-Butyl-hydrazinecarboxylic acid tert-butyl ester, 66b
216
 
 
White solid (32 mg, 68%), mp 77-79 °C; Rf 0.47 (1:1 EtOAc/hexane); υmax (thin film)/cm
-1
 3724, 
3222, 2972, 1709, 1475, 1365, 1288; δH (400 MHz, CDCl3) 5.76 (1H, br s, NH), 3.61 (1H, br s, 
NH), 1.42 (9H, s, O(CH3)3), 1.03 (9H, s, N(CH3)3); δC (101 MHz, CDCl3) 157.5, 80.3, 54.9, 28.5, 
27.2; m/z (CI) 189 (MH
+
, 100%), 150 (99), 133 (64), 52 (27). Found: MH
+
, 189.1601. C9H21N2O2 
requires 189.1603. Data is in agreement with the literature.
216
 
 
N'-((S)-1-Hydroxymethyl-2,2-dimethyl-propyl)-hydrazinecarboxylic acid tert-butyl ester, 66c 
 
White solid (41 mg, 71%, ca. 90% pure by 
1
H-NMR analysis), mp 74-77 °C; Rf 0.53 (1:1 
EtOAc/hexane); υmax (thin film)/cm
-1
 3258, 2954, 1678, 1365, 1292, 1254; δH (400 MHz, CDCl3) 
6.25 (1H, br s, NH), 3.84 (1H, br s, NH), 3.71 (1H, dd, J 11.8, 3.3, CHHOH), 3.43 (1H, dd, J 11.8, 
8.0, CHHOH), 2.42 (1H, dd, J 8.0, 3.3, CH), 1.41 (9H, s, OC(CH3)3), 0.90 (9H, s, CHC(CH3)3); δC 
(101 MHz, CDCl3) 158.5, 81.4, 72.9, 60.6, 34.0, 28.5, 27.3; m/z (CI) 234 (22%), 233 (MH
+
, 100), 
194 (49), 177 (81). Found: MH
+
, 233.1874. C11H25N2O3 requires 233.1865. 
 
N'-((S)-1-Hydroxymethyl-2-methyl-propyl)-hydrazinecarboxylic acid tert-butyl ester, 66d 
 
White solid (39 mg, 71%, ca. 85% pure by 
1
H-NMR analysis), mp 60-62 °C; Rf 0.33 (1:1 
EtOAc/hexane); υmax (thin film)/cm
-1
 3302, 2962, 1692, 1367, 1252; δH (400 MHz, CDCl3) 6.09 
(1H, br s, NH), 3.90 (1H, br s, NH), 3.63 (1H, dd, J 12.0, 3.2, CHHOH), 3.42 (1H, dd, J 12.0, 6.9, 
CHHOH), 2.45 (1H, td, J 7.4, 3.2, CHNH), 1.69 (1H, m, CH(CH3)2), 1.43 (9H, s, OC(CH3)3), 0.98 
(3H, d, J 6.7, CH(CH3)CH3), 0.91 (3H, d, J 6.8, CH(CH3)CH3); δC (101 MHz, CDCl3) 158.4, 81.4, 
68.3, 60.3, 28.5, 28.0, 20.2, 19.6; m/z (CI) 220 (25%), 219 (MH
+
, 100), 192 (29), 180 (63), 163 (80). 
Found: MH
+
, 219.1716. C10H23N2O3 requires 219.1709. 
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One-Pot Synthesis of Pyrazoles using Oxaziridine 65 
 
A solution of tert-butylamine (26 μL, 0.250 mmol) and oxaziridine 65 (72 mg, 0.250 mmol) in 
EtOH (1.0 mL) was stirred at rt (3 d) before the addition of a solution of HCl in EtOH (1 M, 0.5 
mL), prepared by the addition of AcCl (107 μL, 1.50 mmol) to EtOH (0.5 μL) at 0 °C, and the 
solution heated to reflux (3.5 h). The solution was cooled to 0 °C before the addition of Et3N (314 
μL, 2.25 mmol) and enol ether 2 (30 mg, 0.250 mmol) and the solution heated to reflux (1.5 h) 
whereupon the solution was cooled and the solvent removed in vacuo. H2O (20 mL) and EtOAc (20 
mL) were added, the aqueous layer extracted with EtOAc (3 × 20 mL), the organic layer dried 
(Na2SO4), filtered and the solvent removed in vacuo. Purification by column chromatography, 
eluting with EtOAc/hexane (gradient, 0:1 → 1:0) gave 5-amino-1-tert-butyl-1H-pyrazole-4-
carbonitrile, 3
186
 as colourless prisms (23 mg, 56%). Data matches that obtained by pyrazole 
formation from unprotected tert-butylhydrazine. 
 
N-tert-Butoxycarbonyl hydroxylamine, 73
217
 
 
According to the method of Cardillo,
164
 NaHCO3 (3.39 g, 40.3 mmol) was added in portions to a 
stirred suspension of hydroxylamine hydrochloride (1.53 g, 22.0 mmol) in H2O/CH2Cl2 (18 mL, 5:4) 
at 0 °C. After 10 min, di-tert-butyl dicarbonate (4.00 g, 18.3 mmol) was added and the solution 
stirred at rt (22 h), whereupon the reaction was quenched with sat. aq. NaHCO3 (6 mL). The 
reaction mixture was extracted with CH2Cl2 (3 × 50 mL), the organic layer dried (MgSO4) and the 
solvent removed in vacuo. Purification by column chromatography, eluting with ether/petrol (1:1) 
gave the title compound as white crystals (1.66 g, 68%), mp 56-57 °C; Rf 0.24 (1:1 ether/petrol); δH 
(400 MHz, CDCl3) 7.25-6.10 (2H, 2 × br s, NH, OH), 1.45 (9H, s, C(CH3)3); δC (101 MHz, CDCl3) 
158.9, 82.5, 28.4; m/z (CI) 152 (17%), 151 (MNH4
+
, 100), 95 (33), 74 (8), 52 (7). Found: MNH4
+
, 
151.1089. C5H14NO3 requires 151.1083. Data is in agreement with the literature.
217
 
 
N-tert-Butoxycarbonyl-O-toluene-4-sulfonyl hydroxylamine, 74
177
 
 
According to the method of Furukawa,
159
 a solution of TsCl (477 mg, 2.50 mmol) in CH2Cl2 (2.50 
mL) was added dropwise to a stirred suspension of hydroxamic acid 73 (333 mg, 2.50 mmol) and 
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pyridine (404 µL, 5.00 mmol) in CH2Cl2 (5 mL). The resulting solution was heated at reflux (30 
min) and upon cooling, H2O (7.5 mL) was added, extracted with CH2Cl2 (3 × 10 mL), the organic 
layer dried (MgSO4) and the solvent removed in vacuo. Purification by column chromatography, 
eluting with ether/petrol (1:1) gave the title compound as white crystals (643 mg, 90%), mp 106-
107.5 °C; Rf 0.37 (1:1 ether/petrol); δH (400 MHz, CDCl3) 7.86 (2H, d, J 8.3, Ar-H), 7.56 (1H, s, 
NH), 7.34 (2H, d, J 8.2, Ar-H), 2.44 (3H, s, Ar-CH3), 1.28 (9H, s, C(CH3)3); δC (101 MHz, CDCl3) 
154.3, 146.1, 130.8, 129.9, 129.8, 84.1, 27.9, 21.9; m/z (CI) 305 (MNH4
+
, 100%), 249 (48), 174 
(36), 133 (36), 52 (53). Found: MNH4
+
, 305.1178. C12H17NO5S requires 305.1171. Data is in 
agreement with the literature.
177
 
 
N-tert-Butoxycarbonyl-O-methyl-sulfonyl hydroxylamine, 78
218
 
 
According to the method of Furukawa,
159
 a solution of MsCl (386 μL, 5.00 mmol) in CH2Cl2 (5 mL) 
was added dropwise to a stirred suspension of hydroxamic acid 73 (666 mg, 5.00 mmol) and 
pyridine (808 µL, 10.0 mmol) in CH2Cl2 (10 mL). The resulting solution was heated to reflux (45 
min), and once cooled, H2O (20 mL) was added and extracted with CH2Cl2 (3 × 15 mL), the organic 
layer dried (MgSO4) and the solvent removed in vacuo. Purification by column chromatography, 
eluting with ether/petrol (1:1) gave the title compound as white crystals (818 mg, 78%), Rf 0.31 (1:1 
ether/petrol); δH (400 MHz, CDCl3) 8.08 (1H, s, NH), 3.15 (3H, s, SCH3), 1.49 (9H, s, C(CH3)3); δC 
(101 MHz, CDCl3) 154.9, 84.9, 36.5, 28.2; m/z (CI) 440 (16%), 229 (MNH4
+
, 100), 231 (17), 230 
(22), 173 (35). Found: MNH4
+
, 229.0869. C6H13NO5S requires 229.0858. Data is in agreement with 
the literature.
218
 
 
Amination of 2-Phenethylamine with Aminating Reagent 74 or 78 
 
According to the method of Furukawa,
159
 a solution of 2-phenethylamine (76 μL, 0.628 mmol) in 
CH2Cl2 (2 mL) was added dropwise to a stirred solution of sulfonate 74 or 78 (0.157 mmol) and the 
reaction kept at the specified temperature and time shown in Table 8.2. Once brought to rt, the 
solution was washed with sat. aq. NaHCO3 (2 × 10 mL) and water (2 × 10 mL), dried (MgSO4) and 
the solvent removed in vacuo. Purification by column chromatography, eluting with ether/petrol 
(gradient, 1:1 → 1:0) gave the following compounds: 
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N'-Phenethylhydrazinecarboxylic acid tert-butyl ester, 66a
151
 as an off-white solid. Data matches 
that obtained using oxaziridine amination. 
 
N-Phenethyl-N’-tert-butoxyurea, 75a as an off-white solid, mp 76-77 °C; Rf 0.17 (1:1 ether/petrol); 
υmax (thin film)/cm
-1
 3204, 2980, 2935, 1667; δH (400 MHz, CDCl3) 7.32-7.26 (2H, m, Ar-H), 7.23-
7.17 (3H, m, Ar-H), 6.60 (1H, br s, NH), 5.66 (1H, br s, NH), 3.51 (2H, q, 6.8, CH2NH), 2.83 (2H, t, 
J 6.9, CH2Ph), 1.11 (9H, s, C(CH3)3); δC (101 MHz, CDCl3) 161.1, 139.0, 129.0, 128.8, 126.7, 80.7, 
40.8, 36.2, 26.4; m/z (CI) 474 (32%), 473 (73), 254 (23), 238 (28), 237 (MH
+
, 100). Found: MH
+
, 
237.1604. C13H20N2O2 requires 237.1603. 
 
N-(Benzyloxycarbonyl)hydroxylamine, 79
219
 
 
According to the method of Cardillo,
164
 NaHCO3 (3.39 g, 23.9 mmol) was added in portions to a 
stirred suspension of hydroxylamine hydrochloride (1.53 g, 21.9 mmol) in H2O/CH2Cl2 (36 mL, 5:4) 
at 0 °C. After 10 min, benzyl chloroformate (2.80 mL, 19.9 mmol) was added and the solution 
stirred at rt (18 h), whereupon the reaction was quenched with sat. aq. NaHCO3 (6 mL). The 
reaction mixture was extracted with CH2Cl2 (3 × 30 mL), the organic layer dried (MgSO4) and the 
solvent removed in vacuo. Recrystallisation (CH2Cl2) gave the title compound as colourless crystals 
(1.66 g, 68%), mp 70-71 °C; δH (400 MHz, CDCl3) 7.37-7.33 (5H, m, Ar-H), 7.15 (1H, br s, NH), 
5.93 (1H br s, OH), 5.18 (2H, s, CH2). Data is in agreement with the literature.
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N-(Benzyloxycarbonyl)-O-(toluene-4-sulfonyl) hydroxylamine, 80 
 
According to the method of Furukawa,
159
 a solution of TsCl (477 mg, 2.50 mmol) in CH2Cl2 (4.5 
mL) was added dropwise to a stirred suspension of hydroxamic acid 79 (418 mg, 2.50 mmol) and 
pyridine (404 µL, 5.00 mmol) in CH2Cl2 (3 mL) and the resulting solution stirred (5 h). H2O (25 
mL) was added, the aqueous layer extracted with CH2Cl2 (3 × 15 mL), the organic layer dried 
(MgSO4) and the solvent removed in vacuo. Purification by column chromatography, eluting with 
ether/petrol (gradient, 1:2 → 1:1) gave the title compound as a white solid (712 mg, 89%), mp 130-
132 °C; Rf 0.31 (1:1 ether/petrol); υmax (thin film)/cm
-1
 3277, 1771, 1743; δH (400 MHz, CDCl3) 
7.87 (1H, s, NH), 7.83-7.79 (2H, m, Ar-H), 7.34-7.30 (3H, m, Ar-H), 7.24 (2H, d, J 8.0, Ar-H), 
7.20-7.16 (2H, m, Ar-H), 5.01 (2H, s, CH2), 2.41 (3H, s, CH3); δC (101 MHz, CDCl3) 155.5, 146.3, 
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134.7, 130.4, 129.9, 129.8, 128.9, 128.8, 128.5, 68.8, 22.0; m/z (CI) 340 (22%), 339 (MNH4
+
, 100), 
185 (23), 174 (24), 169 (55), 108 (22). Found: MNH4
+
, 339.1013. C15H19N2O5S requires 339.1015. 
 
Amination of 2-Phenethylamine with Aminating Reagent 80 
 
According to the method of Furukawa,
159
 a solution of 2-phenethylamine (76 μL, 0.628 mmol) in 
CH2Cl2 (2 mL) was added dropwise to a stirred solution of sulfonate 80 (50 mg, 0.157 mmol) and 
the reaction stirred at rt for 3 d, whereupon the solution was washed with sat. aq. NaHCO3 (2 × 10 
mL) and water (2 × 10 mL), dried (MgSO4) and the solvent removed in vacuo. Purification by 
column chromatography, eluting with ether/hexane (gradient, 1:3 → 1:0) gave the following 
compounds: 
 
N'-Phenethylhydrazinecarboxylic acid benzyl ester, 66d as a pale yellow solid (7 mg, 16%, ca. 85% 
pure by 
1
H-NMR), Rf 0.63 (ether); υmax (thin film)/cm
-1
 3313, 1719, 1604; δH (400 MHz, CDCl3) 
7.36-7.17 (10H, m, Ar-H), 5.11 (2H, s, OCH2), 3.79 (3H, s, OCH3), 3.15 (2H, t, J 7.3, NHCH2), 
2.77 (2H, t, J 7.3, CH2CH2Ph); m/z (CI) 288 (MNH4
+
, 71%), 272 (32), 271 (MH
+
, 100), 169 (60). 
Found: MH
+
, 271.1442. C16H19N2O2 requires 271.1447. 
 
N-Phenethyl-N’-benzyloxyurea, 75d as a pale yellow oil (12 mg, 28%), Rf 0.48 (ether); υmax (thin 
film)/cm
-1
 1671; δH (400 MHz, CDCl3) 7.35-7.27 (5H, m, Ar-H), 7.26-7.15 (5H, m, Ar-H), 5.65 
(1H, s, NH), 4.68 (2H, s, OCH2), 3.49-3.42 (2H, m, NHCH2), 2.75 (2H, t, J 7.0, CH2CH2Ph); δC 
(101 MHz, CDCl3) 159.9, 139.0, 135.4, 129.3, 129.0, 129.0, 128.9, 128.8, 126.7, 78.8, 40.8, 36.2; 
m/z (CI) 288 (MNH4
+
, 77%), 272 (23), 271 (MH
+
, 100), 182 (20), 52 (23). Found: MH
+
, 271.1448. 
C16H19N2O2 requires 271.1447. 
 
N-(4-Methoxy-benzyloxycarbonyl)hydroxylamine, 82 
 
According to the method of Boivin,
220
 CDI (14.7 g, 90.5 mmol) was added to a solution of 4-
methoxybenzyl alcohol (10.0 g, 72.4 mmol) in THF (150 mL) and stirred at rt for 1 h, whereupon 
NH2OH.HCl (7.54 g, 109 mmol) and imidazole (7.39 g, 109 mmol) were added. The reaction was 
stirred for a further 2 h before the addition of ether (400 mL). The solution was extracted with water 
(2 × 250 mL), the organic layer dried (MgSO4), the solution filtered and the solvent removed in 
vacuo. Purification by recrystallisation (CH2Cl2) gave the title compound as a white solid (9.07 g, 
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65%), mp 106-107 °C; Rf 0.45 (ether); υmax (thin film)/cm
-1
 3305, 1719, 1614, 1516; δH (400 MHz, 
CDCl3) 7.31-7.27 (2H, m, Ar-H), 7.11 (1H, s, NH), 6.89-6.85 (2H, m, Ar-H), 5.90 (1H, s, OH), 
5.11 (2H, s, CH2), 3.79 (3H, s, CH3); δC (101 MHz, CDCl3) 160.1, 159.3, 130.6, 127.6, 114.2, 68.0, 
55.5; m/z (CI) 215 (MNH4
+
, 6%) 155 (10%), 154 (8), 139 (7), 138 (50), 121 (100), 52 (8). Found: 
MNH4
+
, 215.1037. C9H15N2O4 requires 215.1032. 
 
N-(4-Methoxy-benzyloxycarbonyl)-O-(toluene-4-sulfonyl) hydroxylamine, 83 
 
According to the method of Furukawa,
159
 a solution of TsCl (477 mg, 2.50 mmol) in CH2Cl2 (4.5 
mL) was added dropwise to a stirred suspension of hydroxamic acid 82 (493 mg, 2.50 mmol) and 
pyridine (404 µL, 5.00 mmol) in CH2Cl2 (3 mL) and the resulting solution stirred at rt (2 h). H2O 
(15 mL) was added, the aqueous layer extracted with CH2Cl2 (3 × 15 mL), the organic layer dried 
(MgSO4) and the solvent removed in vacuo. Purification by column chromatography, eluting with 
ether/petrol (gradient, 1:3 → 1:1) gave the title compound as a white solid (757 mg, 86%), mp 56-
57 °C; Rf 0.20 (1:1 ether/petrol); υmax (thin film)/cm
-1
 3273, 1771, 1740, 1614, 1516; δH (400 MHz, 
CDCl3) 8.31 (1H, s, NH), 7.77 (2H, d, J 8.3, Ar-H), 7.23 (2H, d, J 8.1, Ar-H), 7.11 (2H, d, J 8.6, 
Ar-H), 6.79 (2H, d, J 8.6, Ar-H), 4.92 (2H, s, CH2), 3.77 (3H, s, OCH3), 2.39 (3H, s, Ar-CH3); δC 
(101 MHz, CDCl3) 160.0, 155.8, 146.1, 130.4, 130.2, 129.8, 129.6, 126.8, 114.0, 68.5, 55.4, 21.9; 
m/z (CI) 369 (MNH4
+
, 15%), 138 (32), 136 (10), 122 (14), 121 (100). Found: MNH4
+
, 369.1130. 
C16H21N2O6S requires 369.1120. 
 
Amination of 2-Phenethylamine with Aminating Reagent 83 
 
According to the method of Furukawa,
159
 a solution of 2-phenethylamine (76 μL, 0.628 mmol) in 
CH2Cl2 (2 mL) was added dropwise to a stirred solution of sulfonate 83 (55 mg, 0.157 mmol) and 
the reaction stirred at rt for 3 d, whereupon the solution was washed with sat. aq. NaHCO3 (2 × 10 
mL) and water (2 × 10 mL), dried (MgSO4) and the solvent removed in vacuo. Purification by 
column chromatography, eluting with ether/hexane (gradient, 1:3 → 1:0) gave the following 
compounds: 
 
N'-Phenethylhydrazinecarboxylic acid 4-methoxy-benzyl ester, 66e as colourless rods (4 mg, 9%), 
mp 79-81 °C; Rf 0.59 (ether); υmax (thin film)/cm
-1
 3338, 2946, 1713, 1612; δH (400 MHz, CDCl3) 
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7.30-7.23 (4H, m, Ar-H), 7.21-7.15 (3H, m, Ar-H), 6.89-6.85 (2H, m, Ar-H), 6.24 (1H, br s, NH), 
5.05 (2H, s, OCH2), 3.79 (3H, s, OCH3), 3.17-3.09 (2H, m, NCH2), 2.76 (2H, t, J 7.3, CH2CH2Ph); 
δC (101 MHz, CDCl3) 159.9, 157.5, 139.5, 130.3, 128.8, 128.7, 128.3, 126.5, 114.2, 67.2, 55.5, 53.1, 
34.5; m/z (ES
+
) 329 (15%), 324 (20), 323 (100), 302 (17), 301 (MH
+
, 79), 121 (16). Found: MH
+
, 
301.1563. C17H21N2O3 requires 301.1552. 
 
N-Phenethyl-N’-(4-methoxy-benzyloxy)urea, 75e as a pale yellow oil (11 mg, 24%), Rf 0.33 (ether); 
υmax (thin film)/cm
-1
 3208, 2936, 1668; δH (400 MHz, CDCl3) 7.33-7.27 (2H, m, Ar-H), 7.25-7.20 
(1H, m, Ar-H), 7.19-7.13 (4H, m, Ar-H), 6.90 (1H, br s, NH), 6.86-6.82 (2H, m, Ar-H), 5.61 (1H, 
br s, NH), 4.60 (2H, s, OCH2), 3.79 (3H, s, OCH3), 3.48-3.42 (2H, m, NCH2), 2.75 (2H, t, J 7.0, 
CH2CH2Ph); δC (101 MHz, CDCl3) 160.3, 160.0, 139.0, 131.1, 129.0, 128.9, 127.5, 126.7, 114.3, 
78.4, 55.5, 40.8, 36.2; m/z (CI) 318 (MNH4
+
, 67%), 301 (MH
+
, 100), 182 (36), 138 (32), 121 (85). 
Found: MH
+
, 301.1557. C17H21N2O3 requires 301.1552. 
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11 Biochemistry – Materials and Methods 
 
Plasmids 
 
N-His6-PKCα(M417A)-pcDNA3 was created by two-step site-directed mutagenesis of N-His6-
PKCα(M417G)-pcDNA3. The 5’ end was generated using sense primer 5’-AATACGACTCACTATAG-
3’ and antisense mutagenic primer 5’-GGTCCCCGCCGTTTACGTACTCCGCGACGAAGT-3’ and the 3’ 
end was generated using antisense primer 5’-GCATTTAGGTGACACTATAGAATAGGG-3’ and sense 
mutagenic primer 5’-CCGGCTGTACTTCGTCGCGGAGTACGTAAACG-3’. The full length strand was 
generated from the overlapping 5’ and 3’ ends using the sense and antisense primers and the 
resulting PCR product was subcloned into pcDNA3 using EcoRI and XbaI. 
 
N-His6-PKCα(M417A)-pKS1 was created by subcloning the N-His6-PKCα fragment from N-His6-
PKCα(M417A)-pcDNA3 into pcDNA3 using EcoRI and XbaI. 
 
PKCα-pcDNA3, PKCα(M417G)-pcDNA3 and PKCα(M417A)-pcDNA3* were created by PCR 
amplification of N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-pcDNA3 and N-His6-
PKCα(M417A)-pcDNA3, respectively, using primers 5’-GGGGGTACCTTCCCGGCCGCCGAGCCGG-3’, 
introducing a 5’ KpnI site and 5’-GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’ introducing a 3’ 
XbaI site. The PCR products were subcloned into pcDNA3 using KpnI and XbaI. 
 
PKCα(M417A)-pcDNA3 was created by subcloning the 5’ end of the coding region including the 
M417A mutation of PKCα(M417A)-pcDNA3* into cat.PKCα-pcDNA3 using SfuI and Kpn2I. 
 
Cat.PKCα-pcDNA3, cat.PKCα(M417G)-pcDNA3 and cat.PKCα(M417A)-pcDNA3 were created by 
PCR amplification of N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-pcDNA3 and N-His6-
PKCα(M417A)-pcDNA3, respectively, using primers 5’- 
GGGGGTACCCTCACGGACTTCAACTTCCTCATGG-3’, introducing a 5’ KpnI site and 5’-
GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’, introducing a 3’ XbaI site. The PCR products 
were subcloned into pcDNA3 using KpnI and XbaI. 
 
Strep-pcDNA3 was created by the insertion of oligonucleotides 5’-
AGCTTCACCATGTGGAGCCACCCGCAGTTCGAAAAAGGGGGTAC-3’ and 5’-
CCCCTTTTTCGAACTGCGGGTGGCTCCACATGGTGA-3’ into cdk2-pcDNA3 using HindIII and KpnI. 
 
N-Strep-PKCα-pcDNA3, N-Strep-PKCα(M417G)-pcDNA3, N-Strep-PKCα(M417A)-pcDNA3, N-
Strep-cat.PKCα-pcDNA3, N-Strep-cat.PKCα(M417G)-pcDNA3 and N-Strep-cat.PKCα(M417A)-
pcDNA3 were created by subcloning the PKCα fragments from PKCα-pcDNA3, PKCα(M417G)-
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pcDNA3, PKCα(M417A)-pcDNA3, cat.PKCα-pcDNA3, cat.PKCα(M417G)-pcDNA3 and 
cat.PKCα(M417A)-pcDNA3, respectively, into Strep-pcDNA3 using KpnI/XbaI. 
 
PKCα-pBacPAK-GST, PKCα(M417G)-pBacPAK-GST and PKCα(M417A)-pBacPAK-GST were 
created by PCR amplification of N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-pcDNA3 and N-
His6-PKCα(M417A)-pcDNA3, respectively, using primers 5’-
GGGCTCGAGACGTCTTCCCGGCCGCCGAGCCGG-3’, introducing a 5’ XhoI site and 5’-
GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’, introducing a 3’ XbaI site. The PCR products 
were subcloned into pBacPAK-GST using XhoI and XbaI. 
 
Cat.PKCα-pBacPAK-GST, cat.PKCα(M417G)-pBacPAK-GST and cat.PKCα(M417A)-pBacPAK-
GST were created by PCR amplification of N-His6-PKCα-pcDNA3, N-His6-PKCα(M417G)-
pcDNA3 and N-His6-PKCα(M417A)-pcDNA3, respectively, using primers 5’-
GGGCTCGAGTGAAGCTCACGGACTTCAACTTCCTCATGG-3’, introducing a 5’ XhoI site and 5’-
GGGTCTAGATCATACCGCGCTCTGCAGGATGGG-3’, introducing a 3’ XbaI site. The PCR products 
were subcloned into pBacPAK-GST using XhoI and XbaI. 
 
N-His6-cat.PKAα(M121G)-pGEM-T was created by two-step site-directed mutagenesis of cat.PKA-
pRSETB. The 5’ end was generated using sense primer 5’-GGATCCATGGGCAACGCCGCCGC-3’ and 
antisense mutagenic primer 5’-CCAGCTACGTACTCCCCGACCATGTACAGGTTTG-3’ and the 3’ end was 
generated using antisense primer 5’-AAGCTTAAAACTCAGTAAACTCCTTGCCACACTTC-3’ and sense 
mutagenic primer 5’-CAAACCTGTACATGGTCGGGGAGTACGTAGCTGG-3’. The full length strand was 
generated from the overlapping 5’ and 3’ ends using the sense and antisense primers and the 
resulting PCR product was T-tailed and ligated into pGEM
®
-T. 
 
The following plasmids were used but not prepared in this research: 
 
N-His6-PKCα-pKS1
64
 A. J. Cameron, Parker lab 
N-His6-PKCα(M417G)-pKS1
55*
 K. C. McCague, Mann lab 
N-His6-PKCα-pcDNA3
55*
 K. C. McCague, Mann lab 
N-His6-PKCα(M417G)-pcDNA3
55*
 K. C. McCague, Mann lab 
cdk2-pcDNA3
221
 Mann lab 
PKCα-pEGFP-C1 M. De Rycker, Parker lab 
pBacPAK-GST
222
 S. Kjær, McDonald lab, CRUK 
Histone H2B-GFP
223
 G. M. Wahl, Salk Institute, USA 
His6-cat.PKCα-pKS1 A. J. Cameron, Parker lab 
c-Src-pGEX-3X S. M. Dilworth, Imperial College 
cat.PKAα-pRSETB
85
 S. S. Taylor lab, UCSD, USA 
                                                 
* Work previously carried out by K. C. McCague as part of MRes degree 
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Antibodies 
 
Anti-PKC MC5 (mouse, monoclonal, Cancer Research UK), anti-PKCα (mouse, monoclonal, BD 
Biosciences), anti-phospho-PKCα (Ser657/Tyr658) (rabbit, polyclonal, Millipore), anti-phospho-
PKCα (Thr497) (rabbit, polyclonal, Cancer Research UK), anti-phospho-PKCα (Thr638) (rabbit, 
polyclonal, Cancer Research UK), Penta His (mouse, monoclonal, Qiagen), GST B14 (mouse, 
monoclonal, Santa Cruz) and anti-mouse/rabbit HRP-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories Inc., Westgrove, PA) were used in this research. 
 
Recombinant DNA Techniques 
 
Transformation of Bacterial Cells via Electroporation 
 
Plasmid DNA (1 μg) was mixed with competent E. coli DH5α or BL21 cells and electroporated in a 
2 mm gap cuvette (Geneflow) at 2.2 kV (Bio-Rad Gene Pulser). LB (1 mL) was added, the resulting 
mixture centrifuged (13 krpm, 1 s) and 800 μL removed. The pellet was resuspended in the 
remaining 200 μL solution, spread onto antibiotic-supplemented agar plates and incubated (37 °C, 
ca. 15 h). 
  
Enzymatic Digestion of DNA 
 
10 μL digests were completed using DNA (0.5 μg), required restriction enzyme(s) (total of 1 μL) 
and the corresponding buffer (1 μL). After incubating the solution (37 °C, 30 min), 5 × TAE 
loading buffer was added and the samples run on a 1% agarose gel. 20 μL digests were carried out 
in the same way but incubated for 1 h. Incompatible enzymatic digestions were digested 
sequentially, and the intermediate purified by gene clean DNA purification. For mini-prep DNA, 5 
μL DNA was used and the 5 × TAE loading buffer was supplemented with RNase A (10 μg/mL). 
 
Agarose Gel Electrophoresis 
 
1% agarose gels were prepared using TAE buffer with ethidium bromide (1 μg/mL). Once loaded, 
the samples were electrophoresed under constant current (80 mA, 45-60 min). DNA was visualised 
using UV-C (non-preparative samples) or UV-A (preparative samples), whereupon the desired 
bands were excised and, where necessary, the DNA extracted using gene clean DNA purification. 
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Gene Clean DNA Purification 
 
The sample was incubated with an equal volume 6 M NaI (65 °C for 5 min) before being bound to 
glass-milk beads (5 μL) on ice (5 min) and subsequently centrifuged (13 krpm, 1 s). The pellet was 
washed with Gene clean solution (3 × 500 μL) and resuspended in water (20 μL) before being 
incubated further (2 min, 65 °C). The sample was centrifuged (13 krpm, 1 min) and the supernatant 
used in ligation reactions or transformation. 
 
DNA Ligation 
 
20 μL ligations were completed using purified insert (16 μL), purified vector (1 μL), ligation buffer 
(2 μL) and T4 DNA ligase (1 μL). After incubating the solution (37 °C, 3-15 h), the resulting 
solution was purified by gene clean DNA purification. Ligation of the ends of a linear plasmid was 
carried out using the same procedure with 17 μL DNA. 
 
PCR Reaction 
 
DNA template(s) (0.5 μL), 5’-primer (0.5 μL) and 3’- primer (0.5 μL) were added to standard PCR 
components (unless otherwise specified) and made up to 23.75 or 24.75 μL, where appropriate, with 
sterile water. The reaction mixture was heated (98 °C, 5 min) before cooling (5 min, 4 °C). KOD 
polymerase (0.25 μL, Novagen) or KOD polymerase (0.25 μL) and Taq polymerase (1 μL) were 
added, the mixture heated (5 min, 98 °C), the PCR reaction run under standard conditions unless 
otherwise stated (15 s, 98 C; 2 s, 55 C; 20 s, 72 C; 25 cycles), and the resulting mixtures 
separated on a 1% agarose gel followed by gene clean DNA purification of the excised DNA. 
 
T-tailing 
 
20 μL T-tailing reactions were carried out using gene-cleaned PCR fragment (6 μL) and Taq 
polymerase (1 μL) with 2.5 mM MgCl2 and 1 mM dATP. The reaction mixture was heated (72 °C, 
20 min) and the product purified by gene clean DNA purification and ligated into pGEM
®
-T 
(Promega). 
 
Annealing of Oligonucleotides 
 
20 µL annealing reactions were completed using oligonucleotides (1 µg of each) and 2 µL KOD 
buffer 1. The reaction mixtures were heated (98 °C, 1 min) before being cooled over 30 min to 4 °C. 
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DNA Sequencing 
 
DNA sequencing was performed commercially (Cogenics). 
 
Preparation of Plasmid DNA 
 
Small Scale Preparation of Plasmid DNA (Mini-Prep) 
 
A single colony was incubated in a shaker at 37 °C in antibiotic-supplemented LB (2 mL) for a 
minimum of 8 h (small culture). 1.5 mL was centrifuged (13 krpm, 20 s) and the pellet resuspended 
in Solution I (100 μL). Lysis of the cells by Solution II (200 μL) was followed by neutralisation by 
Solution III (150 μL), and the contaminants removed by centrifugation (13 krpm, 5 min). The DNA 
was precipitated by the addition of EtOH (1 mL), and the resultant pellet from centrifugation (13 
krpm, 5 min) suspended in sterile water (25-50 μL). 
 
Large Scale Preparation of Plasmid DNA (Maxi-Prep) 
 
The small culture was transferred to antibiotic-supplemented LB (200 mL) and incubated in a 
shaker at 37 °C for ca. 16 h, whereupon the mixture was centrifuged (5 krpm, 5 min, 4 °C) and the 
pellet resuspended in Solution I (10 mL). Lysis of the cells by Solution II (20 mL) was followed by 
neutralisation by Solution III (15 mL), and the contaminants removed by centrifugation (9 krpm, 5 
min, 4 °C). 
i
PrOH (45 mL) was added and the solution centrifuged (9 krpm, 5 min, 4 °C). The 
precipitated DNA was resuspended in sterile water (3 mL) and ice-cold 5 M LiCl (4 mL). The 
solution was kept on ice for 5 min and centrifuged (13 krpm, 5 min) to remove RNA. Cold EtOH 
(14 mL) was added to the supernatant and the resulting pellet from centrifugation (13 krpm, 5 min, 
4 °C) was resuspended in sterile water (600 μL). The solution was incubated with RNase A (10 μL) 
(15 min, 37 °C) to remove the remaining RNA, and the DNA precipitated by the addition of 2.5 M 
NaCl, 20% PEG-4000 solution (600 µL). The pellet was suspended in sterile water (500 μL) and 
the contaminating protein denatured with 1:1 (v/v) phenol/chloroform and the aqueous layer 
separated by centrifugation (13 krpm, 5 min) before being extracted with chloroform to remove 
traces of phenol. 3 M NaOAc, pH 5.2 (50 μL) and EtOH (1 mL) were added to precipitate the DNA, 
which was isolated by centrifugation (13 krpm, 5 min) and resuspended in sterile water to give a 
concentration of ca. 1 μg/μL, as determined by UV (260 nm, Pharmacia LKB UltroSpec III). 
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Cell Lines and Tissue Culture Procedures 
 
Growth and Maintenance of COS-7 and Sf9 Cells 
 
COS7 cells were maintained at 37 °C under a 5% CO2 atmosphere in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% (v/v) Foetal Bovine Serum (FBS) and passaged using 
trypsin/EDTA followed by incubation at 37 °C (ca. 3 min). Cells were mechanically dislodged, 
resuspended in fresh medium and transferred. Sf9 cells were maintained at 27 °C in TC 100 
Medium with L-glutamine (PAA Laboratories) supplemented with 10% FBS. 
 
DNA Transfection via Ca3(PO4)2 Precipitation 
 
Transfections were carried out using plates with various surface areas, and the amounts of DNA, 
buffer and medium were scaled accordingly. DMEM + 10% FBS was removed from the plates and 
replaced with fresh medium (60 μL cm-2). 0.1-0.3 µg cm-2 DNA was added to 0.25 mM CaCl2 
solution (6.5 mL cm
-2
) and added to an equal volume of Hepes-buffered saline (HBS) or BES-
buffered saline (BBS); for BBS, air was bubbled through the buffer as the DNA solution was added 
dropwise. The resulting solution was incubated at rt for ca. 15 min and subsequently pipetted onto 
the cells and the plates incubated at 37 °C at 10 or 5% CO2, respectively. After 8 h, the medium was 
removed and fresh medium added. Cells were harvested after 48 h. 
 
DNA Transfection via Lipofectamine
TM
 LTX 
 
DNA (0.5 µg) was mixed with Opti-MEM
®
 I Reduced Serum Medium (100 µL, Invitrogen). After 
15 min, Lipofectamine
TM
 LTX (1.25 μL, Invitrogen) was added and the solution mixed gently. 
After a further 25 min, the solution (100 μL) was added to a 1.4 cm plate of cells with fresh DMEM 
+ 10% FBS. Cells were harvested after 24 h. 
 
DNA Transfection of Mammalian Cells via Electroporation 
 
COS7 cells were split 24 h prior to electroporation. Cells were trypsinised, resuspended in PBS and 
counted using a haemocytometer. The suspension was centrifuged (1 krpm, 1 min) and an 
appropriate amount of K-PBS was added to the pellet to give ca. 3 × 10
6
 cells per 450 μL. 5 μg 
DNA with or without sheared salmon sperm DNA (50 μg) was placed in a 4 mm gap cuvette (BTX), 
and 450 μL of the cell suspension was added and left at rt for 5 min before being electroporated at 
450 V, 250 μF, ∞ Ω (Bio-Rad Gene Pulser), giving a pulse length of ca. 9.7 ms. The cells were 
retained at rt for 15 min before being added to 7.5 mL DMEM + 10% FBS in a 9 cm plate, and 
incubated at 10% CO2. The cells were washed with PBS after 24 h and fresh DMEM + 10% FBS 
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added. Where necessary, after 48 h, the medium was aspirated and the cells washed with PBS 
solution (2 × 10 mL). Cells were lysed with His purification buffer I (1.5 mL) and scraped off the 
surface of the plate. After tumbling (15 min, 4 °C), the cells were centrifuged (13 krpm, 4 °C, 5 
min). 
 
Baculovirus Recombination in Sf9 Cells 
 
A solution of plasmid (5 µg) and BaculoGold (0.2 µg, BD Biosciences) in TC 100 Medium (100 µL) 
was added to a solution of Lipofectin (20 µg, Invitrogen) in TC 100 Medium (100 µL). After 
incubation for 15 min at rt, TC 100 Medium (1 mL) was added, the solution mixed and added to a 
3.5 cm plate of 5 × 10
5
 Sf9 cells previously incubated at 27 °C for at least 1h. After ca. 16 h, the 
medium was aspirated and TC 100 Medium + 10% FBS (3 mL) was added. After further incubation 
(6 d), the medium was centrifuged (1 krpm, 4 °C, 5 min) and the viral suspension isolated. This was 
sequentially used to infect a 6 cm plate of 2.3 × 10
6
 Sf9 cells (0.5 mL viral suspension), a 9 cm 
plate of 5.8 × 10
6
 Sf9 cells (0.5 mL), a 80 cm
2
 flask of 5.8 × 10
6
 cells (0.5 mL) and a 175 cm
2
 flask 
of 1.3 × 10
7
 cells (1 mL) and the viral suspension harvested after 7 d in each case. 
 
Baculovirus Infection in Sf9 Cells – Small Scale 
 
Sf9 cells were infected with viral suspension (1 mL) and grown at 27 °C (3 d). The cells were 
mechanically removed from the flask and centrifuged (1 krpm, 5 min, 4 °C). The pellet was 
resuspended in NETN (10 mL) and the cells lysed by passage through a 21 G needle (× 5). The 
solution was kept on ice (30 min) before being centrifuged (5 krpm, 5 min, 4 °C). Purification of the 
expressed protein was carried out via GST-tag chelation. 
 
Baculovirus Infection in Sf9 Cells – Large Scale 
 
Sf9 cell pellets from 1 L infections were obtained from the Protein Production Facility (Cancer 
research UK), resuspended in GST purification buffer I (20 mL), sonicated on ice and centrifuged 
(30 krpm, 20 min, 4 °C). 
 
Induction of Expression in E. Coli 
 
Antibiotic-supplemented LB (100 mL) was added to a small culture (10 mL) and incubated with 
shaking (1 h, 37 °C). 1 M IPTG (100 μL) was added to induce protein expression, and the culture 
incubated with shaking at 18, 30 or 37 °C for 2-24 h. The cells were centrifuged (5 krpm, 5 min, 
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4 °C), resuspended in NETN (10 mL), sonicated on ice (18 W, 45 s, Vibra-Cell ultrasonic processor, 
Sonics) and centrifuged (5 krpm, 5 min, 4 °C). 
 
Protein Analysis 
 
Concentration Determination via Bradford Assay 
 
Various concentrations of protein solution (200 µL) were mixed with Bradford reagent (Aldrich) 
(40 µL) and sterile water (160 µL) in a 96-well plate (TC Microwell 96F, Nunc). The optical 
density (OD) was measured at 595 nm (Spectramax 340 PC, Molecular Devices). Alternatively, 
protein solution (6.25-25 µL) was mixed with Bradford reagent (1/5 dilution, 1.25 mL, company) in 
a 1.5 mL semimicro disposable cuvette (Fisher) and the OD measured on an Ultrospec 2000 
(Pharmacia Biotech). The concentration was determined from a standard curve generated using 
solutions of known concentration of BSA. 
 
SDS-Polyacrylamide Gel Electrophoresis 
 
Samples were loaded using SDS loading buffer. SDS-PAGE gels were completed using either 10 or 
15% gels or 4-12% gradient gels (Invitrogen) with SDS running buffer or MOPS-SDS buffer 
(Invitrogen) under a constant voltage (200 or 130 V, respectively) for ca. 1 h. 
 
InstantBlue
TM
 and Coomassie Staining 
 
SDS-PAGE gels were stained with InstantBlue
TM
 (Generon) for ca. 20 min or Coomassie
®
 staining 
solution for ca. 1-2 h, the latter being incubated in Coomassie
®
 destaining solution overnight. 
 
Electrophoretic Transfer 
 
Proteins previously resolved by SDS-PAGE were electrophoretically transferred to a polyvinylidene 
fluoride (PVDF) membrane under constant current (400 mA) for ca. 1 h in electron transfer buffer. 
The membrane was blocked in either milk solution or BSA solution for ca. 30 min before adding 
0.5% (v/v) primary antibody and incubating at 4 °C for ca. 16 h. The non-specifically bound 
primary antibody was washed off by incubating with PBST (3 × 10 min) and the membrane 
incubated with 0.5% (v/v) horseradish peroxidase-conjugated secondary antibody in either milk 
solution or BSA solution for ca. 45 min. The non-specifically bound secondary antibody was 
washed off in the same way and the membrane incubated with enhanced chemiluminescence 
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solution (Millipore/Amersham) for 1 min. The proteins were visualised using the LAS-3000 
Fujifilm imaging system or exposure on photographic film (Amersham). 
 
Dynamic Light Scattering 
 
Measurements were recorded on a Zetasizer Nano (Malvern Instruments) on 50 μL protein solution. 
 
Protein Purification 
 
Purification via His-Tag Chelation 
 
The supernatant from the cell lysis was added to chelating Sepharose
®
 fast flow (GE Healthcare, 
300 μL), pre-washed with sterile water, chelated with 3 mM NiSO4 (1 mL, 5 min, rt) and washed 
with sterile water (3 × 1 mL) and His purification buffer II (4 × 1 mL). The solution was tumbled 
(1-2 h, 4 °C) before being centrifuged (13 krpm, 4 °C, 5 min) and washed with His purification 
buffer II (4 × 500 μL). The protein was either eluted immediately or the volume of buffer was 
reduced to ca. 150 μL, an equal volume of glycerol added, the solution kept on ice for 30 min to 
allow the glycerol to be distributed and subsequently stored at -20 °C. 
 
Purification via GST-Tag Chelation – Small Scale 
 
The supernatant from the cell lysis was added to Glutathione Sepharose
®
 beads (250 μL, GE 
Healthcare), pre-equilibrated by washing with NETN (10 mL). The solution was tumbled (1-2 h, 
4 °C) before being centrifuged (2 krpm, 1 min, 4 °C) and washed with NETN (3 × 10 mL). The 
protein was either eluted or cleaved immediately or the volume of NETN was reduced to ca. 150 μL, 
an equal volume of glycerol added, the solution kept on ice for 30 min to allow the glycerol to be 
distributed and subsequently stored at -20 °C. 
 
Purification via GST-Tag Chelation – Large Scale 
 
The supernatant from the cell lysis was added to Glutathione Sepharose
®
 beads (1 mL), pre-
equilibrated by washing with sterile H2O (15 mL). The solution was tumbled (1 h, 4 °C) before 
being centrifuged (500 g, 10 min, 4 °C) and washed with GST purification buffer II (3 × 15 mL). 
The resulting beads were resuspended in GST purification buffer II (1 mL). 
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Elution from Ni-NTA Beads 
 
The protein was eluted with His elution buffer (500 μL, 30 min, 4 °C) before centrifugation (13 
krpm, 5 min, 4 °C). An equal volume of glycerol was added, the solution mixed well to evenly 
distribute the glycerol and subsequently stored at -20 °C. 
 
HRV-3C Cleavage 
 
The beads were resuspended in GST purification buffer II (1 mL) or His6-HRV-3C cleavage buffer 
(50-250 μL) before the addition of GST-HRV-3C protease (PreScissionTM protease, Amersham 
Biosciences, 8-50 μL) or His6-HRV-3C protease (Novagen, 1-10 μL), respectively, and the solution 
incubated (2-16 h, 4 °C). 
 
Elution from Glutathione Sepharose
®
 Beads 
 
The beads were washed with GST elution buffer I or II (2 × 1 mL) and the protein eluted with GST 
elution buffer III or IV (3 × 200 µL, 5 min, rt) before centrifugation (5 krpm, 1 min, rt). Where 
necessary, glutathione was removed by replacement of the buffer by centrifugation (Amicon
®
 Ultra-
4 Centrifugal Filter, 10,000 NMWL, Millipore). 
 
Gel Filtration Column 
 
The protein solution was filtered before being loaded onto the column (Superdex
®
 gel filtration 
column, Amersham Biosciences). 
 
Assays 
 
In Vitro Kinase Radioassays for Determining Specific Activities 
 
In vitro kinase radioassays were performed with final concentrations of 100 μM (0.5 μCi) [γ-
32
P]ATP (3000 Ci/mmol, Perkin Elmer), 0.16-1.88 nM kinase, 0.25 mg/mL protamine sulfate, 750 
μM CaCl2, 12.5 mM MgCl2, 2.5-4.0 mM Tris-HCl, 50 mM Hepes, 0.4-9.0 mM NaCl, 0.25 mM 
EDTA, 0.5 mM EGTA, 1.25-30 μM DTT, 0.13-3.0% glycerol, 0.0025 % Triton X-100, 2.5% 
DMSO, pH 7.5. After addition of the ATP solution, the reaction was incubated (10 min, 30 °C) 
before a known proportion of the solution was spotted onto phosphocellulose paper (grade P81, 
Whatman), which was washed with 30% AcOH (3  10 min). Incorporation of 
32
P was determined 
by scintillation counting (LS 6500 multi-purpose scintillation counter, Beckman). 
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In Vitro Kinase Radioassays for Determining Inhibition 
 
In vitro kinase radioassays were performed with final concentrations of 20 μM (0.5 μCi) [γ-32P]ATP 
(3000 Ci/mmol, Perkin Elmer), 0.1-100 μM inhibitor/photoaffinity probe, 0.16-1.88 nM kinase, 
0.25 mg/mL protamine sulfate, 750 μM CaCl2, 12.5 mM MgCl2, 2.5-4.0 mM Tris-HCl, 50 mM 
Hepes, 0.4-9.0 mM NaCl, 0.25 mM EDTA, 0.5 mM EGTA, 1.25-30 μM DTT, 0.13-3.0% glycerol, 
0.0025 % Triton X-100, 2.5% DMSO, pH 7.5. After addition of the inhibitor/photoaffinity probe, 
the reaction was incubated (10 min, rt), the ATP solution added before further incubation (10 min, 
30 °C) before a known proportion of the solution was spotted onto phosphocellulose paper (grade 
P81, Whatman), which was washed with 30% AcOH (3  10 min). Incorporation of 
32
P was 
determined by scintillation counting (LS 6500 multi-purpose scintillation counter, Beckman). 
 
Cross-Linking Reaction 
 
Cross-linking reactions were performed in an open tube (1.5 mL transparent SuperSpin
TM
 
microcentrifuge tube, VWR) with final concentrations of 100 μM photoaffinity probe, 0.05 μM 
PKCα, 0.5 μM MBP, 0.5 μM BSA, 1.25 mg/mL PS, 1.25 μM PMA, 750 μM CaCl2, 12.5 mM 
MgCl2, 60 mM Hepes, 12 mM NaCl, 0.25 mM EDTA, 0.5 mM EGTA, 40 μM DTT, 4% glycerol, 
0.25 % Triton X-100, 2.5% DMSO, pH 7.5. After addition of the photoaffinity probe, the reaction 
was incubated (10 min, 30 °C) before being irradiated (254 nm, 45 min, 30 °C, CX-2000 
Crosslinker, UVP LLC). Carrier protein Ribonuclease A (50 μg in 5 μL) was added and the protein 
precipitated by the addition of MeOH (4  reaction volume) followed by vortexing, CHCl3 (1  
reaction volume) followed by vortexing, sterile H2O (3  reaction volume) followed by vortexing 
before being centrifuged (13 krpm, 2 min). The aqueous layer was removed, MeOH (4  reaction 
volume) added, the sample vortexed, centrifuged (13 krpm, 2 min) and the resulting pellet left to 
dry before being resuspended in Huisgen [3+2] cycloaddition buffer. 
 
Huisgen [3+2] Cycloaddition 
 
[3+2] Cycloaddition reactions were performed with final concentrations of 100 μM TAMRA azide 
((tetramethylrhodamine 5-carboxamido-(6-azidohexanyl)) *5-isomer*, Invitrogen), 1 mM CuSO4 (1 
μL) and 50 mM TCEP (1 μL) and 10 mM TBTA (0.5 μL) in Huisgen [3+2] cycloaddition buffer. 
These reagents were pre-mixed before addition to the resuspended pellet from the cross-linking 
reaction, with the reagents added in the order specified, and the TBTA added after incubation (2 
min) to allow reduction of the CuSO4 by TCEP. The reactions were tumbled (1 h, rt), whereupon 
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the protein was precipitated as described previously. The resulting pellet was washed with MeOH 
(4  reaction volume) and resuspended in loading buffer. 
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13 Appendix 
 
13.1 Plasmid Sequences 
 
GAATTCGTCGACCGCGGCAGGAGGCGGCGAGGGACCATGGCTCATCACCATCACCATCACGACGTCTTCCC
GGCCGCCGAGCCGGCGGCGCCGCAGGACGTGGCCAACCGCTTCGCCCGCAAAGGGGCGCTGAGGCAGAAGA
ACGTGCACGAGGTGAAGAACCACCGCTTCATCGCGCGCTTCTTCAAGCAGCCCACCTTCTGCAGCCACTGC
ACCGACTTCATCTGGGGGTTTGGGAAACAAGGCTTCCAGTGCCAAGTTTGCTGTTTTGTGGTTCACAAGAG
GTGCCATGAATTTGTTACTTTTTCTTGTCCGGGGGCGGATAAAGGACCCGACACAGATGACCCGAGGAGCA
AGCACAAGTTCAAGATCCACACGTATGGCAGCCCCACCTTCTGTGATCACTGCGGCTCCCTGCTGTACGGA
CTCATCCACCAGGGGATGAAATGTGACACCTGTGATATGAACGTGCACAAGCAGTGCGTGATCAACGTGCC
CAGCCTCTGCGGGATGGACCACACGGAGAAGAGGGGCCGCATCTACCTGAAGGCCGAGGTCACGGATGAAA
AGCTGCACGTCACAGTACGAGACGCGAAAAACCTAATCCCTATGGATCCAAATGGGCTTTCAGATCCTTAC
GTGAAGCTGAAGCTTATTCCTGACCCCAAGAACGAGAGCAAACAGAAAACCAAGACCATCCGCTCGACGCT
GAACCCCCGGTGGGACGAGTCCTTCACGTTCAAATTAAAACCTTCTGATAAAGACCGGCGACTGTCCGTGG
AAATCTGGGACTGGGATCGAACCACACGGAACGACTTCATGGGGTCCCTTTCCTTTGGGGTCTCGGAGCTG
ATGAAGATGCCGGCCAGCGGATGGTACAAGCTGCTGAACCAAGAGGAGGGCGAGTACTACAACGTGCCGAT
CCCCGAAGGCGACGAGGAAGGCAATGTGGAGCTCAGGCAGAAATTCGAGAAAGCCAAGCTTGGCCCTGCCG
GCAACAAAGTCATCAGTCCCTCCGAGGACAGGAGACAGCCTTCCAACAACCTGGGCAGAGTGAAGCTCACG
GACTTCAACTTCCTCATGGTGCTGGGCAAAGGCAGCTTTGGGAAGGTGATGCTGGCCGACCGAAAGGGGAC
AGAGGAGCTGTACGCCATCAAGATCCTGAAGAAGGACGTGGTCATCCAGGACGACGACGTGGAGTGCACCA
TGGTGGAGAAGCGGGTCCTGGCGCTGCTCGACAAGCCGCCGTTCCTGACGCAGCTGCACTCCTGCTTCCAG
ACGGTGGACCGGCTGTACTTCGTCGCGGAGTACGTAAACGGCGGGGACCTCATGTACCACATCCAGCAGGT
CGGGAAGTTCAAGGAGCCGCAAGCAGTGTTCTATGCAGCAGAGATTTCCATCGGGCTGTTCTTTCTTCATA
AAAGAGGAATCATTTATCGGGACCTGAAGTTAGACAACGTCATGCTGGACTCGGAAGGACACATTAAGATC
GCGGACTTCGGGATGTGCAAGGAGCACATGATGGACGGCGTCACGACCAGGACCTTCTGCGGGACCCCCGA
CTACATCGCCCCAGAGATAATCGCCTATCAGCCGTACGGGAAGTCCGTGGACTGGTGGGCCTACGGCGTCC
TGTTGTACGAGATGTTGGCCGGGCAGCCTCCGTTCGACGGCGAGGACGAGGACGAGCTGTTCCAGTCCATC
ATGGAGCACAACGTCTCGTACCCCAAGTCCTTGTCCAAGGAGGCCGTGTCCATCTGCAAAGGGCTGATGAC
CAAGCACCCCGGGAAGCGGCTGGGCTGCGGGCCCGAGGGCGAGCGCGACGTGCGGGAGCATGCCTTCTTCC
GGAGGATCGACTGGGAGAAGCTGGAGAACCGTGAGATCCAGCCACCCTTCAAGCCCAAAGTGTGCGGCAAA
GGAGCAGAGAACTTTGACAAGTTCTTCACGCGAGGGCAGCCTGTCTTGACGCCGCCCGACCAGCTGGTCAT
CGCTAACATCGACCAGTCTGATTTTGAAGGCTTCTCCTACGTCAACCCCCAGTTCGTGCACCCCATCCTGC
AGAGCGCGGTATGAGACGCCTCGCGGAAGCCTGGTCCGCGCCCCCGCCCCCGCCTCCGCCCCCGCCGTGGG
AAGCGACCCCCACCCTAGGGTTTGCCGGCCTCGGCCCTCCCTGTTCCAGGTGGAGGCCTGAAAACTGTAGG
GTGGTTGTCCCCGCGTGCTCGGCTGCGTCATCTCAGCGGAAGATGACGTCACGTCGGCATCTGCTTGACGT
AGAGGTGACATCTGGCGGGGGATTGACCCTTTCTGGAAAGCAAACAGACTCTGGCCGGTCGACCTCGAGGG
ATCTTCCATACCTACCAGTTCTGCGCCTGCAGGTCGCGGCCGCGACTCTAGA 
 
Figure 13.1 – Sequence of coding region of N-His6-PKCα(M417A)-pcDNA3 
(gray text is non-coding, ATG is the start codon, TGA is the stop codon, CATCACCATCACCATCAC codes for the His6-
tag, GC and A are mutated bases, GCG is the codon for the gatekeeper residue, TACGTA is the engineered SnaBI 
restriction site, GAATTC is the EcoRI restriction site, TCTAGA is the XbaI restriction site, GCGGCCGC is the NotI site) 
 
 
GGTACCCTCACGGACTTCAACTTCCTCATGGTGCTGGGCAAAGGCAGCTTTGGGAAGGTGATGCTGGCCGA
CCGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATCCTGAAGAAGGACGTGGTCATCCAGGACGACGACG
TGGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCTGCTCGACAAGCCGCCGTTCCTGACGCAGCTGCAC
TCCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCXYGGAGTACGTZAACGGCGGGGACCTCATGTACCA
CATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCAGTGTTCTATGCAGCAGAGATTTCCATCGGGCTGT
TCTTTCTTCATAAAAGAGGAATCATTTATCGGGACCTGAAGTTAGACAACGTCATGCTGGACTCGGAAGGA
CACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGCACATGATGGACGGCGTCACGACCAGGACCTTCTG
CGGGACCCCCGACTACATCGCCCCAGAGATAATCGCCTATCAGCCGTACGGGAAGTCCGTGGACTGGTGGG
CCTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCAGCCTCCGTTCGACGGCGAGGACGAGGACGAGCTG
TTCCAGTCCATCATGGAGCACAACGTCTCGTACCCCAAGTCCTTGTCCAAGGAGGCCGTGTCCATCTGCAA
AGGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGCTGCGGGCCCGAGGGCGAGCGCGACGTGCGGGAGC
ATGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGAGAACCGTGAGATCCAGCCACCCTTCAAGCCCAAA
GTGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCTTCACGCGAGGGCAGCCTGTCTTGACGCCGCCCGA
CCAGCTGGTCATCGCTAACATCGACCAGTCTGATTTTGAAGGCTTCTCCTACGTCAACCCCCAGTTCGTGC
ACCCCATCCTGCAGAGCGCGGTATGATCTAGA 
 155 
Plasmid XY Z 
cat.PKCα-pcDNA3 AT C 
cat.PKCα(M417G)-pcDNA3 GG A 
cat.PKCα(M417A)-pcDNA3 GC A 
 
Figure 13.2 – Sequence of coding region of cat.PKCα-pcDNA3, cat.PKCα(M417G)-pcDNA3 and 
cat.PKCα(M417A)-pcDNA3 
 
 (TGA is the stop codon, XYG is the codon for the gatekeeper residue, TACGTA is the engineered SnaBI restriction site, 
GGTACC is the KpnI restriction site, TCTAGA is the XbaI restriction site)  
 
 
GGTACCTTCCCGGCCGCCGAGCCGGCGGCGCCGCAGGACGTGGCCAACCGCTTCGCCCGCAAAGGGGCGCT
GAGGCAGAAGAACGTGCACGAGGTGAAGAACCACCGCTTCATCGCGCGCTTCTTCAAGCAGCCCACCTTCT
GCAGCCACTGCACCGACTTCATCTGGGGGTTTGGGAAACAAGGCTTCCAGTGCCAAGTTTGCTGTTTTGTG
GTTCACAAGAGGTGCCATGAATTTGTTACTTTTTCTTGTCCGGGGGCGGATAAAGGACCCGACACAGATGA
CCCGAGGAGCAAGCACAAGTTCAAGATCCACACGTATGGCAGCCCCACCTTCTGTGATCACTGCGGCTCCC
TGCTGTACGGACTCATCCACCAGGGGATGAAATGTGACACCTGTGATATGAACGTGCACAAGCAGTGCGTG
ATCAACGTGCCCAGCCTCTGCGGGATGGACCACACGGAGAAGAGGGGCCGCATCTACCTGAAGGCCGAGGT
CACGGATGAAAAGCTGCACGTCACAGTACGAGACGCGAAAAACCTAATCCCTATGGATCCAAATGGGCTTT
CAGATCCTTACGTGAAGCTGAAGCTTATTCCTGACCCCAAGAACGAGAGCAAACAGAAAACCAAGACCATC
CGCTCGACGCTGAACCCCCGGTGGGACGAGTCCTTCACGTTCAAATTAAAACCTTCTGATAAAGACCGGCG
ACTGTCCGTGGAAATCTGGGACTGGGATCGAACCACACGGAACGACTTCATGGGGTCCCTTTCCTTTGGGG
TCTCGGAGCTGATGAAGATGCCGGCCAGCGGATGGTACAAGCTGCTGAACCAAGAGGAGGGCGAGTACTAC
AACGTGCCGATCCCCGAAGGCGACGAGGAAGGCAATGTGGAGCTCAGGCAGAAATTCGAGAAAGCCAAGCT
TGGCCCTGCCGGCAACAAAGTCATCAGTCCCTCCGAGGACAGGAGACAGCCTTCCAACAACCTGGGCAGAG
TGAAGCTCACGGACTTCAACTTCCTCATGGTGCTGGGCAAAGGCAGCTTTGGGAAGGTGATGCTGGCCGAC
CGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATCCTGAAGAAGGACGTGGTCATCCAGGACGACGACGT
GGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCTGCTCGACAAGCCGCCGTTCCTGACGCAGCTGCACT
CCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCXYGGAGTACGTZAACGGCGGGGACCTCATGTACCAC
ATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCAGTGTTCTATGCAGCAGAGATTTCCATCGGGCTGTT
CTTTCTTCATAAAAGAGGAATCATTTATCGGGACCTGAAGTTAGACAACGTCATGCTGGACTCGGAAGGAC
ACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGCACATGATGGACGGCGTCACGACCAGGACCTTCTGC
GGGACCCCCGACTACATCGCCCCAGAGATAATCGCCTATCAGCCGTACGGGAAGTCCGTGGACTGGTGGGC
CTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCAGCCTCCGTTCGACGGCGAGGACGAGGACGAGCTGT
TCCAGTCCATCATGGAGCACAACGTCTCGTACCCCAAGTCCTTGTCCAAGGAGGCCGTGTCCATCTGCAAA
GGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGCTGCGGGCCCGAGGGCGAGCGCGACGTGCGGGAGCA
TGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGAGAACCGTGAGATCCAGCCACCCTTCAAGCCCAAAG
TGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCTTCACGCGAGGGCAGCCTGTCTTGACGCCGCCCGAC
CAGCTGGTCATCGCTAACATCGACCAGTCTGATTTTGAAGGCTTCTCCTACGTCAACCCCCAGTTCGTGCA
CCCCATCCTGCAGAGCGCGGTATGATCTAGAGATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTA
GAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCT
TCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCT
GAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATA
GCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGG
TATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTAC
ACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC
CCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAA
AAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT
GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATT
CTTTTGATTTATAAGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTT
AACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAG
AAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCA
GAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCC
CTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGA
GGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAA
AGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATT
GAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACA
ACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCA
AGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACG
GGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGT
GCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGC
GGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCA
 156 
CGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGC
CGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCT
GCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCG
GACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCG
CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGT
TCTTCTGAGCGGGACTCTGGGGTTCGAA 
 
Plasmid XY Z 
PKCα-pcDNA3 AT C 
PKCα(M417G)-pcDNA3 GG A 
PKCα(M417A)-pcDNA3 GC A 
 
Figure 13.3 – Sequence of coding region of PKCα-pcDNA3, PKCα(M417G)-pcDNA3 and 
PKCα(M417A)-pcDNA3 
 
 (gray text is non-coding, TGA is the stop codon, XYG is the codon for the gatekeeper residue, TACGTA is the 
engineered SnaBI restriction site, GGTACC is the KpnI restriction site, TCTAGA is the XbaI restriction site, TCCGGA is 
the Kpn2I restriction site, TTCGAA is the SfuI restriction site) 
 
 
AAGCTTCACCATGTGGAGCCACCCGCAGTTCGAAAAAGGGGGTACCGAGCTCCTGAAATCCTCCTGGGCT
GCAAATATTATTCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCG
GGCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGGACCCCAGAT
GAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTCCCCAAGTGGGCCCGGCAAG
ATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGGAGCTTGTTATCGCAAATGCTGCACTACGA
CCCTAACAAGCGGATTTCGGCCAAGGCAGCCCTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTA
CCCCATCTTCGACTCTGAGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGA 
 
Figure 13.4 – Sequence of coding region of Strep-pcDNA3 
 (gray text is unrequired DNA, ATG is the start codon, light blue text is the strep tag, TTCGAA is the SfuI restriction site, 
AAGCTT is the HindIII restriction site, GGTACC is the KpnI restriction site, TCTAGA is the XbaI restriction site) 
 
 
ATGTGGAGCCACCCGCAGTTCGAAAAAGGGGGTACCCTCACGGACTTCAACTTCCTCATGGTGCTGGGCAA
AGGCAGCTTTGGGAAGGTGATGCTGGCCGACCGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATCCTGA
AGAAGGACGTGGTCATCCAGGACGACGACGTGGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCTGCTC
GACAAGCCGCCGTTCCTGACGCAGCTGCACTCCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCXYGGA
GTACGTZAACGGCGGGGACCTCATGTACCACATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCAGTGT
TCTATGCAGCAGAGATTTCCATCGGGCTGTTCTTTCTTCATAAAAGAGGAATCATTTATCGGGACCTGAAG
TTAGACAACGTCATGCTGGACTCGGAAGGACACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGCACAT
GATGGACGGCGTCACGACCAGGACCTTCTGCGGGACCCCCGACTACATCGCCCCAGAGATAATCGCCTATC
AGCCGTACGGGAAGTCCGTGGACTGGTGGGCCTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCAGCCT
CCGTTCGACGGCGAGGACGAGGACGAGCTGTTCCAGTCCATCATGGAGCACAACGTCTCGTACCCCAAGTC
CTTGTCCAAGGAGGCCGTGTCCATCTGCAAAGGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGCTGCG
GGCCCGAGGGCGAGCGCGACGTGCGGGAGCATGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGAGAAC
CGTGAGATCCAGCCACCCTTCAAGCCCAAAGTGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCTTCAC
GCGAGGGCAGCCTGTCTTGACGCCGCCCGACCAGCTGGTCATCGCTAACATCGACCAGTCTGATTTTGAAG
GCTTCTCCTACGTCAACCCCCAGTTCGTGCACCCCATCCTGCAGAGCGCGGTATGATCTAGA 
 
Plasmid XY Z 
N-Strep-cat.PKCα-pcDNA3 AT C 
N-Strep-cat.PKCα(M417G)-pcDNA3 GG A 
N-Strep-cat.PKCα(M417A)-pcDNA3 GC A 
 
Figure 13.5 – Sequence of coding region of N-Strep-cat.PKCα-pcDNA3, N-Strep-
cat.PKCα(M417G)-pcDNA3 and N-Strep-cat.PKCα(M417A)-pcDNA3 
 
 (ATG is the start codon, TGA is the stop codon, light blue text is the strep tag, XYG is the codon for the gatekeeper 
residue, TACGTA is the engineered SnaBI restriction site, GGTACC is the KpnI restriction site, TCTAGA is the XbaI 
restriction site, TCCGGA is the Kpn2I site) 
 
 
 157 
ATGTGGAGCCACCCGCAGTTCGAAAAAGGGGGTACCTTCCCGGCCGCCGAGCCGGCGGCGCCGCAGGACGT
GGCCAACCGCTTCGCCCGCAAAGGGGCGCTGAGGCAGAAGAACGTGCACGAGGTGAAGAACCACCGCTTCA
TCGCGCGCTTCTTCAAGCAGCCCACCTTCTGCAGCCACTGCACCGACTTCATCTGGGGGTTTGGGAAACAA
GGCTTCCAGTGCCAAGTTTGCTGTTTTGTGGTTCACAAGAGGTGCCATGAATTTGTTACTTTTTCTTGTCC
GGGGGCGGATAAAGGACCCGACACAGATGACCCGAGGAGCAAGCACAAGTTCAAGATCCACACGTATGGCA
GCCCCACCTTCTGTGATCACTGCGGCTCCCTGCTGTACGGACTCATCCACCAGGGGATGAAATGTGACACC
TGTGATATGAACGTGCACAAGCAGTGCGTGATCAACGTGCCCAGCCTCTGCGGGATGGACCACACGGAGAA
GAGGGGCCGCATCTACCTGAAGGCCGAGGTCACGGATGAAAAGCTGCACGTCACAGTACGAGACGCGAAAA
ACCTAATCCCTATGGATCCAAATGGGCTTTCAGATCCTTACGTGAAGCTGAAGCTTATTCCTGACCCCAAG
AACGAGAGCAAACAGAAAACCAAGACCATCCGCTCGACGCTGAACCCCCGGTGGGACGAGTCCTTCACGTT
CAAATTAAAACCTTCTGATAAAGACCGGCGACTGTCCGTGGAAATCTGGGACTGGGATCGAACCACACGGA
ACGACTTCATGGGGTCCCTTTCCTTTGGGGTCTCGGAGCTGATGAAGATGCCGGCCAGCGGATGGTACAAG
CTGCTGAACCAAGAGGAGGGCGAGTACTACAACGTGCCGATCCCCGAAGGCGACGAGGAAGGCAATGTGGA
GCTCAGGCAGAAATTCGAGAAAGCCAAGCTTGGCCCTGCCGGCAACAAAGTCATCAGTCCCTCCGAGGACA
GGAGACAGCCTTCCAACAACCTGGGCAGAGTGAAGCTCACGGACTTCAACTTCCTCATGGTGCTGGGCAAA
GGCAGCTTTGGGAAGGTGATGCTGGCCGACCGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATCCTGAA
GAAGGACGTGGTCATCCAGGACGACGACGTGGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCTGCTCG
ACAAGCCGCCGTTCCTGACGCAGCTGCACTCCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCXYGGAG
TACGTZAACGGCGGGGACCTCATGTACCACATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCAGTGTT
CTATGCAGCAGAGATTTCCATCGGGCTGTTCTTTCTTCATAAAAGAGGAATCATTTATCGGGACCTGAAGT
TAGACAACGTCATGCTGGACTCGGAAGGACACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGCACATG
ATGGACGGCGTCACGACCAGGACCTTCTGCGGGACCCCCGACTACATCGCCCCAGAGATAATCGCCTATCA
GCCGTACGGGAAGTCCGTGGACTGGTGGGCCTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCAGCCTC
CGTTCGACGGCGAGGACGAGGACGAGCTGTTCCAGTCCATCATGGAGCACAACGTCTCGTACCCCAAGTCC
TTGTCCAAGGAGGCCGTGTCCATCTGCAAAGGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGCTGCGG
GCCCGAGGGCGAGCGCGACGTGCGGGAGCATGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGAGAACC
GTGAGATCCAGCCACCCTTCAAGCCCAAAGTGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCTTCACG
CGAGGGCAGCCTGTCTTGACGCCGCCCGACCAGCTGGTCATCGCTAACATCGACCAGTCTGATTTTGAAGG
CTTCTCCTACGTCAACCCCCAGTTCGTGCACCCCATCCTGCAGAGCGCGGTATGATCTAGA 
 
Plasmid XY Z 
N-Strep-PKCα-pcDNA3 AT C 
N-Strep-PKCα(M417G)-pcDNA3 GG A 
N-Strep-PKCα(M417A)-pcDNA3 GC A 
 
Figure 13.6 – Sequence of coding region of N-Strep-PKCα-pcDNA3, N-Strep-PKCα(M417G)-
pcDNA3 and N-Strep-PKCα(M417A)-pcDNA3 
 
 (ATG is the start codon, TGA is the stop codon, light blue text is the strep tag, XYG is the codon for the gatekeeper 
residue, TACGTA is the engineered SnaBI restriction site, GGTACC is the KpnI restriction site, TCTAGA is the XbaI 
restriction site) 
 
 
ATGGGTCATCATCATCACCATCACGGGTCGACCATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCT
TGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATG
AAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGAT
GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGG
TTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGA
GAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAA
ATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTT
GTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTT
TTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCT
TTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGAAGTTCTGTTCCA
GGGGCCCCTAAGCTTGGATCCCTGCAGGCCTCGAGTGAAGCTCACGGACTTCAACTTCCTCATGGTGCTGG
GCAAAGGCAGCTTTGGGAAGGTGATGCTGGCCGACCGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATC
CTGAAGAAGGACGTGGTCATCCAGGACGACGACGTGGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCT
GCTCGACAAGCCGCCGTTCCTGACGCAGCTGCACTCCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCX
YGGAGTACGTZAACGGCGGGGACCTCATGTACCACATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCA
GTGTTCTATGCAGCAGAGATTTCCATCGGGCTGTTCTTTCTTCATAAAAGAGGAATCATTTATCGGGACCT
GAAGTTAGACAACGTCATGCTGGACTCGGAAGGACACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGC
ACATGATGGACGGCGTCACGACCAGGACCTTCTGCGGGACCCCCGACTACATCGCCCCAGAGATAATCGCC
TATCAGCCGTACGGGAAGTCCGTGGACTGGTGGGCCTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCA
GCCTCCGTTCGACGGCGAGGACGAGGACGAGCTGTTCCAGTCCATCATGGAGCACAACGTCTCGTACCCCA
AGTCCTTGTCCAAGGAGGCCGTGTCCATCTGCAAAGGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGC
 158 
TGCGGGCCCGAGGGCGAGCGCGACGTGCGGGAGCATGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGA
GAACCGTGAGATCCAGCCACCCTTCAAGCCCAAAGTGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCT
TCACGCGAGGGCAGCCTGTCTTGACGCCGCCCGACCAGCTGGTCATCGCTAACATCGACCAGTCTGATTTT
GAAGGCTTCTCCTACGTCAACCCCCAGTTCGTGCACCCCATCCTGCAGAGCGCGGTATGATCTAGA 
 
Plasmid XY Z 
cat.PKCα-pBacPAK-GST AT C 
cat.PKCα(M417G)-pBacPAK-GST GG A 
cat.PKCα(M417A)-pBacPAK-GST GC A 
 
Figure 13.7 – Sequence of coding region of cat.PKCα-pBacPAK-GST, cat.PKCα(M417G)-
pBacPAK-GST, cat.PKCα(M417A)-pBacPAK-GST 
 
(ATG is the start codon, TGA is the stop codon, CATCACCATCACCATCAC codes for the His6-tag, lilac text codes for the 
GST tag, CTGGAAGTTCTGTTCCAG codes for the 3C cleavage site, XYG is the codon for the gatekeeper residue, 
TACGTA is the engineered SnaBI restriction site, CTCGAG is the XhoI restriction site, TCTAGA is the XbaI restriction 
site) 
 
 
ATGGGTCATCATCATCACCATCACGGGTCGACCATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCT
TGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATG
AAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGAT
GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGG
TTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGA
GAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAA
ATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTT
GTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTT
TTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCT
TTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGAAGTTCTGTTCCA
GGGGCCCCTAAGCTTGGATCCCTGCAGGCCTCGAGACGTCTTCCCGGCCGCCGAGCCGGCGGCGCCGCAGG
ACGTGGCCAACCGCTTCGCCCGCAAAGGGGCGCTGAGGCAGAAGAACGTGCACGAGGTGAAGAACCACCGC
TTCATCGCGCGCTTCTTCAAGCAGCCCACCTTCTGCAGCCACTGCACCGACTTCATCTGGGGGTTTGGGAA
ACAAGGCTTCCAGTGCCAAGTTTGCTGTTTTGTGGTTCACAAGAGGTGCCATGAATTTGTTACTTTTTCTT
GTCCGGGGGCGGATAAAGGACCCGACACAGATGACCCGAGGAGCAAGCACAAGTTCAAGATCCACACGTAT
GGCAGCCCCACCTTCTGTGATCACTGCGGCTCCCTGCTGTACGGACTCATCCACCAGGGGATGAAATGTGA
CACCTGTGATATGAACGTGCACAAGCAGTGCGTGATCAACGTGCCCAGCCTCTGCGGGATGGACCACACGG
AGAAGAGGGGCCGCATCTACCTGAAGGCCGAGGTCACGGATGAAAAGCTGCACGTCACAGTACGAGACGCG
AAAAACCTAATCCCTATGGATCCAAATGGGCTTTCAGATCCTTACGTGAAGCTGAAGCTTATTCCTGACCC
CAAGAACGAGAGCAAACAGAAAACCAAGACCATCCGCTCGACGCTGAACCCCCGGTGGGACGAGTCCTTCA
CGTTCAAATTAAAACCTTCTGATAAAGACCGGCGACTGTCCGTGGAAATCTGGGACTGGGATCGAACCACA
CGGAACGACTTCATGGGGTCCCTTTCCTTTGGGGTCTCGGAGCTGATGAAGATGCCGGCCAGCGGATGGTA
CAAGCTGCTGAACCAAGAGGAGGGCGAGTACTACAACGTGCCGATCCCCGAAGGCGACGAGGAAGGCAATG
TGGAGCTCAGGCAGAAATTCGAGAAAGCCAAGCTTGGCCCTGCCGGCAACAAAGTCATCAGTCCCTCCGAG
GACAGGAGACAGCCTTCCAACAACCTGGGCAGAGTGAAGCTCACGGACTTCAACTTCCTCATGGTGCTGGG
CAAAGGCAGCTTTGGGAAGGTGATGCTGGCCGACCGAAAGGGGACAGAGGAGCTGTACGCCATCAAGATCC
TGAAGAAGGACGTGGTCATCCAGGACGACGACGTGGAGTGCACCATGGTGGAGAAGCGGGTCCTGGCGCTG
CTCGACAAGCCGCCGTTCCTGACGCAGCTGCACTCCTGCTTCCAGACGGTGGACCGGCTGTACTTCGTCXY
GGAGTACGTZAACGGCGGGGACCTCATGTACCACATCCAGCAGGTCGGGAAGTTCAAGGAGCCGCAAGCAG
TGTTCTATGCAGCAGAGATTTCCATCGGGCTGTTCTTTCTTCATAAAAGAGGAATCATTTATCGGGACCTG
AAGTTAGACAACGTCATGCTGGACTCGGAAGGACACATTAAGATCGCGGACTTCGGGATGTGCAAGGAGCA
CATGATGGACGGCGTCACGACCAGGACCTTCTGCGGGACCCCCGACTACATCGCCCCAGAGATAATCGCCT
ATCAGCCGTACGGGAAGTCCGTGGACTGGTGGGCCTACGGCGTCCTGTTGTACGAGATGTTGGCCGGGCAG
CCTCCGTTCGACGGCGAGGACGAGGACGAGCTGTTCCAGTCCATCATGGAGCACAACGTCTCGTACCCCAA
GTCCTTGTCCAAGGAGGCCGTGTCCATCTGCAAAGGGCTGATGACCAAGCACCCCGGGAAGCGGCTGGGCT
GCGGGCCCGAGGGCGAGCGCGACGTGCGGGAGCATGCCTTCTTCCGGAGGATCGACTGGGAGAAGCTGGAG
AACCGTGAGATCCAGCCACCCTTCAAGCCCAAAGTGTGCGGCAAAGGAGCAGAGAACTTTGACAAGTTCTT
CACGCGAGGGCAGCCTGTCTTGACGCCGCCCGACCAGCTGGTCATCGCTAACATCGACCAGTCTGATTTTG
AAGGCTTCTCCTACGTCAACCCCCAGTTCGTGCACCCCATCCTGCAGAGCGCGGTATGATCTAGA 
 
Plasmid XY Z 
PKCα-pBacPAK-GST AT C 
PKCα(M417G)-pBacPAK-GST GG A 
PKCα(M417A)-pBacPAK-GST GC A 
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Figure 13.8 – Sequence of coding region of PKCα-pBacPAK-GST, PKCα(M417G)-pBacPAK-GST, 
PKCα(M417A)-pBacPAK-GST 
 
 (ATG is the start codon, TGA is the stop codon, CATCACCATCACCATCAC codes for the His6-tag, lilac text codes for 
the GST tag, CTGGAAGTTCTGTTCCAG codes for the 3C cleavage site, XYG is the codon for the gatekeeper residue, 
TACGTA is the engineered SnaBI restriction site, CTCGAG is the XhoI restriction site, TCTAGA is the XbaI restriction 
site) 
 
 
GGATCCATGGGCAACGCCGCCGCCGCCAAGAAGGGCAGCGAGCAGGAGAGCGTGAAAGAGTTCCTAGCCA
AAGCCAAGGAAGATTTCCTGAAAAAATGGGAGACCCCTTCTCAGAATACAGCCCAGTTGGATCAGTTTGA
TAGAATCAAGACCCTTGGCACCGGCTCCTTTGGGCGAGTGATGCTGGTGAAGCACAAGGAGAGTGGGAAC
CACTACGCCATGAAGATCTTAGACAAGCAGAAGGTGGTGAAGCTAAAGCAGATCGAGCACACTCTGAATG
AGAAGCGCATCCTGCAGGCCGTCAACTTCCCGTTCCTGGTCAAACTTGAATTCTCCTTCAAGGACAACTC
AAACCTGTACATGGTCXYGGAGTAZGTAGCTGGTGGCGAGATGTTCTCCCACCTACGGCGGATTGGAAGG
TTCAGCGAGCCCCATGCCCGTTTCTACGCGGCGCAGATCGTCCTGACCTTTGAGTATCTGCACTCCCTGG
ACCTCATCTACCGGGACCTGAAGCCCGAGAATCTTCTCATCGACCAGCAGGGCTATATTCAGGTGACAGA
CTTCGGTTTTGCCAAGCGTGTGAAAGGCCGTACTTGGACCTTGTGTGGGACCCCTGAGTACTTGGCCCCC
GAGATTATCCTGAGCAAAGGCTACAACAAGGCTGTGGACTGGTGGGCTCTCGGAGTCCTCATCTACGAGA
TGGCTGCTGGTTACCCACCCTTCTTCGCTGACCAGCCTATCCAGATCTATGAGAAAATCGTCTCTGGGAA
GGTGCGGTTCCCATCCCACTTCAGCTCTGACTTGAAGGACCTGCTGCGGAACCTTCTGCAAGTGGATCTC
ACCAAGCGCTTTGGGAACCTCAAGAACGGGGTCAATGACATCAAGAACCACAAGTGGTTTGCCACGACTG
ACTGGATTGCCATCTATCAGAGAAAGGTGGAAGCTCCCTTCATACCAAAGTTTAAAGGCCCTGGGGACAC
GAGTAACTTTGACGACTATGAGGAGGAAGAGATCCGGGTCTCCATCAATGAGAAGTGTGGCAAGGAGTTT
ACTGAGTTTTAAGCTT 
 
Plasmid XY Z 
N-His6-cat.PKAα-pGEM-T AT T 
N-His6-cat.PKAα(M121G)-pGEM-T GG C 
 
Figure 13.9 – Sequence of coding region of N-His6-cat.PKAα-pGEM-T and N-His6-
cat.PKAα(M121G)-pGEM-T 
 
(ATG is the start codon, TAA is the stop codon, CATCACCATCACCATCAC codes for the His6-tag, XYG is the codon for 
the gatekeeper residue, TACGTA is the engineered SnaBI restriction site, GGATCC is the BamHI restriction site, 
AAGCTT is the HindIII restriction site, GAATTC is the EcoRI restriction site, GGTTACC is the Eco91I restriction site) 
 
 
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGA
TCTGTACGACGATGACGATAAGGATCGATGGGGATCCATGGGCAACGCCGCCGCCGCCAAGAAGGGCAGCG
AGCAGGAGAGCGTGAAAGAGTTCCTAGCCAAAGCCAAGGAAGATTTCCTGAAAAAATGGGAGACCCCTTCT
CAGAATACAGCCCAGTTGGATCAGTTTGATAGAATCAAGACCCTTGGCACCGGCTCCTTTGGGCGAGTGAT
GCTGGTGAAGCACAAGGAGAGTGGGAACCACTACGCCATGAAGATCTTAGACAAGCAGAAGGTGGTGAAGC
TAAAGCAGATCGAGCACACTCTGAATGAGAAGCGCATCCTGCAGGCCGTCAACTTCCCGTTCCTGGTCAAA
CTTGAATTCTCCTTCAAGGACAACTCAAACCTGTACATGGTCATGGAGTATGTAGCTGGTGGCGAGATGTT
CTCCCACCTACGGCGGATTGGAAGGTTCAGCGAGCCCCATGCCCGTTTCTACGCGGCGCAGATCGTCCTGA
CCTTTGAGTATCTGCACTCCCTGGACCTCATCTACCGGGACCTGAAGCCCGAGAATCTTCTCATCGACCAG
CAGGGCTATATTCAGGTGACAGACTTCGGTTTTGCCAAGCGTGTGAAAGGCCGTACTTGGACCTTGTGTGG
GACCCCTGAGTACTTGGCCCCCGAGATTATCCTGAGCAAAGGCTACAACAAGGCTGTGGACTGGTGGGCTC
TCGGAGTCCTCATCTACGAGATGGCTGCTGGTTACCCACCCTTCTTCGCTGACCAGCCTATCCAGATCTAT
GAGAAAATCGTCTCTGGGAAGGTGCGGTTCCCATCCCACTTCAGCTCTGACTTGAAGGACCTGCTGCGGAA
CCTTCTGCAGGTGGATCTCACCAAGCGCTTTGGGAACCTCAAGAACGGGGTCAATGACATCAAGAACCACA
AGTGGTTTGCCACGACTGACTGGATTGCCATCTATCAGAGAAAGGTGGAAGCTCCCTTCATACCAAAGTTT
AAAGGCCCTGGGGACACGAGTAACTTTGACGACTATGAGGAGGAAGAGATCCGGGTCTCCATCAATGAGAA
GTGTGGCAAGGAGTTTACTGAGTTTTAAGCTT 
 
Figure 13.10 – Sequence of coding region of N-His6-cat.PKAα-pRSETA 
(ATG is the start codon, TAA is the stop codon, CATCACCATCACCATCAC codes for the His6-tag, ATG is the codon for 
the gatekeeper residue, GGATCC is the BamHI restriction site, AAGCTT is the HindIII restriction site) 
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ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCT
TGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAAT
TGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATC
ATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCT
TGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCA
AAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATAT
TTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGA
CCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTG
ATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGC
GACCATCCTCCAAAATCGGATCTGATCGAAGGTCGTGGGATCCCCCGATCCATGGGCAGCAACAAGAGCAA
GCCCAAGGACGCCAGCCAGCGGCGCCGCAGCCTGGAGCCCTCGGAAAACGTGCACGGGGCAGGGGGCGCCT
TCCCGGCCTCACAGACACCGAGCAAGCCCGCCTCCGCCGACGGCCACCGCGGGCCCAGCGCCGCCTTCGTG
CCGCCCGCGGCCGAGCCCAAGCTCTTCGGAGGCTTCAACTCCTCGGACACCGTCACCTCCCCGCAGAGGGC
GGGGCCTCTGGCAGGTGGGGTGACCACCTTTGTGGCCCTCTATGACTATGAGTCACGGACAGAGACTGACC
TGTCCTTCAAGAAAGGGGAGCGGCTGCAGATTGTCAATAACACGAGGAAGGTGGATGTCAGAGAGGGAGAC
TGGTGGCTGGCACACTCGCTGAGCACGGGACAGACCGGTTACATCCCCAGCAACTATGTGGCGCCCTCCGA
CTCCATCCAGGCTGAGGAGTGGTACTTTGGCAAGATCACTAGACGGGAATCAGAGCGGCTGCTGCTCAACG
CCGAGAACCCGAGAGGGACCTTCCTCGTGAGGGAGAGTGAGACCACAAAAGGTGCCTACTGCCTCTCTGTA
TCCGACTTCGACAATGCCAAGGGCCTAAATGTGAAACACTACAAGATCCGCAAGCTGGACAGCGGCGGTTT
CTACATCACCTCCCGCACCCAGTTCAACAGCCTGCAGCAGCTCGTGGCTTACTACTCCAAACATGCTGATG
GCCTGTGTCACCGCCTCACTACCGTATGTCCCACATCCAAGCCTCAGACCCAGGGATTGGCCAAGGATGCG
TGGGAGATCCCCCGGGAGTCCCTGCGGCTGGAGGTCAAGCTGGGCCAGGGTTGCTTCGGAGAGGTGTGGAT
GGGGACCTGGAACGGCACCACGAGGGTTGCCATCAAAACTCTGAAGCCAGGCACCATGTCCCCAGAGGCCT
TCCTGCAGGAGGCCCAAGTCATGAAGAAACTGAGGCACGAGAAACTGGTGCAGCTGTATGCTGTGGTGTCG
GAAGAACCCATTTACATTGTGACAGAGTACATGAACAAGGGGAGTCTGCTGGACTTTCTCAAGGGGGAAAC
GGGCAAATATTTGCGGCTACCCCAGCTGGTGGACATGTCTGCTCAGATCGCTTCAGGCATGGCCTATGTGG
AGCGGATGAACTATGTGCACCGGGACCTTCGAGCCGCCAATATCCTAGTAGGGGAGAACCTGGTGTGCAAA
GTGGCCGACTTTGGGTTGGCCCGGCTCATAGAAGACAACGAATACACAGCCCGGCAAGGTGCCAAATTCCC
CATCAAGTGGACCGCCCCTGAAGCTGCTCTGTACGGCAGGTTCACCATCAAGTCGGATGTGTGGTCCTTTG
GGATTCTGCTGACCGAGCTCACCACTAAGGGAAGAGTGCCCTATCCTGGGATGGTGAACCGTGAGGTTCTG
GACCAGGTGGAGCGGGGCTACCGGATGCCTTGTCCCCCCGAGTGCCCCGAGTCCCTGCATGACCTTATGTG
CCAGTGCTGGCGGAAGGAGCCCGAGGAGCGGCCCACCTTCGAGTACCTGCAGGCCTTCCTGGAAGACTACT
TTACGTCCACTGAGCCACAGTACCAGCCCGGGGAGAACCTATAGGGACTGTGTGCGCAGAACTGTCACCTC
TAGGCTTCCGGGTGTTGCCTCCGATGCACCTGCCTCCCTTCATCCTCTCTCTGGGGCTGCGTTGCCTCGGC
AATGCCCCTTTTGGAGCATGGAAGGGCTTCAGGGATGGGGCAGCCTGGAAGGACAGGTGGAGGCTGGTACA
GTGACTGTCCCATGCCTGCCATGGATCGGGCTGCAGGAATTC 
 
Figure 13.11 – Sequence of coding region of c-Src-pGEX-3X 
 (gray text is non-coding, ATG is the start codon, TAG is the stop codon, lilac text codes for the GST tag, 
ATCGAAGGTCGT codes for the Factor Xa cleavage site, GGATCC is the BamHI restriction site, GAATTC is the EcoRI 
restriction site) 
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13.2 Vector Maps 
 
 
 
Figure 13.12 – Maps of pcDNA3, pAcC4, pBacPAK-GST, pRSETA, pRSETB and pGEM-T 
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13.3 Solution Constitutions 
 
BBS 50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 
6.95 
BSA solution PBST + 3% BSA 
Coomassie
®
 destaining solution  10% (v/v) AcOH, 10% (v/v) MeOH 
Coomassie
®
 staining solution  0.25% (w/v) Coomassie
®
 blue dye, 10% (v/v) 
AcOH, 10% (v/v/) MeOH  
DMEM low glucose: contains 1000 mg L
-1
 glucose, L-
glutamine, NaHCO3 
Electrophoresis transfer buffer 10 mM Tris-HCl, 80 mM glycine, 10% (v/v) 
MeOH 
Gene clean solution 50 mM NaCl, 10 mM Tris-HCl, 2.5 mM EDTA, 
50% (v/v) EtOH, pH 7.5 
GST elution buffer I 20 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 5% 
glycerol, pH 7.4 
GST elution buffer II 100 mM Tris-HCl, pH 8.0 
GST elution buffer III 20 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 5% 
glycerol, 20 mM glutathione, pH 7.4 
GST elution buffer IV 100 mM Tris-HCl, 20-50 mM glutathione, pH 8.0 
GST purification buffer I 20 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 1 
mM NaF, 1 mM Na3VO4, 5% glycerol, complete 
EDTA-free protease inhibitor cocktail (Roche, 1 
tablet per 50 mL), pH 7.4 
GST purification buffer II 20 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 1 
mM NaF, 1 mM Na3VO4, 5% glycerol, EDTA-free 
complete protease tablet (1 tablet per 50 mL), pH 
7.4 
HBS 50 mM Hepes, 280 mM NaCl, 10 mM KCl, 1.5 
mM Na2HPO4, 12 mM glucose, pH 7.05 
His elution buffer 20 mM Tris-HCl, 120 mM NaCl, 0.02% (v/v) 
Triton X-100, 2 mM β-mercaptoethanol, 20 mM 
NaF, 1 mM Na3VO4, 1 mM p-
nitrophenylphosphate, 100 mM imidazole, pH 7.5 
His6-HRV-3C cleavage buffer 150 mM NaCl, 50 mM Tris-HCl, pH 7.5 
His purification buffer I 20 mM Tris-HCl, 120 mM NaCl, 1% (v/v) Triton 
X-100, 2 mM β-mercaptoethanol, 20 mM NaF, 1 
mM Na3VO4, 1 mM p-nitrophenylphosphate, 5 mM 
imidazole, pH 7.5 
His purification buffer II 20 mM Tris-HCl, 120 mM NaCl, 0.02% (v/v) 
Triton X-100, 2 mM β-mercaptoethanol, 20 mM 
NaF, 1 mM Na3VO4, 1 mM p-
nitrophenylphosphate, 5 mM imidazole, pH 7.5 
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HRV-3C cleavage control protein 1 mg mL
-1
 protein, 100 mM NaCl, 50 mM Tris-
HCl, 10 mM EDTA, 50% (v/v) glycerol, pH 7.4 
His6-HRV-3C protease 2 U μL
-1
 HRV-3C protease, 150 mM NaCl, 50 mM 
Tris-HCl, 1 mM EDTA, 0.5 mM THP, 50% (v/v) 
glycerol, pH 8.0 
KOD buffer 1 1.2 M Tris-HCl, 100 mM KCl, 60 mM (NH4)2SO4, 
1% (v/v) Triton X-100, 0.01% (w/v) BSA, pH 8.0 
KOD buffer 2 1.2 M Tris-HCl, 100 mM KCl, 60 mM (NH4)2SO4, 
1% (v/v) Triton X-100, 0.01% (w/v) BSA, pH 8.8 
K-PBS 30.8 mM NaCl, 120.7 mM KCl, 8.1 mM Na2HPO4, 
1.5 mM KH2PO4, 25 mM MgCl2, pH 7.14 
LB 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% 
(w/v) bactoyeast extract, pH 7.0 
Milk solution PBST + 5% (w/v) non-fat dried milk 
NETN 0.5% (v/v) NP40, 20 mM Tris-HCl, 100 mM NaCl, 
1 mM EDTA, pH 8.0 
PBS 140 mM NaCl, 3 mM KCl, 10 mM Na3PO4, 2 mM 
K3PO4, pH 7.4 
PBST PBS + 0.1% (v/v) Tween-20 
Standard KOD PCR components KOD buffer 1 (2.5 μL), 25 mM MgCl2 (2 μL), 2 
mM dNTPs (2.5 μL) 
5 × SDS loading buffer 160 mM Tris-HCl, 24% (v/v) glycerol, 5% (w/v) 
SDS, 12.5% (v/v) β-mercaptoethanol, 0.1% (w/v) 
bromophenol blue, pH 6.8 
SDS-MOPS buffer 40 mM sodium-MOPS, 5 mM sodium citrate, 0.5 
mM EDTA 
SDS-PAGE stacking gel 0.1% (v/v) SDS, 5% (v/v) acrylamide, 0.1 M Tris-
HCl, pH 6.8 
SDS-PAGE resolving gel 0.2% (v/v) SDS, 10% (v/v) acrylamide, 0.4 M Tris-
HCl, pH 8.8 
SDS running buffer 7.8 mM Tris-HCl, 80 mM glycine, 10% (v/v) 
MeOH, 10% (w/v) SDS 
Solution I 50 mM glucose, 25 mM Tris-HCl, 10 mM EDTA, 
pH 8 
Solution II 0.2 M NaOH, 1% SDS 
Solution III 3 M KOAc, 5 M glacial acetic acid 
TAE 40 mM Tris-acetate, 1 mM EDTA, pH 8.0 
5 × TAE loading buffer TAE + 0.04% (w/v) bromophenol blue, 2.5% (w/v) 
ficoll 
Trypsin-EDTA 0.0002% (w/v) Trypsin, 680 μM EDTA, 5.6 mM 
glucose, 140 mM NaCl, 26 mM KCl, 6.9 mM 
NaHCO3 
 
